The electrophysiological effects of Endothelin-1 in human atrial myocytes by Redpath, Calum J.
The electrophysiological effects of Endothelin 1 in 
human atrial myocytes. 
 
 
 
 
 
Calum Jon Redpath M.B.,Ch.B. M.R.C.P.(UK) 
 
 
This thesis is being submitted for the degree of Ph.D. at the University of Glasgow 
 
This work was carried out in the Section of Cardiology (Royal Infirmary), Division of 
Cardiovascular & Medical Sciences at The University of Glasgow. 
     ii 
Abstract 
 
 
Introduction:  Chronic  heart  failure  (CHF)  is  associated  with  an increased  incidence  of 
atrial fibrillation (AF) and elevated levels of catecholamines and endothelin 1 (ET 1), each 
of which affects the atrial L type calcium current (ICaL) and consequently action potentials. 
 
Hypotheses: ET 1 modulates the effects of isoproterenol (ISO) on ICaL and action potentials 
in human atrial myocytes. 
 
Methods:  Atrial  myocytes  were  isolated  enzymatically  from  samples  of  right  atrial 
appendage obtained from consenting patients in sinus rhythm undergoing cardiac surgery. 
The nystatin perforated whole cell patch clamp technique was used at 37ºC to record ICaL 
and action potentials in voltage clamp and current clamp mode respectively. 
  
Results: The current voltage relationship of ICaL was bell shaped, peaking at +10 mV with 
a current density of  4.8±0.4 pA/pF (mean± s.e.m., n=89 cells, 34 patients). ISO, 0.1 nM to 
1   M,  increased  peak  ICaL  in  a  concentration dependent  manner  (n=4 46  cells)  with  a 
maximum response of 250± 53% above control and an approximate EC50 of 0.06  M. 
Isoproterenol at 0.05  M significantly increased peak ICaL from  4.7± 0.4 to  12.2± 0.9 
pA/pF (P<0.05, Students t test; n=64 cells). This adrenergic effect was reversed by ET 1 at 
all  concentrations  tested  from  0.01  to  10  nM  and  was  partially  reversible  upon  ET 1 
washout and in the presence of the specific ET A receptor antagonist, FR139317 (n=5 12 
cells). Neither ET 1 alone nor the ET B receptor agonist Sarafotoxin S6c, at 10 nM, had an 
effect on ICaL.  
 
     iii 
Isoproterenol  (0.05   M)  prolonged  the  action  potential  duration  at  50%  repolarisation 
(APD50) from 30± 7 to 46± 7 ms (P< 0.05, n=15 cells), but had no effect on APD90 nor the 
cellular ERP. These adrenergic effects on APD50 and SDs were also abolished by ET 1 at 
10 nM (P< 0.05, n=15 cells). Superfusion with ET 1 (10 nM) alone had no significant 
effect  on  APD50,  APD90,  nor  ERP  (n=21  cells).  There  were  no  significant  interactions 
between these electrophysiological effects and diseases states or chronic pre operative drug 
therapy. 
 
Spontaneous  activity,  defined  as  a  depolarisation  occurring  during  phase  3  of  action 
potential repolarisation or a depolarisation of greater than 3 mV amplitude during phase 4, 
frequently interrupted action potential recordings during, but not prior to, superfusion with 
ISO.  Using  a  repetitive  stimulation  protocol,  ISO  at  0.05   M  produced  spontaneous 
depolarisations in 5 of 7 cells studied (P< 0.05, χ2 test). Endothelin 1 at 10 nM abolished 
these depolarisations in all 5 cells (P< 0.05). Superfusion with ET 1 (10 nM) alone was 
associated with spontaneous depolarisations in significantly fewer cells (P< 0.05, n=2 of 
13 cells). 
 
In a retrospective univariate analysis, patient comorbidity and pre operative drug therapy 
were not found to influence the electrophysiological effects observed. 
 
Conclusions: ET 1 reversed adrenergically induced increases in peak ICaL, APD50 and SDs 
in human atrial myocytes. This anti adrenergic effect may be expected to influence the 
occurrence of AF in patients irrespective of comorbidity or pre operative drug therapy.                     iv 
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1  GENERAL INTRODUCTION 
1.1  Atrial Fibrillation  the clinical problem 
 
Atrial Fibrillation (AF) is the most common sustained cardiac arrhythmia in humans 
and  epidemiological  studies  have  demonstrated  that  the  incidence  of  AF  is 
increasing
1.  Characterised  by  multiple  electrical  wavelets  spreading  chaotically 
throughout the atrium resulting in rapid irregular stimulation of the ventricles via 
the atrioventricular node (AVN), AF causes an irregular tachycardia. Ventricular 
contraction in AF is both irregular in frequency and force of contraction as a result 
of the Frank Starling mechanism
2. This may produce an unpleasant sensation of 
palpitation,  and  in  addition,  the    tachycardia,  if  prolonged,  results  in  atrial 
contractile  dysfunction,  a  pro thrombotic  state  predisposing  to  thrombo embolic 
disease and a reduction in cardiac output which can precipitate heart failure
3;4.  
Patients who develop AF suffer increased morbidity and an approximate doubling 
of  mortality  compared  with  aged matched  controls
5.  Treatment  has  traditionally 
aimed  at  either  terminating  the  arrhythmia  by  cardioverting  the  patient  back  to 
sinus rhythm, ‘rhythm control’, or slowing the ventricular rate in AF via drugs which 
increase  the  refractory  period  of  the  AVN,  ‘rate  control’.  Recent  evidence  has 
demonstrated that the increased morbidity and mortality in AF is maintained in 
both rhythm and rate control strategies due to the combination of anti arrhythmic 
drug  toxicity,  insufficient  anti coagulation  to  prevent  thromboembolism  and  the 
high relapse rate of AF
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1.2  Fundamental mechanisms of arrhythmogenesis in 
human atria 
 
The three fundamental mechanisms underpinning arrhythmogenesis are triggered 
activity, reentry and abnormal automaticity the occurrence of which is promoted by 
several  pathophysiological  remodelling  processes  (Figures  1.1 1.4).  In  order  to 
understand  any  potential  effects  on  human  atrial  arrhythmogenesis  a  brief 
description of the ionic flux during a normal human atrial action potential will be 
followed by a discussion of each of the three fundamental mechanisms in turn. 
 
Under normal circumstances the rapid upstroke of the human atrial myocyte action 
potential (phase 0), mediated by INa, occurs as an all or none response if the cell is 
depolarised to threshold ( 50 mV) by its neighbour from the resting potential of 
approximately  75 mV. This rapid upstroke reaches positive potentials (+40 to +60 
mV) and is immediately followed by transient repolarisation comprised of rapidly 
inactivating fast sodium current (INa) and activation of the repolarising  transient 
outward  and  ultra rapid  rectifying  potassium  currents  Ito  and  IKur  (phase  1)
9. 
Membrane depolarisation (above  40 mV to peak activation at +10 mV) activates 
L type calcium current (ICaL) which maintains the action potential plateau (phase 2) 
providing the electrochemical driving force for K
+ efflux, and as ICaL inactivates, the 
rapid and delayed rectifier repolarising currents IKur, IKr, IKs and IKATP predominate 
returning the membrane voltage back towards the resting potential (phase 3)
9. The 
atrial myocyte is relatively quiescent during phase 4, in readiness for subsequent 
stimulation (Figure 1.4). 
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Figure 1.1 Schema indicating the complex inter relationships between the fundamental mechanisms 
of  arrhythmogenesis,  human  atrial  electrophysiological  remodelling  and  atrial  pathophysiologies 
known to be associated with AF in humans. 
 
A            B 
 
 
 
 
Figure  1.2  Representations  of  A)  EADs  and  B)  DAD  in  human  atrial  myocytes  adapted  from 
Workman et al, Heart Rhythm 2008;5:S1 S6. Typical human atrial action potentials in bold with 
shaded lines indicating the impact of early or late depolarisations on action potential morphology and 
subsequent generation of triggered activity, indicated by star symbol. 
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Figure 1.3 Schema displaying the formation of a 2 dimensional reentrant circuit. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Schema displaying abnormal automaticity due to accelerated depolarisation of phase 4 of 
a stylised action potential. 
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1.2.1 Triggered Activity 
Triggered activity, by definition, are abnormal afterdepolarisations dependent on 
the  preceding  action  potential  for  their  generation  which,  if  reaching  threshold, 
trigger a subsequent action potential. These diastolic oscillations in the membrane 
potential are classified according to the phase of the preceding action potential 
during which they occur (Figure 1.2). 
 
Early depolarisations (EADs), which by definition disrupt repolarisation in phase 2 
or 3 of the action potential, are associated with prolongation of repolarisation and 
bradycardia  or  pause  dependent  mechanisms
10.  Delayed  afterdepolarisations 
(DADs), however,  which occur during phase 4 of the action potential are often 
associated  with  tachycardia.  In  the  presence  of  β   adrenergic  stimulation  both 
EADs and DADs may occur at physiological heart rates due to cellular calcium 
loading albeit by differing mechanisms
10;11. If an EAD is sufficiently large it can 
cause the cell to reach threshold and result in a new subsequent action potential 
manifesting as an ectopic beat on the surface electrocardiogram (ECG) or, as a 
result  of  electrotonic  interaction  with  surrounding  myocardial  cells  in  various 
stages  of  refractoriness,  can  result  in  initiation  of  a  reentrant  arrhythmia
12;13. 
Triggered activity has been almost exclusively studied in ventricular preparations, 
although occasional atrial experiments have been reported
14 16. 
 
EADs are associated with a reduction in rapid and slow activating delayed rectifier 
currents IKr and IKs combined with augmentation of ICaL and late INa which prolongs 
the APD sufficiently to allow ICaL to recover from inactivation and reactivate during 
the plateau of the action potential
10;11;17 20. EADs have consistently been induced 
by  stimulation  of  beta adrenoceptors  (β AR)  by  ISO
21;22  resulting  in 
aftercontractions
22;23. EADs were initially thought to be particular to the conducting Calum Jon Redpath    Chapter 1 6 
tissue or Purkinje network
24 but more recently have been demonstrated in atrial 
preparations although their clinical relevance remains to be determined
15;20;25. 
 
DADs are a result of spontaneous SR calcium release at the end of the action 
potential which activates the transient inward current (Iti) comprised primarily of the 
sodium calcium  exchange  current  (INaCa)  and  the  calcium  activated  chloride 
current  (ICa(Cl))  under  conditions  that  favour  cellular  calcium  overload
11;16;20;26 29. 
Under normal circumstances calcium entry via ICaL and reverse mode INaCa acts as 
the  trigger  for  calcium  induced  calcium  release  (CICR)  from  the  sarcoplasmic 
reticulum  (SR)  resulting  in  a  calcium  transient
30 33.  The  local  control  theory
34 
linking the close proximity of the ICaL pores with the ryanodine receptors of the SR 
in the dyadic cleft explains how calcium sparks can be graded and both temporally 
and spatially summated into global calcium transients depending on the magnitude 
of the whole cell ICaL, SR calcium content and ryanodine receptor status
35 43. The 
direction and magnitude of INaCa is dependent on the myocyte membrane potential 
and the local concentration gradients across the plasmalemma of Ca
2+ and Na
+ 
and the stoichiometry of the reverse mode INaCa results in a net inward current 
prolonging myocyte repolarisation and APD
44. 
 
Confocal  microscopy  has  demonstrated  differing  spatial  features  of  EADs  as 
compared with DADs
45, with greater homogeneity demonstrated following an EAD, 
as expected with membrane bound electrophysiological mechanisms, as opposed 
to  the  focal  spontaneous  SR  calcium  release  resulting  in  a  DAD,  although 
significant  overlap  may  exist
10;22;45 47.  Indeed  recent  evidence  has  identified  a 
potential role for INaCa in EAD formation both as conditioning agent and as charge 
carrier
10;11;17;48;49. 
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ET 1 was, at first, thought likely to predispose to EADs and DADs by reducing IK 
and  causing  increased  intracellular  calcium  loading
50  via  augmenting  ICaL.  The 
Pulmonary Vein sleeves, thought by many to be the predominant driver behind 
most AF
51, may be particularly prone to triggered arrhythmia
52;53. Although results 
from initial experiments investigating potential arrhythmogenic effects of ET 1 in 
cardiac  tissue  remain  difficult  to  interperet
54 60,  several  groups  reported  focal 
‘arrhythmia’ or spontaneous contractions following acute exposure to ET 1
56;61 64. 
The potential for ET 1 to have arrhythmogenic effects in human atrium remains to 
be determined. 
 
1.2.2 Intra atrial Reentry 
Intra atrial  reentry  occurs  when  a  depolarising  wavefront  being  propagated 
between atrial myocytes encounters an area of unidirectional block. If the aetiology 
of block is functional, should the wavefront travel in another direction and return to 
this refractory tissue when it is no longer refractory it will now conduct creating a 
circuit  (2  dimensional  circuit  represented  in  Figure  1.3).  Conduction  within  the 
circuit will be maintained if in the intervening period neighbouring myocytes have 
regained excitability. If the wavefront travels along the entire circuit (Conduction 
Time) sufficiently slowly (Conduction Velocity) that all points within the circuit (Path 
Length) recover from refractoriness the circuit may be maintained indefinitely. The 
wavelength is the product of refractory period and conduction velocity and as such 
it represents the distance traveled by an impulse in one refractory period. The 
wavelength  determines  the  shortest  circuit  that  may  accommodate  functional 
reentry.  Thus  any  factor  that  reduces  conduction  velocity  and  refractoriness  or 
increases path length or conduction time will promote reentry and ultimately AF. 
Decreased  INa  and  upstroke  velocity  (Vmax),  decreased  ICaL  or  increased  IK, Calum Jon Redpath    Chapter 1 8 
decreased action potential duration (APD) and effective refractory period (ERP), 
atrial dilation and stretch all promote reentry. 
 
Traditionally  considered  in  terms  of  the  “leading circle  model”,  as  illustrated  in 
Figure 1.3, recent developments in biophysical theory have suggested the utility of 
a “spiral wave model” of reentry
65;66. In cardiac tissue, a spiral wave of reentry can 
occur following an ectopic beat, howsoever generated, that initiates a depolarising 
wavefront which traverses the trajectory of a previous sinus beat and encounters 
tissue  in  various  stages  of  repolarisation.  This  second  wavefront  blocks  in 
refractory tissue, however is able to propagate across non refractory tissue, albeit 
tangentially  in  3 dimensions,  curving  towards  newly  excitable  myocytes
65.  The 
major  difference  between  the  leading circle  and  spiral  wave  models  of  reentry, 
other  than  level  of  complexity,  is  the  improved  correlation  of  the  impact  of  INa 
blockade on re entrant circuit characteristics predicted by the spiral wave model. 
 
1.2.3 Abnormal Automaticity 
Abnormal  automaticity  in  the  atrium  occurs  when  atrial  or  pulmonary  vein 
myocytes, which are not normally pacemaker cells, begin to spontaneously fire as 
a result of accelerated phase 4 depolarisation (See Figure 1.4). If the rate at which 
these cells reach threshold exceeds that of the sino atrial node (SAN), then an 
ectopic  rhythm  will  supervene.  This  form  of  regular  tachycardia  may  act  as  a 
trigger to atrial tissue that is vulnerable to reentry which may fractionate, or may 
result in fibrillatory conduction because the atrial myocardium is not capable of 
maintaining  1:1  conduction for  some  reason  (see below).  Although  the primary 
phase 4 depolarising current, If, is expressed in atrial tissue from patients suffering 
AF  and  in  porcine  CHF  models  no  direct  evidence  for  a  role  of  abnormal 
automaticity has been identified to date in human patients
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1.3  AF begets AF: electrophysiological remodelling 
It  has  long  been  established  that  the  longer  the  duration  of  AF  the  lower  the 
likeliehood  of  successful  cardioversion  and  subsequent  maintainance  of  sinus 
rhythm indicating that the arrhythmia itself is associated with changes which result 
in perpetuation of the arrhythmia
70;71. More recently in animal models using rapid 
atrial  pacing  to  induce  AF  and  in  observational  clinical  studies,  atrial 
electrophysiological  and  cellular  changes  have  been  shown  to  rapidly  occur 
favouring  the  arrhythmia  becoming  permanent
72 74.  The  electrical  changes, 
collectively  termed  electrophysiological  remodelling,  result  in  a  shortened  atrial 
action potential duration (APD) and an abbreviated atrial effective refractory period 
(ERP)
73. In addition the normal physiological rate adaptation of human atrial APD 
and  ERP  which  results  in  proportional  shortening  of  the  APD  and  ERP  with 
increasing heart rate is lost
73. Combined with decreases in conduction velocity
75 77 
and increased heterogeneity in atrial repolarisation
78 these AF induced changes in 
APD and ERP create a substrate for the multiple wavelet circuit re entry necessary 
to perpetuate AF.  
 
Isolated  human  atrial  myocyte  electrophysiology  experiments  corroborate  these 
changes in APD and ERP and indicate that the ionic mechanisms which underpin 
electrophysiological remodelling can be attributed, at least in part, to alterations in 
the L type calcium current (ICaL)
79;80. Reductions in human atrial myocyte peak ICaL 
current density have been associated with chronic atrial fibrillation in a number of 
studies
81 84  ranging  from  50%  (Christ),  63%  (Workman)  to  75%  (Skasa)  in  the 
presence  (Christ)  and  absence  (Workman)  of  a  change  in  current  voltage 
relationship
79  and  have  been  attributed  to  various  protein  expression 
downregulation  of  the  pore  forming  α 1c  subunit
85 87,  although  this  remains 
controversial
88;89.  More  recently  the  interaction  of  intracellular  kinases  and Calum Jon Redpath    Chapter 1 10 
phosphatases have been implicated
84;90 92. These observations only partly explain 
AF induced remodelling however. 
 
1.4  AF begets AF: cellular remodelling 
The multiple re entry circuits of AF produce very high frequency electrical activity 
in the atrium in vivo, typically up to 600 beats per minute
93. Rapidly increasing 
rates of electrical stimulation of human atrial myocytes in vitro are associated with 
large increases in calcium influx contributing to calcium overload
94. In chronic rapid 
atrial pacing models of AF, calcium overload has been implicated in alterations in 
atrial  myocyte  subcellular  apparatus;  sarcoplasmic  reticulum  disruption, 
mitochondrial swelling
74;95, dedifferentiation and hypertrophy resulting in apoptotic 
cell death
96. Similar ultrastructural changes have been described in human atrial 
myocytes from patients in AF
97. During the first few days of AF the time course of 
the  development  of  atrial  contractile  dysfunction  parallels  that  of  electrical 
remodelling
98,  suggesting  that  these  two  processes  share  similar  or  common 
mechanisms. However the offset kinetics are different in that although electrical 
remodelling reverses within days, atrial mechanical dysfunction persists for some 
weeks
99.  Down  regulation  of  synthesis  of  calcium  handling  and  ICaL  channel 
proteins have been reported
85;100 102 in response to calcium overload. The time 
course  of  mRNA  regulation  and  ultimately  expression  of  calcium  handling 
apparatus  is  in  the  order  of  3  months,  many  times  longer  than  that  of 
electrophysiological remodelling
100;102. Experimental evidence supports the pivotal 
role of ICaL in these maladaptive processes. The calcium channel blocking drug 
verapamil reduced both electrical remodelling and contractile dysfunction while, in 
contrast, calcium loading of the cell with the dihydropyridine agonist BAY 8644 had 
the  opposite  effect
103;104.  The  administration  of  intracellular  calcium  lowering Calum Jon Redpath    Chapter 1 11 
agents  to  patients  has  been  demonstrated  to  reduce  the  AF  recurrence  rate 
following successful DC cardioversion
105. 
 
1.5  Atrial Fibrillation and Chronic Heart Failure   
AF  does  occur  in  the  absence  of  structural  heart  disease,  however  it  is  more 
commonly  associated  with  cardiac  disease,  particularly  chronic  heart  failure 
(CHF). Observational studies have associated CHF with an approximate six fold 
increase in the development of AF, and AF is positively correlated with the severity 
of CHF
5;106. The incidence of AF and CHF doubles for every successive decade of 
age and is estimated to increase, in part, due to an ageing population
1;107 110. In 
patients with CHF the development of AF is associated with a further deterioration 
in morbidity and mortality
4. Atrial Fibrillation induced atrial contractile dysfunction 
combined  with  the  irregular  tachycardia  immediately  compromises  ventricular 
filling and if the tachycardia persists can lead to dilated cardiomyopathy
111. 
 
1.6  CHF induced atrial electrophysiological and 
structural remodelling 
 
Several possible contributing pathophysiological mechanisms link AF and CHF. 
Rapid  ventricular  pacing  induced  CHF  in  dogs  and  was  associated  with 
electrophysiological remodelling in atrial myocytes
112;113. These ventricular paced 
CHF induced reductions in atrial ICaL (~30%) are smaller than those reported in 
rapid atrial pacing induced ionic remodelling (~70%)
113. However in human atrial 
myocytes  from  patients  with  CHF  reductions  in  ICaL  (~80%)
114  are  similar  in 
magnitude to those associated with AF (~65%)
79;81. CHF causes elevated filling 
pressures resulting in haemodynamic stretch producing atrial dilatation which is 
also  associated  with  diminished  atrial  ICaL
115  and  the  development  of  AF
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Histological examination of atrial myocytes from patients with CHF demonstrated 
myocyte hypertrophy with evidence of local atrial conduction slowing, interstitial 
fibrosis  and  apoptosis,  creating  a  suitable  substrate  for  arrhythmia
117;118.  Such 
changes in the atria of animals with heart failure have been shown to be effective 
substrates  of  anisotropic  and/  or  very  slow  conduction  which  could  permit  the 
development  of  multiple  circuit  re entry  even  within  very  small  areas  of  the 
atrium
119.  These  results  demonstrate  that  the  electrophysiological  changes 
associated with AF/ rapid atrial pacing and CHF share the common mechanism of 
ICaL remodelling. 
 
1.7  CHF induced neurohormonal activation 
The  publication  of  a  large  number  of  negative  results  from  trials  examining 
haemodynamic interventions in heart failure stimulated investigation of alternative 
pathophysiological  mechanisms  in  CHF.  The  neurohormonal  hypothesis  of 
CHF
120;121 postulated that a number of neurohormones such as catecholamines, 
Angiotensin  II  (A II)
122  and  Endothelin 1
123;124  are  elevated  acutely  during 
myocardial embarrassment in order to preserve cardiac output and maintain vital 
organ perfusion. Initially beneficial, if the reduction in cardiac output is irreversible, 
as in CHF, the ensuing ventricular dysfunction produces persistent atrial stretch, 
baroreceptor  dysfunction,  excessive  adrenergic  activation,  neurohormonal 
activation
125 and a positive feedback cycle resulting in a progressive deterioration 
in cardiac function. The ability of the failing ventricle to respond to endogenous or 
exogenous  catecholamines  becomes  markedly  attenuated
126  and  a  new 
cardiovascular equilibrium is reached in which peripheral vasoconstriction and fluid 
overload supervenes. Perfusion of the other vital organs, most notably the kidney, 
is adversely affected resulting in yet further sympathetic activation until cardiac 
output is insufficient to maintain life.  Calum Jon Redpath    Chapter 1 13 
Elevation  in  the  serum  concentrations  of  catecholamines  and  endothelin 1  are 
positively correlated with deteriorating left ventricular systolic function, regardless 
of  aetiology
122;125;127  and  are  associated  with  poor  outcome  in  patients  with 
CHF
122;128;129.  In  patients  with  CHF,  elevated  serum  levels  of  the  endothelin 
precursor big ET 1 are independently predictive of the development of AF
130, and 
the onset of AF in these patients is associated with yet further elevation of serum 
levels  of  ET 1
131  and  a  poorer  prognosis
4.  Interruption  of  the  neurohormonal 
positive feedback cycle by beta blockers (β B)
132;133, formerly contraindicated in 
patients with CHF due to their adverse haemodynamic impact, are now of proven 
mortality  benefit  in  patients  with  CHF
134 137  and  thus  are  now  recommended 
therapy
138.  Atrial  Fibrillation  commonly  complicates  CHF,  indeed  often  causing 
haemodynamic  decompensation
1;139;140.  There  is  also  increasing  evidence  that 
beta blockers have a role in both 'rhythm control'
141 143 and 'rate control' treatment 
strategies  and  this  is  supported  by  mechanistic  evidence  for  an  adaptive  atrial 
cellular electrophysiological response to chronic beta blockade in patients termed 
‘pharmacological remodelling’
144. 
 
1.8  Endogenous and exogenous catecholamines 
The  endogenous  catecholamines,  dopamine,  norepinephrine  (NE)  and 
epinephrine (E) are sympathomimetic amines derived from L tyrosine which act as 
neurotransmitters throughout the nervous system in humans.  During periods of 
physiological  stress  the  adrenal  medulla  acts  as  a  neuroendocrine  transducer, 
transforming  efferent  impulses  from  the  pre ganglionic  sympathetic  fibres  into 
hormonal signals, releasing NE and E into the peripheral blood to mediate the 
“fight or flight” response. Under normal conditions the neurohormones E and NE 
are  both  detectable  in  low  concentration  in  peripheral  blood.  However  in  CHF 
patients the concentrations of catecholamines in peripheral blood are chronically Calum Jon Redpath    Chapter 1 14 
elevated  and  correlate  with  CHF  severity
122.  Catecholamines  acting  as 
neurohormonal first messengers bind to membrane bound alpha (α AR) and beta 
(β AR) adrenoceptors throughout the body. These two types of adrenoceptors can 
be differentiated by their sensitivity to agonists. α AR are most sensitive to NE; β 
AR are most sensitive to the synthetic sympathomimetic amine isoproterenol (ISO) 
and  the  response  to  epinephrine  is  intermediate.  Isoproterenol  is  the  isopropyl 
analogue of E and acts almost exclusively at β AR. β AR are further classified into 
two types, β1 AR and β2 AR, both of which are expressed on the sarcolemmae of 
human atrial myocytes in the ratio of (β1 AR 4:1 β2 AR)
145 and both employ cAMP 
as a second messenger
146.  
 
The binding of ISO with either of the β ARs produces conformational change in the 
cytosolic  membrane  bound  guanyl nucleotide  regulatory  protein  (G protein) 
complex
147.  In  human  atrial  myocytes  there  are  two  types  of  heterotrimeric  G 
proteins  associated  with  the  β AR:  Gs  and  Gi,  which  stimulate  and  inhibit 
adenylylcyclase catalysing the formation of cyclic AMP (cAMP) from adenosine 
triphosphate (ATP), respectively. This enzyme cascade is further extended by the 
action  of  cAMP  to  activate  protein  kinase  A  (PKA),  which  phosphorylates 
intracellular  effector  proteins  and  this  is  counter balanced  by  cellular 
phosphatases and phosphodiesterases (PDE) which degrade cAMP. 
 
1.9  The positive inotropic effect of Isoproterenol  
The force frequency relationship is similar in human atrium and ventricle, however, 
important  differences  in  atrial  microarchitecture
148  and  intracellular  calcium 
processing exist
149;150. In isolated strips of human ventricle selective stimulation of 
β2 AR results in at most 50% of the maximal positive inotropic effect
151, whereas 
selective stimulation of β2 AR in human atrial myocardium results in a maximal Calum Jon Redpath    Chapter 1 15 
inotropic  response
152.  Isoproterenol  acting  via  both  β1 AR  and  β2 AR  has  a 
positive inotropic effect
153, maximal in micromolar concentrations, mediated by the 
cAMP second messenger system
146;154. ISO induces an increase in intracellular 
calcium, both cytosolic via phosphorylation of ICaL
155 and within the sarcoplasmic 
reticulum (SR) via PKA dependent phosphorylation of phospholamban
156.  
 
This  ISO induced  positive  inotropic  effect  can  be  modified  by  a  range  of 
physiological,  pathophysiological  and  therapeutic  processes.  Increased 
senescence was associated with impaired responsiveness to ISO in the absence 
of altered receptor expression and a combination of reduced catalytic activity of 
adenylate  cyclase  and  increased  Gi  in  human  atria
157  in  contrast  to  human 
ventricular  myocytes  in  which  reduced  β1 AR  and  Gs  expression  were 
demonstrated
158.  In  atrial  tissue  obtained  from  patients  with  CHF  the  maximal 
positive  inotropic  effect  of  ISO  was  preserved  despite  reduced  levels  of  beta 
adrenoceptors expression
158;159 in contrast to human ventricular papillary muscle 
in  which  the  positive  inotropic  effect  of  ISO  was  blunted  in  association  with 
reduced  beta  adrenoceptor  expression
159.  The  positive  inotropic  effect  of 
catecholamines is greater in atrial tissue obtained from patients receiving selective 
β1 AR antagonists
152 despite a lack of effect on β2 AR density or affinity,  due to 
enhanced β2 AR Gs protein coupling
160. 
 
1.10 The effect of ISO on ICaL and action potentials 
Influx of calcium ions via ICaL depolarises the atrial myocyte contributing to the 
action potential plateau
161 and stimulates calcium dependent calcium release from 
the sarcoplasmic reticulum thereby permitting excitation:contraction coupling
162. A 
wide  number  of hormones and  second messengers  acting  via  the  cAMP/  PKA 
pathway  can  phosphorylate  the  calcium  channel  and  thus  modulate  inward Calum Jon Redpath    Chapter 1 16 
calcium  current.  At  physiological  temperature  ICaL  is  larger  with  more  rapid 
activation and inactivation
161 than at room temperature
155. ISO, on binding to β 
AR, activates Gs protein adenylylcyclase and via temperature dependent enzyme 
cascades culminates in the phosphorylation of dihydropyridine sensitive calcium 
channels  resulting  in  increased  ICaL
90;147;161.  No  changes  in  ICaL  single  channel 
conductance, reversal potential, or the numbers of channels available have been 
observed in response to β AR stimulation with ISO
90. In human atrial myocytes 
ISO at 1 M almost doubled ICaL current density and resulted in an elevation in the 
action potential plateau
161. Relatively little is known regarding the effects of ISO on 
APD and ERP in human atrial myocytes, and there have been no reports in the 
literature of the impact of pre cardiac surgery β B therapy or heart failure on the 
effects of ISO on ICaL, APD and ERP with respect to arrhythmogenesis. 
 
1.11 The pro arrhythmic effects of ISO 
Increased adrenergic stimulation alone or in combination with increased rates of 
electrical  stimulation  causes  an  increase  in  the  frequency  and  amplitude  of 
diastolic calcium sparks
162. If the SR calcium load is sufficiently enhanced, waves 
of  calcium induced calcium release  propagate  in  cardiac  myocytes,  activating 
pacemaker  currents  and  stimulating  delayed  afterdepolarisations  and  triggered 
arrhythmia
162.  Increased  cytosolic  calcium  concentration  accelerates  ICaL 
inactivation
161;163  which  predisposes  to  early  afterdepolarisations.  In  addition  to 
effects  on  calcium  handling  in  human  atria,  ISO  has  effects  on  outward 
repolarising  currents.  ISO  reversibly  increased,  in  a  concentration  dependent 
manner, the delayed rectifier potassium currents IK
164 and the ultrarapid delayed 
rectifier  potassium  current  Ikur
165.  Furthermore  ISO  increased  the  pacemaker 
current  (If)  amplitude,  shifting  the  voltage  of  activation  towards  more  positive 
values in human atrial cells
166 which in combination would increase the probability Calum Jon Redpath    Chapter 1 17 
of delayed afterdepolarisations and predispose to re entry in human atrium. The 
ability  of  catecholamines  to  induce  afterdepolarisations  in  human  ventricle  and 
animal  atrium  is  well  recognised
167.  However  despite  the  many  reports  of  the 
effects of ISO on isolated currents in human atrium, the pro arrhythmic effects of 
isoproterenol to induce afterdepolarisations in isolated human atrial myocytes has 
not been previously demonstrated. 
 
1.12 Endothelin 1  
Endothelin 1  is  a  relatively  short  21  amino acid  peptide  first  isolated  from  the 
cultured  supernatant  of  porcine  aortic  endothelial  cells,  unrelated  to  previously 
identified  vasoconstrictor  peptides
168.  The  first  and  most  abundant  of  the  three 
endogenous isoforms to be identified, mature ET 1, is generated by the action of 
endothelin  converting  enzyme  (ECE)  on  big  ET 1  which  has  previously  been 
cleaved  from  intrinsic  or  circulating  preproET 1,  a  200  amino  acid  polypeptide. 
Endothelin 1 has been demonstrated to have vasoconstrictive effects in several 
vascular beds in numerous mammalian species including humans
168 171 and has a 
multitude  of  other  effects;  stimulating  the  release  of  NO  and  prostacyclin  from 
vascular endothelial cells
172, stimulating proliferation in smooth muscle cells
173 and 
myocardial  cell  hypertrophy
174,  in  addition  to    positively  inotropic
175 178  and 
lusitropic
179 effects in human atrial myocytes. Endothelin 1 binds with two distinct 
endothelin receptor subtypes, ET A which has a greater affinity for ET 1
180 and ET 
B
181 which has almost equal affinity for all three endothelins (ET 1, ET 2 & ET 3). 
Both  endothelin  receptor  subtypes,  ET A  and  ET B,  are  seven  transmembrane 
domain spanning, Gq protein coupled receptors (GPCR) that are widely expressed 
throughout  the  normal  and  diseased  human  heart
182 184.  In  human  right  atrial 
specimens  the  endothelin  receptor  subtype  expression  ratio  ET A:  ET B  was 
approximately 2:1
184. In patients with CHF, levels of ET 1 are elevated
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from failing  hearts  ECE  mRNA  was  upregulated  and  ET 1  peptide  levels  were 
increased, while ET A mRNA was unaltered and ET B mRNA was downregulated 
in failing hearts
185. The human atrial endothelin system is also altered in AF
131. 
The  amount  of  ET A  and  ET B  receptor  proteins  were  significantly  reduced  in 
patients with AF, as was ET B mRNA when compared with tissue from patients in 
sinus rhythm
186. In human right atrial myocytes ET 1, via ET A receptors, inhibits 
adenylate cyclase via Gi protein and also activates protein kinase C (PKC) via Gq 
protein  coupled  phospholipase  C  (PLC)
184;187.  This  is  in  contrast  to  human 
ventricular myocytes in which ET A receptors are not coupled to Gi inhibition of 
adenylate cyclase
188. In human right atrial strips, ET 1 in concentration dependent 
manner  from  0.1  nMol  to  1   Mol,  increased  inositol  tri phosphate  (IP3) 
accumulation but had no effect on cAMP under basal conditions
187.  
 
1.13 The positive inotropic effect of endothelin 1 
An  endothelin  system  has  been  described  in  human  atrial  and  ventricular 
myocardium
185;189.  Evidence for  an autocrine  or  paracrine  effect  of  ET 1  in  the 
human heart is growing
56;57;190. In human cardiac tissue nanoMolar concentrations 
of ET 1 had a greater positive inotropic effect via ET A receptors in right atrial than 
in  ventricular  preparations
175;188;191.  The  positive  inotropic  effect  of  ET 1  is 
maintained
191 or enhanced
188 in atrial tissue from failing compared to non failing 
hearts.  The  positive  inotropic  effect  of  ET 1  results  from  an  ET A  mediated 
activation of PKC increasing intracellular calcium concentrations and an increased 
myofilament sensitivity to calcium via PKC activated increases in Na/H exchanger 
activity
177;178;188;191 194.  Initially  it  was  speculated  that  the  increased  cytosolic 
calcium concentration required to create the positive inotropic effect of ET 1 was 
due to an ET 1 induced increase in ICaL. However, subsequently it has been shown 
that ET 1 can produce a positive inotropic effect in the absence of an increase in Calum Jon Redpath    Chapter 1 19 
ICaL
195 197.  In  rat  atrium  ET 1  had  a  powerful  positive  inotropic  effect  raising 
intracellular calcium concentration by 50% in the presence of the ICaL blocker PN 
200 110
197.  ET 1,  although  positively  inotropic,  was  significantly  less  positively 
inotropic than ISO
193 in human right atrial tissue. The positive inotropic effect of 
ET 1 but not ISO was abolished when PKC or Na/ H exchange was inhibited
177. 
ET 1 did not activate adenylate cyclase and therefore appears to have a positive 
inotropic effect independent of cAMP. Thus the positive inotropic effect of ET 1 is 
mediated differently to that of ISO and potentially independent of ICaL in human 
atrial tissue.  
 
1.14 The effect of ET 1 on ICaL and action potentials 
A direct effect of ET 1 on inward calcium current was suggested in the original 
paper isolating ET 1 as, in porcine coronary artery, the vasoconstrictor effect of 
ET 1  was  inhibited  in  the  absence  of  extracellular  calcium  ions  and  in  the 
presence of Nicardipine, a selective dihydropyridine calcium channel blocker
168. 
Endothelin 1 at 10 nM had no effect on the affinity or density of dihydropyridine 
binding  sites  and  at  100  nM  failed  to  displace  bound  radio labelled  calcium 
channel agonists in rat cardiac membranes suggesting that ET 1 does not interact 
with the dihydropyridine calcium channel at the level of the membrane receptor
198. 
The effect of ET 1 on human atrial ICaL is controversial. In two studies, at room 
temperature  employing  the  ruptured  patch  method,  ET 1  has  been  found  to 
increase
199,  decrease
199;200  and  have  no  effect
199  on  human  atrial  ICaL.  The 
stimulatory effect of ET 1, where detected, was antagonised by the ET A receptor 
antagonist  BQ 123  and  the  inhibitory  effect  of  ET 1  antagonised  by  the  ET B 
receptor antagonist BQ 788
199. However the ET A receptor antagonist BQ 123 can 
directly modulate ICaL in animal experiments
201. It is recognised that temperature 
affects ICaL and that results from ruptured patch experiments can be difficult to Calum Jon Redpath    Chapter 1 20 
interpret  because  of  a  lack  of  reversibility  of  effect  and  'rundown'  of  ICaL.  The 
perforated  patch  technique  permits  a  more  physiological  intracellular  milieu, 
prolonging  the  ability  of  the  cell  to  respond  to  neurohormones  and  avoiding 
disruption of the normal intracellular calcium buffering mechanisms
202. Previously 
apparent controversy in the literature relating to results from animal experiments 
were resolved by utilisation of the perforated patch technique demonstrating that 
ET 1 alone under more physiological recording conditions did not modulate basal 
ICaL
203. The absence of any effect of ET 1 on basal ICaL is supported by the lack of 
effect of ET 1 on cAMP under basal conditions in human atrium
187;203.  
 
1.15 The proarrhythmic effect of ET 1 
In human cardiac myocytes ET 1 was found to induce arrhythmic contractions in 
right atrial trabeculae, and those occurred more frequently in tissues excised from 
patients receiving, when compared with those not receiving, β B preoperatively
191. 
In one small study, ET 1 had no appreciable effect on action potentials in human 
atrial trabeculae despite the positive inotropic effect remaining intact
176. However 
the separation of a vasoconstriction induced ischaemic arrhythmic effect from an 
intrinsic  effect  on  arrhythmogenesis  remains  controversial
59;204.  Yorikane
61  first 
demonstrated that ET 1 causes APD prolongation in the right bundle branch of 
canine  myocardial  tissue  and  that  this  APD  prolongation  is  followed  by  early 
afterdepolarisations, suggesting a direct arrhythmogenic effect of ET 1 on cardiac 
cells. The direct arrhythmogenic effect of ET 1 has not been studied in human 
atrial myocytes. 
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1.16 The interaction of ISO and ET 1 on ICaL and action 
potentials 
 
In contrast to the differing effects observed of ET 1 alone on basal ICaL in both 
previous studies in isolated human atrial myocytes, ET 1 (10 nM) had a consistent 
ET A  receptor  mediated,  pertussis  toxin  sensitive,  anti adrenergic  effect  to 
decrease  ICaL  following  pre stimulation  of  ICaL  with  ISO
199;200.  This  effect  was 
irreversible  and  no  data  are  available  to  determine  whether  the  effect  of  ET 1 
could be overcome with increasing concentrations of ISO. ET 1, via ET A receptors 
has been shown to have an anti adrenergic effect on other currents in human atrial 
myocytes. The cAMP activated chloride current (ICl, cAMP) which is controversial as 
it can only be demonstrated under conditions of adrenergic stimulation in some 
atrial myocyte preparations, was activated with 1 M ISO and subsequently was 
significantly inhibited by ET 1 (30 nM) by 75%± 6%
205. This anti adrenergic effect 
of ET 1 could be explained by the effect of nanoMolar concentrations of ET 1 to 
decrease ISO/ forskolin induced increases in cAMP in human right atrial strips. 
There have been no previous reports examining the interaction of effects of ISO 
and ET 1 on APD and ERP in human atrial myocytes, and there have been no 
reports in the literature of the impact of 'pharmacological remodelling' nor CHF on 
the interaction of effects of ISO and ET 1 on ICaL, APD and ERP. 
 
1.17 The potential mechanisms for ISO and ET 1 to affect 
arrhythmogenesis in human atrial myocytes 
 
Atrial  Fibrillation  has  been  described  as  multiple  re entrant  waves  conducted 
chaotically throughout the atria. Electrical heterogeneity in the atria, whether due 
to ischaemia, structural heart disease or heart failure is central to the phenomenon 
of  re entry.  Re entrant  waves  are  formed  when  electrically  coupled  tissue  has Calum Jon Redpath    Chapter 1 22 
differing properties of refractoriness or structural discontinuities produce lines of 
unidirectional  conduction  block.  When  a  wavefront  meets  refractory  tissue  the 
direction of the impulse changes traversing around these refractory areas of tissue 
and  thus  may  either  be  extinguished  if  the  tissue  encountered  is  completely 
refractory or electrically inert, or propagating daughter wavelets  and yet further 
fibrillatory waves resulting in arrhythmia perpetuation. 
 
Cardiac  arrhythmogenesis,  however,  requires  a  trigger  to  initiate  an  electrical 
impulse in addition to a substrate of conducting tissue capable of maintaining the 
arrhythmia. More recently, at the level of the whole heart in vivo, the trigger for AF 
has  been  identified  in  patients  as  originating  in  the  pulmonary  veins
51.  At  the 
cellular level, triggered activity such as early afterdepolarisations (EAD), which are 
secondary  depolarisations  occurring  prior  to  full  repolarisation  of  the  action 
potential,  or  delayed  afterdepolarisations  (DAD),  initiated  after  myocyte 
repolarisation  is  complete,  can  result  in  impulse  propagation  and  formation  of 
wavelets capable of being conducted throughout the atria and thus compete with 
the sinus node for non refractory atrial myocytes. 
 
Prolongation  of  the  APD  has  been  implicated  in  the  generation  of  EADs
206.  A 
number of mechanisms have been demonstrated to contribute to this prolongation  
a  reduction  in  repolarising  K
+  currents  resulting  in  more  slowly  inactivating 
INa
207;208.  Also  small  calcium  transients  may  result  in  complete  ICaL  inactivation 
increasing the likeliehood of inward ICaL reactivation in the AP and thus EADs
11;209. 
 
Abnormalities in calcium handling have a pivotal role in the generation of DADs. 
Activation  of  β adrenoceptors  augments  ICaL  and  increases  SR  calcium  uptake 
resulting  in  intracellular  calcium  overload  which  in  turn  increases  calcium 
dependent calcium release  from  the  SR  activating  arrhythmogenic  transient Calum Jon Redpath    Chapter 1 23 
inward  current  Iti
210;211.  Atrial  myocyte  calcium  loading  is  further  potentiated  in 
heart  failure  due  to  tachycardia  and  increased  ‘reversed’  sodium calcium 
exchange  current  (INCX)  combined  with  decreased  IK1,  thus  for  any  given  SR 
calcium  release  more  INCX  will  result  in  more  calcium  activated  Iti  and  hence 
DADs
162;210. Indeed for a given Iti a greater DAD will result, as a reduced IK1 results 
in a less stable Em
210. Thus in heart failure approximately 50% of the normal SR 
calcium  release  is  required  to  initiate  a  DAD  of  sufficient  magnitude  to  reach 
threshold  and  trigger  an  action  potential  which  may  be  propagated  into  an 
arrhythmia
162. 
 
1.18 Hypothesis 
It is my hypothesis that endothelin 1 modulates the effects of isoproterenol on ICaL 
and consequently action potentials in human atrial myocytes. Such modification 
may  occur  at  the  level  of  the  ligand receptor  complex  or  via  interaction  of 
secondary  messenger  systems.  Any  such  modification  of  ICaL  by  endothelin 1, 
whether  alone  or  in  combination  with  isoproterenol  will  have  implications  for 
arrhythmogenesis in the human atrium. 2 25 
2  METHODS 
2.1   Ethical Approval 
 
Ethical  approval  was  obtained  from  the  Ethics  Committee  of  Glasgow  Royal 
Infirmary  for  the  use  of  human  atrial  tissue  for  electrophysiology  studies  from 
consenting patients undergoing cardiac surgery. This investigation conformed with 
the principles established in the Declaration of Helsinki 
212. Patients were identified 
from the cardiac surgery theatre schedule and their consent to participate was 
obtained.  
 
2.2  Patient Characteristics 
 
Clinical characteristics of all patients from whom samples of right atrial appendage 
were obtained were recorded in a database (Microsoft Access). Information was 
obtained from the clinical case sheets relating to age, gender, operative procedure 
and comorbidity. Data retrieval was complete in more than 97% of instances. In a 
small number of cases incomplete data was collected due to non availability of 
complete  records.  This  thesis  is  based  on  all  available  information  in  order  to 
maximise  utility,  thus  small  variabilities  in  sample  size  will  be  presented.  Pre 
operative drug therapy was assessed from prescription charts. Patients who had 
been  receiving  beta adrenoceptor  blocking  drugs  for  less  than  30  days  pre 
operatively  were  excluded  from  further  analysis.  None  of  the  patients  had 
undergone  previous  cardiac  surgery,  ablation  procedures  or  were  prescribed 
Amiodarone or Sotalol preoperatively.  
 
Information  on  cardiac  rhythm  and  rate  was  assessed  using  the  pre operative 
ECG. Only those patients in sinus rhythm with no documented episodes of atrial Calum Jon Redpath    Chapter 2 26 
fibrillation  in  the  preceding  6  months  prior  to  surgery  were  included. 
Postoperatively, case records were later re examined for evidence of AF up to 
seven days postoperatively. 
 
2.3  Cell Isolation 
 
 
The  tip  of  the  right  atrial  appendage  was  removed  at  the  time  of  cardiac 
cannulation  for  aortopulmonary  bypass.  The  tissue  sample  was  immediately 
transported to the laboratory, within five minutes of excision, immersed in 50 ml 
oxygenated  warmed  modified  Tyrode's  solution  (NaCl  150  mM,  KCl  5.4  mM, 
MgCl2 1.2 mM, NaHEPES 5 mM, glucose 10 mM, CaCl2 1 mM; titrated to pH 7.4 
with  HCl  1M  solution).  Atrial  cells  were  isolated  by  enzymatic  dissociation  and 
disaggregation using a modified 'chunk' method first described by Escande
213 and 
subsequently modified by Harding
158 and Workman
79. 
 
Excised tissue was blotted dry and weighed (mass 0.386 ±0.03 g n= 63) then 
placed on a glass slide, cleaned of visible connective tissue and fat and chopped 
with scalpels into ~1 mm
3 chunks. These chunks were then transferred to a beaker 
which was placed into a water bath maintained at 37°C, shaken at 130 strokes per 
minute and continuously oxygenated in 40 ml nominally Ca free solution 'B' (NaCl 
120 mM, KCl 5.4 mM, MgSO4 5 mM, pyruvate 5 mM, glucose 20 mM, taurine 20 
mM, NaHEPES 10 mM, nitrilotriacetic acid 5 mM and titrated to pH 7.0 with NaOH 
1 M solution). The 'chunks' were hand filtered through nylon gauze (200  m mesh, 
Barr & Wray, Lanark, UK) and transferred to another beaker containing a fresh 
sample  of  40  ml  oxygenated  solution  ‘B’  at  three  minute  intervals  in  order  to 
prevent  hypoxia  and  remove  any  toxic  metabolites.  After  a  total of  12 minutes 
agitation  the  sample  was  transferred  to  another  beaker  containing  15  ml  of Calum Jon Redpath    Chapter 2 27 
solution ‘C’ (NaCl 120 mM, KCl 5.4 mM, MgSO4 5 mM, pyruvate 5 mM, glucose 20 
mM, taurine 20 mM, NaHEPES 10 mM, nitrilotriacetic acid 5 mM, CaCl2 50  M 
and titrated to pH 7.0 with NaOH 1M solution) with protease (Type XXIV, Sigma, 4 
IU/ml)  added  and  were  incubated  under  identical  conditions  for  a  further  45 
minutes. 
 
This semi digested sample was then placed in another 12 ml of modified solution 
‘C’ with collagenase (CLS 1 Type 1, Worthington 330 IU/ml) added in the absence 
of protease and incubated for consecutive periods of 15, 15 and 20 minutes. Each 
of  these  three  cell  suspensions  were  filtered  through  nylon  gauze,  as  before. 
These  three  “filtrates”  formed  three  consecutive  aliquots  which  were  then 
centrifuged  (Model  PK110,  A.L.C.  International)  for  two  minutes  at  40  g.  The 
resulting  supernatant  was  aspirated  by  hand  and  discarded  and  the  remaining 
cells were re suspended for a maximum of 10 minutes in 1 ml of Kraftbrühe (KB) 
solution
214  (KOH  70  mM,  KCl  40nM,  L glutamic  acid  50  mM,  taurine  20  mM, 
KH2PO4 20 mM, MgCl2 3 mM, glucose 10 mM, NaHEPES 10 mM, EGTA 0.5 mM 
and  titrated  to  a  pH  of  7.2  with  1M  KOH  solution)  in  order  to  wash  off  any 
remaining enzymes. 
 
The centrifugation process was then repeated and after removing as much of the 
KB  solution  as  possible  the  cells  were  re suspended  in  1  ml  of a  low  calcium 
solution (NaCl 130 mM, KCl 4 mM, CaCl2 0.2 mM, MgCl2 1 mM, NaHEPES 10 
mM, glucose 10 mM and titrated to a pH of 7.4 with 1M NaOH solution). Each of 
the  three  aliquots  was  transferred  to  a  separate  petri dish  for  storage  at  room 
temperature prior to use in experiments. Cells were examined under high power 
(x40)  light  microscopy  (Nikon  TMS  microscope)  and  cells  which  were  isolated, 
striated,  elongated,  straight edged  and  stable  in  the  perfusion  chamber  were 
selected for electrophysiological recordings (Photograph 1 Figure 2.1). Calum Jon Redpath    Chapter 2 28 
2.4  Electrical Recording Techniques 
 
2.4.1 Patch clamp recording 
The extracellular patch clamp method, first described by Neher and Sakmann
215, 
permits  the  observation  and  recording  of  ionic  currents  from  biological 
membranes.  This  technique  employs  a  small  highly  polished  glass  pipette 
containing a predetermined specific ‘internal’ solution surrounding a silver filament 
electrode  attached  to  an  amplifier  and  recording  equipment.  The  pipette  was 
advanced  into  the  external  solution  containing  the  cell  to  be  examined  under 
positive  pressure  to  prevent  contamination.  The  tip of  the pipette  was  pressed 
gently against the cell membrane in order to form an electrical seal. The electrical 
resistance of the pipette membrane seal obtained by this technique was increased 
from  50  M 
215  to  approximately  100  G ,  using  micro pipettes  of  smaller  tip 
diameter and the application of negative pressure to the cell membrane as contact 
was achieved as advised by Hamill et al
216. The advantage of a pipette membrane 
seal of greater resistance, termed a giga seal, is that background electrical noise 
or interference is reduced, less current ‘leaks’ around the pipette into the perfusion 
chamber  reducing  inaccuracy  of  measurements  and  the  mechanical  stability  is 
improved.  
 
However, this ‘standard’ ruptured patch whole cell recording technique, also called 
the continuous single electrode voltage clamp (cSEVC), has been shown to suffer 
two  major  drawbacks  when  investigating  ICaL.  The  cell  membrane  is  physically 
disrupted,  or  intentionally  ruptured,  using  negative  pressure  permitting  washout 
and  disruption  of  intracellular  calcium  buffering  mechanisms  resulting  in  rapid 
rundown of ICaL magnitude, alteration of the I: R relationship and desensitisation to 
adrenergic  receptor  activated  second  messengers
202;217 219.  This  problem  was 
overcome by adding the polyene antibiotic, nystatin, to the internal solution (see Calum Jon Redpath    Chapter 2 29 
below) in the pipette. Nystatin containing pipette solutions have previously been 
demonstrated to form voltage independent, highly selective monovalent cationic 
pores  of  0.4  nM  diameter  in  cell  membranes  without  compromising  the  cell’s 
integrity
202, increasing the signal to noise ratio,  preventing ICaL rundown
220;221 and 
maintaining  sensitivity  to  isoproterenol  for  up  to  90  minutes  recording
221.  The 
combination of a high seal resistance around the pipette with the small 0.4 nM 
pores within the pipette permit only monovalent ions and substances up to 200 D 
molecular weight to dialyse with the internal pipette solution, establishing stable 
electrical access with preservation of the normal intracellular cytoplasm. Nystatin 
itself does not enter the cell nor does it cross the glass membrane seal, however it 
is  not  without  its  disadvantages.  Nystatin  solution  loses  its  pore forming  ability 
within  4  hours  at  room  temperature  requiring  fresh  stock  solutions  during  an 
experimental  day.  This  becomes  obvious  by  the  inability  to  obtain  satisfactory 
series  resistance  within  approximately  20  minutes.  Successful  pore  formation 
precludes  any  manipulation  of  the  intracellular  constituents  of  the  cell  under 
investigation  via  the  patch  pipette,  limiting  opportunities  for  experimentation.  In 
addition  the  formation  of  junction  potentials  and  subsequent  intracellular 
hypertonicity  during  long  experimental  protocols  can  occur
202.  This  can  be 
minimised by ionic substitution in the internal pipette solution, use of electrodes of 
low resistance and effective delivery of sufficient nystatin to the tip of the pipette to 
ensure excellent seal and low series resistance
202. 
 
Thus the nystatin perforated whole cell patch clamp technique
202 was employed 
both to limit ICaL rundown
221 and also preserve the internal milieu of the myocyte
202 
during  experimental  protocols.  In  order  to  limit  vibration  artefact  cells  were 
permitted  to  sediment  in  the  perfusion  bath  (RC 24E  fast  exchange  perfusion 
chamber, Warner instruments) (Figure 2.1) positioned on an air suspension table Calum Jon Redpath    Chapter 2 30 
(Wentworth  laboratories)  (Figure  2.2)  coupled  with  an  Axopatch 1D  amplifier 
(Axon instruments) (Figure 2.3). 
 
2.4.2 Micropipette electrodes 
Fine  borosilicate  glass  pipette  microelectrodes  (Clark  Electromedical)  were 
constructed by hand during cell sedimentation using a vertical micropipette puller 
(Narishige PP 83) using a two stage thinning process and then heat polished to 
resistances (Rp) of 2 5 M  (mean Rp= 2.7 ±0.1 M  n= 148). First the capillary was 
loaded onto the micropipette puller and thinned at high power increasing capillary 
length by approximately 8 to 10 mm. Then the thinned capillary was re centred at 
the heating element and low power heating used until the capillary split into two 
identical pipettes. Each of these pipettes was then loaded in turn onto the heat 
polisher under direct visualization via light microscopy. The tip of the pipette was 
manoeuvred  close  to  the  glowing  filament  for  a  few  seconds  causing  a  subtle 
change in shape and a darkening of the silhouette. Pipettes with resistances in the 
range of 2  5 M  have an internal opening diameter of ≤1  m
216. The optimal 
shape  of  the  micropipette  is  depicted  in  Figure  2.4A.  The  Rp  associated  most 
frequently with successful electrical access to the atrial myocyte was found to be 2 
M  as depicted in Figure 2.4B.  
 
The electrode was formed from a silver wire which was polished to ensure a clean 
surface prior to being coated by silver chloride (Ag/AgCl) by anodising in a solution 
of sodium hypochlorite (NaOCl) prior to loading on the head stage (Figure 2.3). 
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2.4.3 Solutions  Internal 
Micropipettes  were  back filled  with  a  caesium  based  ‘internal’  solution  (Cs 
methanesulphonic  acid  100  mM,  NaCl  5  mM,  CsCl  30  mM,  MgCl2  1  mM, 
NaHEPES 5 mM, pH 7.4 with 1 M CsOH) in order to block K
+ currents during 
voltage clamp experiments recording ICaL. For action potential recordings with the 
amplifier in current clamp mode micropipettes were back filled with a potassium 
based internal solution (K methanesulphonic acid 100 mM, NaCl 5 mM, KCl 30 
mM, MgCl2 1 mM, NaHEPES 5 mM, pH 7.4 with 1 M CsOH). Nystatin (Sigma 184 
 M) was dissolved in DMSO (Sigma 120  L) and added to fresh internal pipette 
solution at hourly intervals in order to maintain the selective pore forming ability of 
the Nystatin solution
202. 
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Figure  2.1  Schemata  of  the  perfusion  chamber  apparatus  with  a  photograph  of  human  atrial 
myocyte (not to scale) 
 
 
2.4.4 Solutions  External 
Cells were superfused in the sedimentation chamber with a physiological ‘external’ 
salt solution (NaCl 130 mM, KCl 4 mM, CaCl2 2 mM, MgCl2 1 mM, NaHEPES 10 
mM,  glucose  10  mM,  titrated  to  pH  7.4  with  a  1  M  NaOH)  at  1.5  ml/  min 
maintained  at  37ºC  via  an  in line  heater  (SH27 B,  Warner  instruments)  as 
determined  by  a  digital  thermometer  (Model  410,  Rapid  electronics).  Reagents 
were stored in lightproof sealed containers in a commercial refridgerator as per the 
manufacturers’ recommendations. On the morning of the experiment pre specified 
amounts of reagent were weighed and dissolved in de ionised water which had 
been micro pipetted to the required volume. Reagent solutions were then diluted 
to the desired concentration using de ionised water and stored in lightproof sealed  
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Figure 2.2. Schemata representing electrophysiology recording rig with photographic image. 
1   Micromanipulators 
2   Microscope 
3   In line heater 
4   Solution reservoirs 1 5 
5   Thermometer 
6   Head stage 
7   Micropipette 
8   Air table 
9   Light source 
10 Salt bridge 
11 Signal out to Digidata 
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Figure 2.3 Schemata representing digital recording equipment. 
1 Digidata Interface 
2 Oscilloscope 
3 Axopatch 1 D amplifier 
4 Microcomputer and VDU 
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Figure 2.4 Schemata of Micropipette manufacture and frequency distribution of pipette resistance 
(Rp) 
A Schemata to scale of longitudinal and end on appearances of optimal micropipette 
B Frequency distribution of pipette resistance (Rp) associated with successful electrical access to the 
cell (Mean Rp of successful seal formation 2.7 ±0.1 M  n= 148 pipettes). 
0                                  20 
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containers attached to the perfusion chamber for the duration of the experiment at 
room temperature. During superfusion the in line heater ensured that the ambient 
temperature within the perfusion chamber was maintained at 37
oC (as above). 
 
2.4.5 Liquid Junction Potentials 
 
Using this configuration of solutions with the earth electrode maintained in a 3M 
KCl  bath  connected  via  an  agar  salt  bridge  to  the  perfusion  chamber  a  liquid 
junction potential (LJP) of +5 mV (±0.1 mV n=5) was measured (bath relative to 
pipette) using the method described by Neher
222 as follows. The patch clamp rig 
was prepared as above with both the micropipette and perfusion chamber filled 
with  internal  solution.  The  Axopatch  amplifier  was  switched  to  current clamp 
mode, held at 0 pA, and the offset voltage nulled manually. The perfusion chamber 
was then evacuated and refilled with external solution. The voltage reading was 
permitted to stabilise and this solution specific LJP was recorded in the lab book. 
This recorded liquid junction potential was compared with other work performed in 
this laboratory
79;223 and found to correlate well. This method of calculating the LJP 
permits  a  priori  compensation,  prior  to  seal  formation,  of  the  LJP  by WinWCP 
software  by  inserting  a  junction  potential  correction  of  equal  size  but  opposite 
polarity, however it mandates that the 3M KCl solution in which the salt bridge is 
bathed is refilled at frequent intervals during the experimental process. 
 
2.4.6 Myocyte selection 
 
The perfusion chamber was thoroughly examined with the microscope, initially on 
low power, to determine the most suitable myocyte for patch clamp recordings. 
Myocytes were selected as suitable for recordings if positioned in the perfusion 
chamber within reach of the pipette and if they remained geographically stable. Calum Jon Redpath    Chapter 2 37 
Cells  which  remained  isolated,  elongated,  and  striated  under  high  power 
microscopy during superfusion with control solution containing 2 mM calcium (a 10 
fold increase from the low calcium storage solution) were selected. Myocytes were 
approached obliquely under light microscopy maintaining slight positive pressure 
in the pipette in order to avoid surface contaminants increasing the resistance of 
the  microelectrode  and  consequently  inhibiting  seal  formation.  The  pipette  was 
advanced  to  within  micrometres  of  the  sarcolemma  using  a  micromanipulator 
(Narishige NW 3) under gentle positive pressure per orum via a small rubber tube 
with two O rings attached to the micropipette mounting and then when optimally 
positioned vis a vis the myocyte gentle negative pressure was applied to attach 
the tip of the pipette to the cell membrane until a gigaohm seal was obtained. The 
giga seal was not lost on any occasion when the negative pressure on the pipette 
was released prior to electrical compensation. 
 
2.4.7 Series Resistance (Rs) and Capacitance (C) Compensation 
 
When the membrane potential was manipulated, there was a significant current 
transient  required  to  charge  the  membrane  capacitance  during  which  it  is 
impossible to record meaningful data. The settings of the whole cell capacitance 
controls  to  eliminate  this  capacitative  transient  are  unique  to  the  cell  being 
clamped. The values of the cell membrane capacitance and the access resistance 
can be directly read from the Axopatch amplifier controls. The absolute value of 
the membrane capacitance was displayed on the whole cell capacitance dial after 
the whole cell current transient has been eliminated. This value may be used to 
estimate the surface area of the cell assuming that the membrane capacitance per 
unit area is 1  F/cm
2. Capacitance compensation was used to reduce the effective 
value of any remaining capacitance error. The Axopatch amplifier injected ‘extra’ 
current into a capacitor connected to the input. At the ideal setting of the amplifier Calum Jon Redpath    Chapter 2 38 
gain, the current injected is exactly equal to the current that passes through the 
stray capacitance to ground hence eliminating error. However, this compensation 
must be implemented cautiously for if the amplifier gain is increased beyond the 
ideal  setting,  the  current  injected back  will  cause  the  input  signal  to  overshoot 
resulting in circuit oscillation and mycocyte death. 
 
When electrical access to the cell was gained the internal pipette solution formed 
an electrical continuity with the interior of the myocyte. However, this continuity 
was imperfect and there remained a small electrical resistance across the pipette 
of the order 1 10 M . This resistance is termed the series resistance Rs and is 
electronically  compensated  in  a  positive  feedback  loop  by  increasing  the 
command potential proportional to the potential drop across the pipette. The Rs 
must  be  minimised  as  it  introduces  both  a  voltage  error  and  also  lowers  the 
temporal  resolution  of  the  voltage  clamp.  In  the  steady  state,  the  amplifier  will 
clamp the potential across the pipette while one is aiming to clamp the potential 
across  the  cell  membrane  resulting  in  an  error  which  can  be  minimised  by 
maintaining as small a Rs as possible. During depolarisation, rapid step changes 
(see  below)  in  potential  initiated  by  command  from  the  amplifier  will  produce 
changes in cellular Vm with a time lag potentially of milliseconds duration. In order 
to overcome this problem the patch clamp amplifier continuously computes the 
potential drop across the pipette and injects a correction signal to the command, 
effectively reducing the error by a factor of (1  correction factor) thus Rs of 80% 
correction results in an 80% reduction in voltage error and an 80% reduction in 
time lag. Caution must be exercised, however, as compensation was increased 
the stability of the electrical circuit decreased and oscillations occurred resulting in 
myocyte death above 80% Rs compensation. 
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The Series Resistance (Rs) (mean Rs= 7.2± 0.2 M  n= 255 cells from 67 patients) 
and Capacitance (C) (mean C= 82.9± 0.8 pF n= 255 cells from 67 patients) of 
these selected myocytes were measured and electronically compensated (mean 
Rs% compensation = 68.2± 0.2% n= 161) following the formation of the perforated 
patch and prior to recording. 
 
Cells  were  rejected  if,  after  stabilisation,  the  Rs was  >20  M    due  to  potential 
voltage  errors  in  recording  accuracy  within  the  Axopatch  1D  amplifier.  The 
software programme utilised, WinWCP (J. Dempster, Strathclyde University) on a 
microcomputer  (Gateway  microcomputers  with  Pentium  III  microprocessor) 
permitted simultaneous stimulation and recording. Current and voltage data were 
low passed filtered at 5 kHz and digitised at a rate of 15 kHz (Digidata 1200 A D 
converter, Axon instruments) prior to storage on compact discs. 
 
2.4.8 Resting Membrane Potential (Vm) 
 
Following  Rs  and  C  compensation  the  cell  was  permitted  approximately  60 
seconds quiescence following which the resting membrane potential under control 
conditions  (Vm)  was  recorded  in  current  clamp  mode.  This  was  performed  by 
nulling  the  voltage  clamp  and  recording  the  potential  difference  across  the 
myocyte membrane prior to recording ICaL or action potentials. The mean Vm for all 
cells was  19± 4 mV (n= 81 cells from 23 patients). 
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2.5  Experimental Protocols 
 
2.5.1 Voltage Clamp: ICaL current: voltage relationship 
 
During voltage clamp experiments the membrane voltage of the myocyte under 
investigation is held constant and the trans membrane current required to maintain 
that  voltage  across  the  cell  membrane  is  measured.  This  artificial  process,  if 
performed carefully, eliminates the capacitive current bar the immediate voltage 
step and permits control of activation and inactivation of voltage dependent ICaL. 
The  resultant  recorded  current  is  directly  proportional  to  the  membrane 
conductance of ICaL. 
 
Once a giga seal was obtained and electrically stable access to the cell achieved 
the cells were voltage clamped at a holding potential (HP) of  40 mV. This was 
chosen  in  order  to  avoid  contamination  of  ICaL  by  rapid  and  large  inward  Na
+ 
currents which might be present at more negative potentials. The current voltage 
(IV) relationship of ICaL was determined using repeated stepwise incremental +10 
mV depolarising pulse steps of 350 ms duration every 3 seconds from the holding 
potential  of   40 mV up  to  a  maximum of  +60 mV  at  physiological  temperature 
(37°C)  (See  Figure  2.5).  This  physiological  temperature  was  chosen  as  it  has 
previously  been  shown  that  ICaL  has  temperature  dependent  time  course  of 
activation and inactivation
161. Previous work examining ICaL has demonstrated that 
a depolarising stimulus frequency of 0.33 Hz permits full recovery of ICaL prior to 
the next depolarising pulse
94. 
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2.5.2 Voltage Clamp: peak ICaL time course effects 
Experiments examining the time course of the effects of both ISO and ET 1 were 
performed using a  40mV Holding Potential with repeated identical voltage steps 
from a HP of  40 mV to +10 mV of 350 ms duration at a fixed frequency of 0.2 Hz 
while  the  perfusion  chamber  was  maintained  at  37°C  (Figure  2.6).  This  step 
potential was chosen as the previously obtained ICaL IV relationship peaked at +10 
mV  which  is  consistent  with  other  reports  in  the  literature  using  similar 
experimental conditions 
79;161. 
 
2.5.3 Current Clamp: action potential recordings 
During a current clamp experiment a constant or pre specified time varying current 
is  applied  to  the  myocyte  and  the  resultant  change  in  membrane  potential  is 
measured. Technically more challenging than voltage clamping in the laboratory, 
current clamping recreates the response of a myocyte to electrical stimulation or 
depolarisation in vivo, that is, the generation of action potentials. 
 
Myocytes  in  the  resting  state  were  current  clamped  to   80±  5  mV  and 
subsequently  the  holding  current  was  maintained  <150  pA  thereafter.  Action 
potentials were stimulated at 75 beats per minute (bpm) using 5 ms current pulses 
of  120%  threshold  strength.  The  stimulus  threshold  was  initially  determined  by 
repetitively stimulating the cell with a train of three 5 ms current pulses, the first 
and second stimuli being of equal supra threshold amplitude and the third pulse of 
lesser amplitude increasing in 50 pA increments from 0 pA until a regenerative 
action potential was stimulated. Calum Jon Redpath    Chapter 2 42 
 
 
 
 
 
 
 
Figure 2.5 Diagram of the protocol for determining the current voltage relationship of ICaL. 
 
 
 
 
 
 
 
 
 
Figure 2.6 Diagram of the protocol for determining the time course of effects on peak ICaL. 
 
This threshold was then increased by a factor of 1.2 and this ‘supra threshold’ 
stimulus  was  maintained  constant  throughout  the  experiment  in  that  cell  (See 
Figure  2.7).  The  entire  train  of  stimulated  action  potentials  was  visible  on  the 
oscilloscope, however, in order to maximize resolution, only the final two S1 action 
potentials and the S2 action potential were recorded. The APD was calculated as 
the interval between the action potential upstroke and repolarisation to the level of 
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50% (APD50) and 90% (APD90) of the upstroke amplitude (See Chapter 5 Methods 
section).  
 
2.5.4 Current Clamp: Measurement of the effective refractory 
period (ERP) 
 
The ERP of each cell was determined using a standard S1 S2 protocol consisting 
of an 8 pulse conditioning train of 5 ms pulses at 75 bpm (S1) followed by one 
pulse of equal magnitude and duration which was delivered at 10 ms progressively 
shorter  intervals  (S2)  (See  Figure  2.7).  The  cellular  ERP  was  defined  as  the 
shortest S1 S2 interval which elicited a regenerative action potential of amplitude 
greater than 80% of the preceding S1 action potential.  
  
2.5.5 Current Clamp: Spontaneous depolarisations 
During  ERP  experiments  it  was  noted  on  the  oscilloscope  that  following 
superfusion with 0.05  M ISO a number of cells became electrically unstable. On 
inspection of this phenomenon it appeared that during the train of S1 stimuli the 
appearance  of  'spontaneous  depolarisations'  preceded  electrical  instability.  The 
ERP protocol was modified to a repetitive protocol ('REP') in which the final S2 
stimulus was replaced with another S1 stimulus and the entire train was recorded 
(See Figure 2.7). 
2.6  Data Analysis and Statistics 
 
 
WinWCP raw data records were analysed visually and an absolute value of ICaL for 
every record was obtained by subtraction of the steady state current at the end of 
the depolarising step from the peak inward current. The magnitude of peak ICaL 
absolute current (pA) was corrected for cell capacitance (pF) and the consequent Calum Jon Redpath    Chapter 2 44 
ICaL  current  density  (pA/pF)  was  used  to  control  for  variation  in  cell  size.  This 
current density value measured in WinWCP was recorded and stored in Microsoft 
Excel and transferred into the data records of Graphpad Prism software. Mean 
data pertaining to individual myocyte recordings in WinWCP traces were obtained 
using this Prizm software and related mean data graphs constructed. 
 
Myocytes,  wherever  possible,  acted  as  their  own  control.  Sample  size  was 
primarily  determined  by  number  of  myocytes,  however  the  number  of  human 
subjects required to provide samples of right atrial appendage from which these 
cells were isolated was also recorded. Data relating to ICaL were expressed as 
mean± standard error of the mean (s.e.m.) with nc= number of cells studied and 
np= number of patients from whom these cells were obtained. The mean values 
were  compared  using  a  two tailed  paired  or  unpaired  Student’s  t test  as 
appropriate. A Chi squared (χ
2) test was used to assess the level of significance of 
differences in the incidence of events between groups. Statistical significance was 
predetermined at a level of P< 0.05 throughout. Calum Jon Redpath    Chapter 2 45 
 
A   APD & ERP protocol 
 
 
 
 
 
B  REP protocol 
 
Figure 2.7 Diagrammatical representations of the current clamp protocols. 
A Schemata of the protocol used to record Action Potentials and the Effective Refractory Period. 
B Schemata of the protocol used to record Action Potentials and Spontaneous Depolarisations. 
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3  RESULTS (i) 
L type calcium current recordings 
3.1  Introduction and aims 
 
L type calcium current (ICaL) is the large, voltage and time dependant, long lasting 
inward current, by convention designated with a negative polarity, which enters 
atrial myocytes during the plateau phase of the action potential. L type calcium 
channels  are  heterotrimeric  proteins  which  span  the  plasmalemma  and  are 
activated by the voltage changes occurring during the initial depolarisation phase 
of the action potential under physiological conditions. In human atrial myocytes the 
inward calcium current contributes to the plateau phase of the action potential and 
this calcium entry triggers calcium induced calcium release from the sarcoplasmic 
reticulum  resulting  in  myofilament  contraction
158;162.  Numerous  roles  have  been 
attributed  to  ICaL  in  the  human  cardiovascular  system  and  this  current  is  of 
particular  interest  because  of  its  role  in  excitation contraction  coupling  and 
arrhythmogenesis
224;40;162;163. 
 
Although extensively studied in human ventricular myocardium fewer studies have 
sought to characterise this current in human atrium and the majority of those have 
investigated  current  characteristics  at  room  temperature.  Modification  of  the 
function  or  density  of  human  atrial  ICaL  has  been  associated  with  chronic  drug 
therapy
94;114;155 and disease states
113;115;158 and these altered electrophysiological 
characteristics have been postulated to be both protective against and contributing 
factors in altered contractile function and arrhythmogenesis
162.  
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Human atrial ICaL has been described by a small number of groups who have used 
the  ruptured  patch  clamp  technique  either  at  room
114;155;163;225  or  physiological 
temperature
79;144;161;223, and although broadly similar results have been reported 
important differences in current characteristics have emerged
161. 
 
The effects of adrenoceptor agonism by ISO in human right atrium both in vivo
226 
and  in  vitro
146;227 233  have  long  been  recognised  as  a  potential  mechanism  for 
investigation of human ion current characteristics
234, indeed many early reports 
describe  augmenting  inward  calcium  current  in  order  to  reproducibly  identify 
calcium  currents
155;235.  The  increase  in  ICaL  inward  current  flow  due  to  β AR 
stimulation is accepted to be due to an increase in the probability of a calcium 
channel being open as a result in an increase in the fraction of calcium channels 
available to open during depolarisation in the absence of increased single channel 
conductance, altered reversal potential or the total number of channels per unit 
membrane
236 239. In contrast, the stimulatory effect of catecholamines on ICaL at 
physiological  temperature  with  the  perforated  patch 
technique
92;114;155;161;163;199;224;240 has not previously been studied and differences 
in temperature and recording techniques have previously been shown to alter ion 
current characteristics considerably
161. 
 
Endothelin,  a  21  amino acid  peptide,  was  first  discovered  in  1988  as  a  potent 
vasoconstrictor in the supernatant of cultured porcine aortic endothelial cells
168. 
Acting  in  concert  with  other  neurohormones,  such  as  Angiotensin  II  (A II)  and 
adrenergic stimulation, ET 1 released either in an autocrine or paracrine manner, 
has  direct  and  indirect  effects  on  inotropy
241 243,  chronotropy
241 243,  myocyte 
hypertrophy
244 and ICaL
245 249.  
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Initial experiments with intra aortic endothelin infusions resulted in a concentration 
dependent reduction in coronary perfusion and thereafter induced a concentration 
dependent negative chronotropic and inotropic effect on Langendorff mounted rat 
hearts. The threshold effect of ET 1 was in the nanoMolar range but even with 
nanoMolar  concentrations,  experimental  models  have  struggled  to  divorce  the 
electrophysiological  effects  of  ischaemia  resulting  from  ET 1  induced  coronary 
vasoconstriction from any direct intrinsic inotropic effect
250. 
  
It  has  long  been  noted  that  plasma  endothelin  levels  are  elevated  in 
CHF
123;125;128;132;251;252  and  correlate  with  poor  functional  status  and 
prognosis
123;125;128;129;251;253;254. Circulating levels of ET 1 in plasma from patients 
with CHF can be as high as 10 pg/ml
253;255 and have been demonstrated to be 
similar in right and left atria
256. In human patients with CHF circulating plasma ET 
1 concentrations correlate with right atrial pressure and decrease in response to 
BB  therapy
132  occasionally  returning  to  normal  levels  if  treatment  renders  the 
patient asymptomatic
123;125;252;254;257. Whether elevated circulating levels in plasma 
or  local  concentrations  of  ET 1  are  primarily  important  in  determining  the 
physiological  effects  of  ET 1  remains  open  to  debate.  Intuitively,  as  ET 1  is 
thought  to  act  in  an  autocrine  or  paracrine  matter,  local  concentrations  are 
deterministic. The time course of neurohormonal activation in patients with CHF is 
not known.  
 
Endothelin 1 has been shown in animal models to be both pro and anti arrhythmic 
depending  on  the  physiological  setting  and  animal  model  under  investigation. 
Initial  reports  described  stimulatory
196;248;258;259,  inhibitory
195;196;248;260 263  or  no 
effect
203;247;249;264 of ET 1 on ICaL, with an EC50 between 1 and 10 nM, mediated via 
ET A receptors in animal models
195;196;203;248;249;258 264. In addition to the possible 
effects on calcium current, activation of the Sodium Hydrogen exchange current Calum Jon Redpath    Chapter 3 49 
(NHE)
265 and Sodium Calcium Exchange current (NCX)
266 268 via PKC, inhibition of 
K
+ outward currents
62;269 272 and ICl via inhibition of PKA/ adenylate cyclase
273 have 
been described.  
 
Despite  promising  results  from  trials  of  long  term  ET A  receptor  blockade  in 
animals
274;275,  results  of  trials  in  human  patients  with  CHF  have  been 
disappointing
276  indeed  two  larger  studies  identified  an  unexpected  increase  in 
atrial
277 and ventricular
278 arrhythmia prior to early termination.  
 
CHF  is  associated  with  systemic  circulating  elevated  ET 1  levels,  although  the 
local levels in the human atria during CHF are not known. ET 1 is reported to have 
potential  direct  and  indirect  electrophysiological  actions  but  further  study  is 
required. CHF is also associated with progressive cellular and electrophysiological 
remodelling  that  predisposes  to  AF.  We  sought  to  identify  the  acute 
electrophysiological effects of ET 1 on human atrial myocyte ICaL and, later, action 
potentials  to  determine  whether  this  could  in  part  explain  CHF  induced 
electrophysiological remodelling. 
 
The aims of these experiments were as follows: 
•  To determine the range of concentrations of ISO which would reproducibly 
augment  ICaL  under  the  recording  conditions  being  used  and  define  the 
concentration: response relationship. 
•  To  select  a  concentration  of  ISO  approximate  to  the  EC50  which  would 
reliably ‘pre stimulate’ peak ICaL resulting in a sufficiently stable peak current 
to permit interpretation of any subsequent effect(s) of ET 1 or its analogues 
on peak ICaL. Calum Jon Redpath    Chapter 3 50 
•  To  assess  the  impact  of  the  nystatin perforated  as  compared  to  the 
nystatin ruptured  patch  technique  of  electrical  access  on  the  stimulatory 
effect of ISO on ICaL. 
•  To  investigate  whether  patient  senescence,  chronic  preoperative  drug 
therapy  or  pre existent  comorbidity  were  associated  with  an  altered 
adrenergic stimulatory effect of ISO on ICaL. 
•  To investigate the effect(s), if any, of ET 1 on ICaL and to determine the ET 
1 receptor(s) subtypes involved in mediating any ET 1 effect on ICaL. 
•  To investigate the effect(s) on ICaL of ET 1 and ISO in combination. 
 
3.2 Methods 
The nystatin perforated whole cell patch clamp technique was used to record ICaL 
as described in detail in Methods section 2.4. Data were obtained with the patch 
clamp amplifier in voltage clamp mode using a Caesium based ‘internal’ solution in 
order to block K
+ currents. 
 
Following examination of the ICaL traces obtained in the early experiments it was 
apparent  that  stable  recordings  obtained  with  a  sufficiently  good  seal  were 
associated with a greater inward current than ‘leak’ tail current. The ratio of leak 
tail  current  to  peak  inward  current  was  assessed  first  subjectively  and  then 
calculated objectively and if this ‘leak to peak’ ratio (LtP ratio) was greater than 1 
the cell was excluded as shown in Figure 3.1A. 
 
Figure 3.1B illustrates an acceptable recording of ICaL under control conditions. 
Following a voltage step of 350 msec duration at 0.2 Hz from the holding potential 
 40 mV to +10 mV, while the cell and the superfusate are maintained at 37°C, a 
rapid and reproducible increase in inward calcium current occurred which reached Calum Jon Redpath    Chapter 3 51 
a maximum in less than 5 ms and which appeared to decay in a bi exponential 
fashion. Subtraction of the steady state current at the end of the depolarising step 
from the peak inward current permitted estimation of the absolute magnitude of 
ICaL  for  any  given  record.  Recordings  from  cells  were  excluded  from  further 
analysis if this LtP ratio was ≤ 1, such as that depicted in Figure 3.1A. 
 
In early experiments electrical artefact and rapid ICaL rundown in addition to ‘leak to 
peak’ ratio suggested a time cut off of March 2002, approximately two months 
(eight  experiments)  into  the  project.  This  date  was  selected  as,  in  retrospect, 
stable recordings associated with a ‘leak to peak ratio’ of less than 1 were in the 
minority until that date and is taken to reflect the author’s ‘learning curve’. 
 
Cells were not immediately excluded, pending subsequent analyses, if electrical 
access to the cell was formed abruptly, i.e. ruptured, as opposed to perforated, 
patch  clamping  (Figure  3.2).  Cells  in  which  the  Rs  dropped  so  rapidly  as  to 
preclude  simultaneous  Rs  compensation  (Figure  3.2A)  were  designated  as 
Nystatin Ruptured (NR) cells and comprised 29% of the total myocyte recordings. 
A comparison between the time courses of ruptured and perforated seals can be 
seen in Figure 3.2. The mean time course of the drop in series resistance (Rs) 
during the formation of perforations in all cells is depicted in Figure 3.3. 
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Figure 3.1 Variability of ICaL recordings: demonstration of leak to peak exclusion criterion. 
A  peak  ICaL  current  trace from  human  atrial  myocyte  depolarised  for  350  msec  from a  holding 
potential of  40 mV to +10 mV at physiological temperature using the nystatin perforated patch clamp 
method demonstrating a peak ICaL which when corrected for leak current is less than or equal to 1.  
B ICaL current trace obtained using identical methodology exhibiting leak to peak ratio greater than 1 
and hence excluded from further analysis. 
 
Leak to Peak ratio = peak current (pA) 
                leak current (pA) 
 
200 pA 
10 ms 
peak 
peak 
leak 
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Figure 3.2 Representative examples of the time course of electrical access to the cell.  
A Nystatin ruptured patch (NR), in 29% of myocytes there was no drop in Rs prior to electrical 
access (n= 74 cells from 39 patients). 
B Nystatin perforated patch (NP), in 71% of myocytes Rs compensation was constantly adjusted 
during pore formation prior to electrical access (n= 181 cells from 60 patients). 
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Figure 3.3 The mean time course of the formation of nystatin perforated patch electrical access to 
atrial myocytes as indicated by the falling electrical resistance (Rs) with time mean ± s.e.m. (n= 165 
cells from 55 patients). 
 
3.3  Protocols 
Recordings of ICaL were made using both the stepwise voltage pulse protocol to 
determine the current:voltage (IV) relationship and the repetitive time course peak 
ICaL  protocol  as  described  in  Methods  section  2.4.1..    Figure  3.1B  illustrates  a 
typical recording of ICaL under control conditions using the stepwise voltage pulse 
protocol.  Following  a  voltage  step  from  the  holding  potential  ( 40  mV)  in 
incremental +10 mV depolarising pulses of 350 ms duration at 0.2 Hz, the cell and 
the superfusate were maintained at 37°C, a rapid and reproducible increase in 
inward calcium current occurred which reached a maximum in less than 5 ms and 
which appeared to decay in a bi exponential fashion (Figure 3.1B) consistent with 
previous reports of human atrial ICaL
161. 
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3.4  Statistics & data analysis 
Data were recorded and analysed off line as described in Methods section 2.5.1.. 
Subtraction of the steady state current at the end of the depolarising step from the 
peak inward current permitted estimation of the absolute magnitude of ICaL for any 
given record. In order to assess the effect of ISO and ET 1 on the time constants 
of  ICaL  inactivation  the  WCP  traces  were  scaled  and  transposed  into  pCLAMP 
version 10 software Clampfit data analysis tables (Axon Instruments). 
 
In  order  to  determine  the  most  appropriate  statistical  tests  to  employ,  the 
distribution of values of peak ICaL was assessed. As can be seen from Figure 3.4 
the distribution of the direct observations of ICaL current density was not Gaussian, 
with  a  leftward  skew.  However  after  logarithmic  transformation  of  ICaL  current 
density  the  data  did  have  a  normal  distribution  and,  therefore,  the  unpaired 
Student’s t test was employed to determine the degree of difference between sub 
analysed samples of ICaL under control conditions. This test was selected as it is 
the  most  valid  test  with  which  to  assess  the  probability  of  a  similar  or  more 
extreme result being arrived at by chance in samples of small size. This precedent 
has been set in other published work examining the electrophysiology of human 
atrial myocytes
79;144;161;223. Where a comparison between two differing populations 
of data are presented the variance of the two groups has been assessed to permit 
the use of the unpaired Student’s t test, and if paired data are being compared the 
distribution of the variable being assessed was recorded and the paired Students’ t 
test was employed. This report is based on all available information in order to 
maximise utility. In a small number of cases incomplete data was collected from 
patient records, comprising <3% data points, resulting in small variability in sample 
size depending on analysis undertaken. Calum Jon Redpath    Chapter 3 56 
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Figure 3.4 Frequency distribution graphs of peak ICaL (n= 176 cells from 49 patients). 
A Observed peak ICaL current density under control conditions 
B Logarithmic transformation of the magnitude of peak ICaL current density under control conditions. 
 
 
B 
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3.5 Results 
3.5.1 Patients’  clinical  characteristics  and  methodological 
considerations 
 
Clinical characteristics of all patients from whom samples of right atrial appendage 
were obtained are illustrated in Table 3.1. Post operative Atrial Fibrillation (AFpcs) 
occurred in 19 of 65 patients (29%) within 7 days. None of the patients’ clinical 
characteristics  were  significantly  associated,  by  univariate  analysis,  with  the 
development of AFpcs and the data is presented in Table 3.2. 
 
Cells  from  patients  who  were  receiving  ACE inhibitor  (ACE I)  therapy  pre 
operatively were associated with a significantly greater Rs, 7.66± 0.36 M  (n= 114 
cells from 32 patients, mean± s.e.m.) as compared with those from patients who 
were not receiving ACE I therapy, 6.73± 0.28 M  (n=130 cells from 33 patients, 
mean±  s.e.m.,  p<  0.05).  There  were  no  other  significant  associations  between 
patients’ clinical characteristics and Rs C nor Vm demonstrated. 
 
While there were no significant univariate associations between patients’ clinical 
characteristics  and  mode  of  electrical  access  (Table  3.3),  it  can  be  seen  from 
Figure 3.5 that fewer periods of enzymatic incubation of cells and greater myocyte 
capacitance  are  associated  with  successful  perforated  patch  recordings  in  the 
absence of any significant effect on Vm (NR myocytes 75.3± 2.6 pF n=74 cells 
from  39  patients  v.  NP  myocytes  86.4±  2.3  pF  n=181  cells  from  63  patients, 
mean± s.e.m., p< 0.05, Figure 3.5). 
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        Table 3.1 Patients’ clinical characteristics. 
    np  % 
Male  52  80 
Age (years)  63.9± 1.2   
Female  13  20 
Patient demographics 
Age (years)  67.3± 2.2   
Beta Blocker  48  72 
Calcium Channel Blocker  21  32 
Drug Therapy 
ACE  Inhibitor  32  49 
CABG  58  89 
AVR  6  9 
Operative Procedure 
CABG & AVR  1  2 
None (Normal)  32  50 
Mild   12  19 
Moderate  16  25 
LVSD 
Severe  4  6 
Hypertension  37  58  Comorbidity 
Previous MI  33  51 Calum Jon Redpath    Chapter 3 59 
 
    Post op AF 
yes 
np (%) 
Post op AF 
no 
np (%) 
Male  13 (25)  39 (75) 
Female  6 (46)  7 (54) 
Age <75 (years)  14 (25)  42 (75) 
Age ≥75 (years)  5 (56)  4 (44) 
Pre op HR <60 (bpm)  10 (33)  20 (67) 
Patient 
demographics 
Pre op HR ≥60 (bpm)  8 (24)  26 (76) 
Beta Blocker  13 (28)  34 (72) 
No Beta Blocker  7 (39)  11 (61) 
Calcium Channel Blocker  5 (24)  16 (76) 
No CCB  14 (32)  30 (68) 
ACE  Inhibitor  8 (25)  24 (75) 
Drug Therapy 
No ACE  Inhibitor  11 (33)  22 (67) 
CABG  15 (26)  43 (74)  Operative 
Procedure  AVR  3 (50)  3 (50) 
Mild or None  12 (27)  32 (73) 
Moderate or Severe  6 (30)  14 (70) 
Ischaemic LVSD  6 (30)  14 (70) 
LVSD 
Non ischaemic LVSD  3 (30)  7 (70) 
Hypertension  11 (30)  26 (70) 
No Hypertension  8 (30)  19 (70) 
Previous MI  9 (27)  24 (73) 
Comorbidity 
No Previous MI  10 (31)  22 (69) 
Table 3.2 Patients’ clinical characteristics and univariate analysis for post op AF. 
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    Ruptured 
Patch 
nc (%) 
Perforated 
Patch 
nc (%) 
Male  53 (29)  130 (71) 
Female  20 (33)  41 (67) 
Age <75 (years)  65 (30)  150 (70) 
Patient 
demographics 
Age ≥75 (years)  9 (23)  31 (77) 
Beta Blocker  59 (33)  122 (67) 
No Beta Blocker  15 (20)  59 (80) 
Calcium Channel Blocker  22 (28)  57 (72) 
No CCB  51 (31)  114 (69) 
ACE  Inhibitor  28 (25)  86 (75) 
Drug Therapy 
No ACE  Inhibitor  45 (35)  85 (65) 
CABG  67 (32)  145 (68)  Operative 
Procedure 
AVR  4 (15)  23 (85) 
Mild or None  53 (32)  111 (68) 
Moderate or Severe  20 (25)  60 (75) 
Ischaemic LVSD  18 (21)  68 (79) 
LVSD 
Non ischaemic LVSD  15 (34)  29 (66) 
Hypertension  43 (31)  96 (69) 
No Hypertension  27 (27)  74 (73) 
Previous MI  30 (25)  92 (75) 
Comorbidity 
No Previous MI  43 (35)  79 (65) 
Table 3.3 Patients’ clinical characteristics and univariate analysis for mode of electrical access. Calum Jon Redpath    Chapter 3 61 
Perforated patch recordings (NP) were associated with larger series resistance Rs 
than those obtained with ruptured patch (NR 5.35± 0.28 M  n=74 cells from 39 
patients v. NP pipettes 7.97± 0.26 M  n=181 cells from 63 patients, mean± s.e.m., 
p< 0.05, Figure 3.5). 
 
Consistent with previous reports
202;221;223 nystatin perforations formed consistently 
over a period of thirty minutes, indeed in this study more rapidly than ruptured 
patch seals (time to NR access 768± 67 s n=39 cells from 24 patients v. NP 473± 
25 s n=143 cells from 55 patients, mean± s.e.m., p< 0.05, Figure 3.6). Perforated 
patch  recordings  were  associated  with  more  stable  ICaL  recordings  of  longer 
duration as compared to ruptured patch recordings (NR ICaL duration 458± 46 s 
n=48 cells from 26 patients v. NP 657± 39 s n=103 cells from 40 patients, mean± 
s.e.m., p< 0.05, Figure 3.6). 
 
3.5.2 ICaL kinetics 
 
The ICaL activation time was 4.1± 0.12 ms under control conditions (n= 7 cells from 
7 patients). The ICaL inactivation data were confirmed to fit a bi exponential relation 
with mean time constants of tauf (rapid phase time constant) = 11.8± 2.1 ms, taus 
(slow phase time constant)= 57.2± 5.7 ms n= 7 cells from 7 patients (Figures 3.7 
and 3.8). Calum Jon Redpath    Chapter 3 62 
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Figure 3.5 The possible interactions between methodology and cellular characteristics on mode of 
seal formation. ￿ = ruptured patch nystatin present in pipette (NR)  ￿ =  perforated patch nystatin 
present in pipette (NP) Values are mean± s.e.m..  
A Effect of increasing 10 minute periods of enzymatic incubation on the mechanism of electrical 
access to the cell. (NR n= 74 cells from 39 patients, NP n= 174 cells from 60 patients) p< 0.05. χ2 
test for incidence of NP access in cells from incubation 2 rather than incubation 1 or 3 p<0.05.  
B Lack of effect of pipette resistance on mode of seal formation. (NR n= 49 cells from 25 patients, 
NP n= 50 cells from 28 patients).  
C Effect of mode of seal formation on steady state series resistance. (NR n= 74 cells from 39 
patients, NP n= 181 cells from 63 patients) p< 0.05.   
D Effect of cell capacitance on mode of electrical access. (NR n= 74 cells from 39 patients, NP n= 
181 cells from 63 patients) p< 0.05.  
E Lack of effect of mode of seal formation on resting membrane potential (NR n= 13 cells from 9 
patients, NP n= 68 cells from 20 patients). Calum Jon Redpath    Chapter 3 63 
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Figure 3.6 Effect of the mechanism of electrical access to the myocyte on duration of experiment.  
￿ = ruptured patch nystatin present in pipette (NR) ￿ =  perforated patch Nystatin present in 
pipette (NP) Values are mean± s.e.m.. 
A Effect of the mechanism of electrical access to the myocyte on time taken to form electrical seal in 
seconds (NR n= 39 cells from 24 patients, NP n= 143 cells from 55 patients) p< 0.05. 
B Effect of method of electrical access on the duration of stable ICaL recordings in seconds.   
(NR n= 48 cells from 26 patients, NP n= 103 cells from 40 patients) p<  0.05. 
 
 
3.5.3 The current: voltage relationship of ICaL 
The mean current: voltage relationship of inward current recorded under control 
conditions at physiological temperature was a characteristic bell shaped curve as 
shown in Figure 3.9A. At potentials more negative than  30 mV and more positive 
than  +40  mV  little  inward  current  was  detectable.  Peak  inward  current  was 
recorded at +10 mV with a mean current density of  4.8± 0.4 pA/pF (n= 89 cells 
from 29 patients, mean± s.e.m.) corresponding with previous reports of ICaL
161;163. 
 
 
3.5.4 ICaL peak current density 
 
The peak current density, recorded at +10 mV, was noted in all cells in which ICaL 
was measured. The mean peak current density from all cells (Figure 3.9B) was  
5.1±  0.3  pA/pF  (n=  176  cells  from  49  patients,  mean±  s.e.m.)  consistent  with 
previously published work from this laboratory and others
79;144;161;223. The mean 
peak ICaL per patient or ‘patient’ mean was also calculated to be  4.8± 0.4 pA/pF Calum Jon Redpath    Chapter 3 64 
(n= 49 patients, mean± s.e.m.) and there was no significant difference between 
the ‘cell’ mean peak ICaL and the ‘patient’ mean peak ICaL(Figure 3.9B). Unless 
specifically stated to the contrary all mean values will refer to cell mean. 
 
3.5.5 The time course of ICaL rundown under control conditions 
Peak ICaL was recorded repetitively under control conditions in order to ascertain 
the degree of initial rundown (Figure 3.10). Cells which demonstrated irreversible 
rundown under control conditions (Figure 3.10B) were not immediately excluded 
from initial analysis in order to examine whether this property of cells could be 
predicted.  Fortunately  the  number  of  cells  which  demonstrated  irreversible 
rundown during control was only 12 from 188 recordings (6.4%). The vast majority 
of these recordings were made in the initial stages of the project, eleven in the first 
twenty  recordings  consistent  with  the  author’s  learning  curve.  There  were  no 
significant  differences  in  the  cellular  characteristics  of  those  cells  exhibiting 
irreversible  rundown.  Electrophysiological  data  relating  to  these  cells  is  not 
incorporated further into this thesis. Calum Jon Redpath    Chapter 3 65 
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Figure 3.7 An example of a raw inward current trace (top) obtained using the voltage pulse protocol 
(lower) under control conditions with stepwise depolarisations, increasing in 10 mV increments from 
a holding potential of  40 mV to a maximum of +60 mV demonstrating the rapid inward current with 
biexponential decay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.8  Representative  example  of  peak  ICaL  under  control  conditions  demonstrating  rapid 
activation and biexponential decay of ICaL (tauf = 11.9± 1.4 ms, taus = 57.4± 2.9 ms)  
Mean values± s.e.m. tauf = 11.8± 2.1 ms, taus = 57.2± 5.7 ms (n= 7 cells from 7 patients). 
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Figure 3.9 The I:V relationship of ICaL and comparison of cell v. patient mean. 
A The mean current:voltage relationship obtained in all cells (n= 89 cells from 29 patients mean± 
s.e.m.).  
B Comparison of ‘cell’ mean v ‘patient’ mean peak current density of ICaL in all cells (n= 176 cells 
from 49 patients, mean± s.e.m.) 
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Figure 3.10 Comparison of stable ICaL recordings with ‘run down’. 
A Example of stable ICaL under control conditions with ‘permissible’ rundown with time.  
B Example of unstable ICaL under control conditions with ‘unacceptable’ rundown with time. 
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3.5.6 Impact of the method of seal formation on ICaL 
 
There was no significant difference (Figure 3.11) in the I:V relationship of ICaL in 
those myocytes in which the seal was obtained via a ruptured patch as compared 
with those cells in which the seal was a perforated patch. There was no significant 
difference in the magnitude of peak ICaL in those myocytes in which the seal was 
obtained via a ruptured patch  4.7± 0.4 pA/pF (n= 65 cells from 31 patients, mean± 
s.e.m.) as compared with those cells in which the seal was a perforated patch,  
5.4± 0.4 pA/pF (n=111 cells from 41 patients, mean± s.e.m., Figure 3.12A). Figure 
3.18B illustrates that there was no significant difference in the variance between 
the two groups and therefore the Students’ t test is a valid test to compare the two 
groups. 
3.5.7 Impact of patients’ clinical characteristics on ICaL 
3.5.7.1  Patient age and ICaL characteristics 
 
The mean I: V relationship of ICaL recorded from myocytes isolated from patients 
aged 75 years or older was found to be similar to that obtained from patients aged 
younger than 75 years (Myocytes from patients aged ≥75 years n= 19 cells from 6 
patients, v.  Myocytes from patients aged <75 years n= 70 cells from 23 patients, 
mean  ±  s.e.m.).  Mean  peak  ICaL  under  control  conditions  was  not  significantly 
different between myocytes isolated from patients aged ≥75 years and that from 
younger  patients  (Myocytes  from  patients  aged  ≥75  years  peak  ICaL   5.2±  0.8 
pA/pF, n= 33 cells from 8 patients, v.  Myocytes from patients aged <75 years 
peak ICaL  5.1± 0.3 pA/pF, n= 143 cells from 41 patients, mean± s.e.m.). 
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3.5.7.2  Gender and ICaL characteristics 
 
There was no significant difference in the current: voltage relationship of ICaL in 
those myocytes obtained from male as compared with female patients. There was 
no  significant  difference  in  peak  ICaL  in  those  myocytes  obtained  from  male 
patients when compared with myocytes obtained from female patients. (Male cells 
 5.3± 0.3 pA/pF, n= 143 cells from 40 patients, v.  Female cells  4.5± 0.5 pA/pF, 
n= 33 cells from 9 patients, mean± s.e.m.). 
 
3.5.8 Impact of chronic pre operative beta adrenoceptor blocking 
(β B) therapy on ICaL 
3.5.8.1  Pre operative heart rate and β B therapy 
All  48 patients  (72% of  total)  received  beta adrenoceptor  blocking  drugs  (beta 
blockers, β B) continuously for a minimum of 30 days pre operatively until the peri 
operative period. The most common agent used was Atenolol (39 patients, 81%) 
in dosages ranging from 25 75 mg daily (mean dose 41 mg, mode 50 mg). Other 
agents were Bisoprolol (4 patients, 9%), Metoprolol (3 patients, 6%) and Carvedilol 
(2 patients 4%). No patient was receiving Sotalol. The preoperative heart rate as 
recorded on the 12 lead electrocardiogram was significantly lower in those patients 
receiving beta blockers (BBY 59± 1 bpm v BBN 76± 1 bpm, n= 48 and 16 patients 
respectively P< 0.05). 
3.5.8.2  β B therapy and ICaL characteristics 
There was no significant difference in the current: voltage relationship nor peak 
ICaL in those myocytes obtained from patients who had, as opposed to had not, 
received chronic pre operative β B therapy (I: V relationship Figure 3.21A: peak 
ICaL: BBY  5.4± 0.3 pA/pF, n= 124 cells from 36 patients, v. BBN  4.5± 0.4 pA/pF, 
n=52 cells from 13 patients, mean± s.e.m.). Calum Jon Redpath    Chapter 3 70 
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Figure  3.11  Lack  of  effect  of  method  of  electrical  access  on  L type  calcium  current  (ICaL) 
current:voltage relationship under control conditions.  ￿ = ruptured patch nystatin present in pipette 
(NR) (n= 41 cells from 21 patients)  ￿ =  perforated patch Nystatin present in pipette (NP) (n= 48 
cells from 23 patients). Values are mean± s.e.m. Calum Jon Redpath    Chapter 3 71 
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Figure 3.12 Comparison of mode of electrical access and peak ICaL. ￿ = ruptured patch nystatin 
present in pipette (NR) (n= 65 cells from 31 patients)  ￿ =  perforated patch Nystatin present in 
pipette (NP) (n= 111 cells from 41 patients). Values are mean± s.e.m. 
A Lack of effect of method of electrical access on peak (measured at +10 mV) L type calcium current 
(ICaL) density under control conditions.  
B Lack of significant difference in variance in the distribution of peak ICaL recordings related to 
method of electrical access. 
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3.5.9 Impact of chronic pre operative calcium channel blocker 
(CCB) therapy on ICaL 
3.5.9.1  Pre operative heart rate and CCB therapy 
 
All  21  patients  (32%  of  total)  received  calcium  channel  blocking  drugs  (CCB) 
continuously for a minimum of 3 months pre operatively and throughout the peri 
operative  period.  The  most  common  agent  used  was  Amlodipine  (15  patients, 
72%) at either 5 or 10 mg. One patient was receiving Nifedipine. The remaining 5 
patients (24%) were prescribed Diltiazem betweem 60 and 300 mg. No patients 
were prescribed Verapamil. The preoperative heart rate as recorded on the 12 
lead electrocardiogram was not significantly different in those patients receiving 
calcium  channel  blocking  drugs  from  those  not  receiving  CCB  drugs  pre 
operatively  (CCBY  62±  2  bpm  v  CCBN  64±  1  bpm,  n=  21  and  43  patients 
respectively). 
3.5.9.2  CCB therapy and ICaL characteristics 
 
There was no significant difference in either the current: voltage relationship or 
peak  ICaL  in  those  myocytes  obtained  from  patients  who  had  received  chronic 
calcium channel blocking therapy pre operatively (CCBY  4.7± 0.4 pA/pF, n= 55 
cells from 17 patients, v.  CCBN  5.4± 0.3 pA/pF, n=121 cells from 32 patients, 
mean± s.e.m.). 
3.5.10  The impact of chronic Angiotensin Converting Enzyme 
Inhibitor (ACE I) therapy on ICaL 
 
All  32  patients  (49%  of  total)  received  ACE I  medications  continuously  for  a 
minimum of 3 months pre operatively until the peri operative period. In 11 patients 
(34%)  this  medication  was  withheld  on  the  last  preoperative  day.  The  most 
common agent used was Ramipril (20 patients, 63%) in dosages ranging from 2.5 
10 mg daily (mean dose 7.7 mg, mode 10 mg). Other agents were Lisinopril (8 Calum Jon Redpath    Chapter 3 73 
patients, 25%), Enalapril (2 patients, 6%), Perindopril and Trandolapril (1 patient 
each 3%). There was no significant difference in the current: voltage relationship 
of ICaL in those myocytes obtained from patients who had received chronic ACE I 
therapy.  There  was  no  significant  difference  in  peak  ICaL  in  those  myocytes 
obtained  from  patients  who  had  received  chronic  pre operative  ACE I  therapy 
when  compared  with  myocytes  obtained  from  patients  who  had  not  received 
preoperative  ACE I  therapy  (ACE I  Y   5.4±  0.5  pA/pF,  n=  112  cells  from  28 
patients, v.  ACE I N  5.0± 0.3 pA/pF, n=64 cells from 21 patients, mean± s.e.m.). 
3.5.11  Impact of pre operative left ventricular systolic 
dysfunction (LVSD) on ICaL 
 
There was no significant difference in the current: voltage relationship between 
either  normal  compared  with  abnormal  Left  Ventricular  Systolic  Dysfunction 
(LVSD),  as  defined  by  pre operative  echocardiography,  nor  between  the 
aggregated groups of Normal & Mild LVSD compared with Moderate & Severe 
LVSD. There was no significant difference between the peak current density in 
those cells from patients with normal compared to abnormal LVSD (Normal LV 
systolic  function  peak  ICaL   5.0±  0.4  pA/pF  n=  77  cells  from  23  patients,  v. 
Abnormal  LV  systolic  function  peak  ICaL   5.1±  0.4  pA/pF  n=  77  cells  from  21 
patients, Figure 3.13A). However the peak current density recorded from cells with 
moderate  and  severe  LVSD  was  statistically  significantly  greater  than  that 
recorded from cells with normal or mild LVSD (Normal and Mild LVSD peak ICaL  
4.8± 0.3 pA/pF n= 108 cells from 32 patients, v. Moderate and Severe LVSD peak 
ICaL  5.6± 0.6 pA/pF n= 46 cells from 12 patients p< 0.05, Figure 3.13B). Calum Jon Redpath    Chapter 3 74 
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Figure 3.13 Impact of LVSD on peak ICaL. Values are mean± s.e.m. 
A Lack of effect of any degree of pre operative Left Ventricular Systolic Dysfunction (LVSD) on peak 
ICaL under control conditions.   ￿ = patients without LVSD (n= 77 cells from 23 patients)   ￿ =  
patients with LVSD (n= 77 cells from 21 patients).  
B Effect of moderate or severe pre operative Left Ventricular Systolic Dysfunction (LVSD) on peak 
ICaL under control conditions.  ￿ = patients with mild or no LVSD (n= 108 cells from 32 patients)  ￿ 
=  patients with moderate or severe LVSD (n= 46 cells from 12 patients). p< 0.05. 
 
A 
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3.5.12  Impact of prior Myocardial Infarction on ICaL 
 
There was no significant difference in the current: voltage relationship between 
patients who had suffered a prior Myocardial Infarction (MI), as recorded in the 
clinical case sheets, and those patients who had not had a documented previous 
MI (Figure 3.14A). In contrast, myocytes isolated from patients who had suffered a 
documented MI pre operatively had a significantly greater peak ICaL current density 
on comparison with myocytes from patients who had not suffered a prior MI (MIN  
4.52± 0.35 pA/pF, n= 83 cells from 23 patients v. MIY  5.55± 0.36 pA/pF, n= 88 
cells from 25 patients, p< 0.05 Figure 3.14B). 
3.5.13  Impact of aetiology of Left Ventricular Systolic 
Dysfunction (LVSD) on ICaL 
 
There was no significant difference in the current: voltage relationship between 
patients  who  had  ischaemic  cardiomyopathy  (ICM)  and  those  suffering  non 
ischaemic  cardiomyopathy  (NICM).  However,  ICaL  was  of  a  significantly  lower 
density  from  myocytes  isolated  from  patients  with  NICM  when  depolarised  to 
potentials more positive than zero. p< 0.05 (Figure 3.15A). Peak ICaL, however, 
was  of  a  significantly  lower  density  from  myocytes  isolated  from  patients  with 
NICM when compared to myocytes from patients with ischaemic cardiomyopathy 
(NICM  3.52± 0.3 pA/pF, n= 25 cells from 6 patients, ICM  5.87± 0.47 pA/pF, n= 
62 cells from 17 patients, p< 0.05 Figure 3.15B). 
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Figure 3.14 Impact of prior Myocardial Infarction (MI) on ICaL.  ￿ = patients who have not sustained 
previous MI (MIN)  ￿ = patients who have sustained previous MI (MIY) Values are mean± s.e.m.. 
A Lack of effect of prior MI on ICaL I: V relationship under control conditions. (MIN n= 41 cells from 13 
patients, MIY n= 48 cells from 16 patients). 
B Effect of prior MI on peak ICaL under control conditions (MIN n= 83 cells from 23 patients, MIY n= 
88 cells from 25 patients) p< 0.05. 
B 
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Figure  3.15  Impact  of  aetiology  of  LVSD  on  ICaL.    ￿  =  patients  who  have  non ischaemic 
cardiomyopathy (NICM)  ￿ = patients who have ischaemic cardiomyopathy (ICM) Values are mean± 
s.e.m.. 
A Lack of effect of aetiology of LVSD on ICaL I: V relationship under control conditions. (NICM n= 15 
cells from 4 patients, ICM n= 28 cells from 10 patients). 
B Effect of aetiology of LVSD on peak ICaL under control conditions (NICM n= 25 cells from 6 
patients, ICM n= 62 cells from 17 patients).p< 0.05.  
B 
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3.5.14  The effect of ISO on ICaL current: voltage relationship 
Isoproterenol at 0.1  M significantly increased the magnitude of the inward current 
without  altering  the  current:  voltage  relationship  of  ICaL  (Figure  3.16A)  at 
physiological temperature. (n= 4 cells from 3 patients, paired data, mean± s.e.m. 
p< 0.05.) An example of the paired peak (+10 mV) current traces is depicted in 
Figure 3.16B. 
 
3.5.15  The effect of ISO on activation and inactivation of ICaL 
Isoproterenol at 0.05  M had no significant effect on the activation time (control 
4.13± 0.15 ms v. 4.3± 0.37 ms n= 4 cells from 4 patients) or time constant of 
inactivation  of  ICaL  (control  54.0±  10.1  ms  v.  55.2±  14.8  ms  n=  4  cells  from  4 
patients). Figure 3.16B is an example of raw current tracings demonstrating this 
lack of effect and mean data are presented in histograms in Figure 3.17. 
 
3.5.16  The effect of ISO on peak ICaL 
3.5.16.1  Time course of ISO effect on peak (+10 mV) current density 
 
There  were  four  differing  patterns  of  change  in  peak  ICaL  following  acute 
superfusion of ISO which we classified into four response ‘types’ (Figures 3.18 and 
3.19). The type O response, in which there was no discernible effect of ISO on 
peak ICaL, occurred in only 3% of cells (Figure 3.18A). Due to the combination of 
the rarity of this type of response, the early loss of seal, the subjective visible signs 
of cell death (shrinkage, spherication, crenation, loss of discernable striations) and 
the  literature  describing  the  consistent  positive  effect  of  ISO  to  increase 
ICaL
81;94;114;144;155;161;199;200;221;225;279 282
  these  cells  were  excluded  from  further 
analysis. Calum Jon Redpath    Chapter 3 79 
The  most  common  adrenergic  response,  designated  the  type  1  response, 
occurred in 60% of cells. This response was characterised by a stable augmented 
ICaL  current  density  persisting  as  a  plateau  on  the  time  course  curve plot,  see 
Figure 3.18B. 
 
A type 2 response in which the initial increase in peak ICaL current density was 
temporary but an intermediate plateau was reached which was of greater current 
density than that recorded under control conditions but less than the peak initial 
response occurred in 10% of cells (see figure 3.19A). 
  
Finally a type 3 response to ISO was that of an initial increase in ICaL which did not 
reach a plateau and peak ICaL irreversibly ran down to control levels and occurred 
in 30% of cells (Figure 3.19B). 
 
3.5.16.2 ISO effect on peak (+10 mV) current density 
 
An example of the effect of acute superfusion with 0.05  M ISO on the raw current 
tracings can be seen in Figure 3.20A. The significant mean increase in peak ICaL 
following acute superfusion with 0.05  M ISO in absolute terms can be seen in 
Figure  3.20  and  the  relative  increase,  that is  the  magnitude of  the  increase  in 
current density expressed as a percentage of the current density under control 
conditions was 218.8± 17.4 % (n= 87 cells from 36 patients, paired data, mean± 
s.e.m. p< 0.05). 
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3.5.16.3 Concentration: response relationship of ISO on peak ICaL 
 
Isoproterenol, at concentrations equal to or less than 10
 9 had no significant effect 
on the magnitude of peak ICaL (+10 mV), however at all concentrations tested in 
the range from 10
 8 to 10
 6 M, acute superfusion with ISO significantly increased 
the magnitude of peak ICaL (Figures 3.21 and 3.22). 
 
An interim concentration: response curve of the maximal initial effects of ISO on 
peak ICaL was constructed during the early stages of the project in order to select a 
suitable concentration of ISO for later experiments (Figure 3.22A). From this curve 
we calculated that the EC50 of ISO was approximately 0.05  M ISO and that the 
maximal response was likely to occur at approximately 1.0  M ISO. 
 
As can be seen from the final concentration: response curve of the adrenergic 
effect of ISO on peak ICaL (Figure 3.22B) the true EC50 of ISO was approximately 
0.013  M ISO, consistent with initial experience with the nystatin perforated patch 
clamp recordings of ICaL
221. 
 
3.5.16.4 Time to maximal ISO effect on peak (+10 mV) current density 
 
The mean time to peak effect of ISO on ICaL was 95± 4 seconds (n= 113 cells from 
39 patients Figure 3.23A). There was no significant difference in the time to peak 
effect of increasing ISO concentration (Figure 3.23A). There was no significant 
difference in the time taken to peak ISO effect of either method of electrical access 
(Figure  3.23B).  However,  ISO  at  0.05   M,  had a  significantly  more  rapid peak 
effect on ICaL in cells from patients who had received chronic pre operative beta 
adrenoceptor antagonists (Figure 3.23C). 
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Figure 3.16 The effect of acute superfusion of ISO at 0.1  M on of ICaL. 
A The effect of ISO 0.1  M on the I: V relationship of ICaL. ￿ = control  ￿ =  ISO 0.1  M ISO (n=4 
cells from 3 patients, paired data, mean± s.e.m. p< 0.05.)  
B Examples of two superimposed raw current tracings of peak ICaL recorded from the same myocyte: 
i) under control conditions ii) following acute superfusion with ISO 0.1  M. 
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ii) 
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Figure 3.17 The effect of acute superfusion of ISO at 0.05  M on activation and inactivation time 
constants of ICaL.  ￿ = control  ￿ =  ISO 0.05  M ISO (n=4 cells from 4 patients, paired data, mean± 
s.e.m.). 
A The lack of effect of ISO 0.05  M on the activation time of ICaL (ms)  
B The lack of effect of ISO 0.05  M on the rapid (tauf) time constant of inactivation of ICaL (ms). 
C The lack of effect of ISO 0.05  M on the slow (taus) time constant of inactivation of ICaL (ms). Calum Jon Redpath    Chapter 3 83 
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Figure 3.18 Examples of the type 0 and type 1 time course of effect of ISO on ICaL. 
A Type 0 effect; perpetual rundown from an initial peak ICaL until cell death following superfusion with 
ISO.These cells were excluded from further analysis. 
B  Type  1  effect;  stable  ICaL  under  both  control  conditions  and  following  exposure  to  ISO  until 
experiment electively terminated. 
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Figure 3.19 Examples of the type 2 and type 3 time course of effect of ISO on ICaL. 
A Type 2 effect; stable ICaL under control conditions prior to superfusion with ISO, however the 
adrenergic effect was an initial rise in peak ICaL follwed by rundown which stabilised at a plateau 
greater than under control conditions.   
B Type 3 effect; following addition of ISO to the superfusate, an initial rise in peak ICaL was followed 
by irreversible rundown of ICaL until cell death. 
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Figure  3.20  Effect  of  acute  superfusion  with  0.05   M  isoproterenol  on  a  human  atrial 
myocyte.  
A Examples of the raw inward current traces recorded under control conditions (i) and (ii) 
during acute superfusion with 0.05  M isoproterenol.  
B Representative example of the time course of the adrenergic effect of ISO (0.05  M) on 
peak ICaL. Timing of the addition of ISO to the superfusate is indicated by the solid black bar. 
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3.5.17  Repetitive applications of ISO 
 
Initial experimental protocols were of a stepwise increase in the concentration of 
ISO  in the  superfusate following  the  adrenergic  effect  reaching a  steady  state. 
However, this stepwise effect of ISO was achieved in few cells (Figure 3.24). The 
estimation of the magnitude of the effect of second and subsequent applications of 
ISO were hampered by failure of initial plateau formation (type 3 responses), the 
initial rundown prior to plateau formation negating the impact of further adrenergic 
effects with increasing concentrations of ISO (type 2 response) See Figure 3.24B. 
 
3.5.18  Impact  of  the  method  of  seal  formation  on  the    
adrenergic effect of 0.05  M ISO on ICaL 
Mode of electrical access, (NR v NP), was not associated with any specific ‘type’ 
of response of human atrial myocyte ICaL following acute superfusion with ISO in 
concentrations ranging from 10
 10 to 10
 6 M. There was no significant difference 
(NR v NP) in the magnitude of the adrenergic effect of 0.05  M ISO on peak ICaL 
(NR 176.1± 24.8% v. NP 246± 24.8% increase in peak ICaL, n= 22 cells from 15 
patients and n= 65 cells from 21 patients respectively). 
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Figure 3.21 The significant adrenergic effect of acute superfusion with increasing concentrations of 
ISO on peak ICaL. ￿ = control  ￿ =  ISO (varying concentrations as indicated) paired data, values 
are mean± s.e.m. 
A 0.0001  M ISO (n=  4 cells from 3 patients) 
B 0.001  M ISO (n=  4 cells from 3 patients) 
C 0.01  M ISO (n=  5 cells from 4 patients, p< 0.05.) 
D 0.05  M ISO (n=  87 cells from 36 patients, p< 0.05.) 
E 0.1  M ISO (n=  20 cells from 13 patients, p< 0.05.) 
F 1.0  M ISO (n=  17 cells from 10 patients, p< 0.05.) Calum Jon Redpath    Chapter 3 88 
 
Figure 3.22 Concentration: response curve of the effect of Isoproterenol on ICaL. Data from which an 
unrestrained sigmoidal plot using the Hill equation calculated the EC50 to be 0.06± 0.014  M ISO, 
the minimal and maximal effects of ISO were estimated to be 16.5± 21% and 199.3± 43% increases 
in ICaL compared to baseline respectively  (n= 4  46 cells from 3  22 patients). 
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Figure 3.23 Analysis of time to maximal adrenergic effect of ISO on peak ICaL. 
A The mean time to maximal effect of differing concentrations of ISO on peak ICaL all values are 
paired data mean± s.e.m. ￿ = 0.05  M ISO (n=  87 cells from 36 patients)  ￿ = 0.1  M ISO (n=  17 
cells from 12 patients)  ￿ = 1.0  M ISO (n=  11 cells from 7 patients) 
B The lack of impact of method of electrical seal on the time to peak ISO effect on ICaL (nystatin 
perforated patch (NR) n= 92 cells from 38 patients v nystatin ruptured patch (NR) n= 21 cells from 13 
patients, mean± s.e.m.) 
C Chronic pre operative β B therapy results in an expedited peak response to ISO (mean± s.e.m.). 
n= 97 cells from 37 patients receiving chronic pre operative β B therapy (BBY). n= 16 cells from 7 
patients not receiving chronic pre operative β B therapy (BBN).  
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Figure 3.24 Differing cellular responses to repetitive applications of increasing concentrations of 
Isoproterenol. 
A Repetitive application of ISO in which subsequent addition of an increased concentration of ISO to 
the superfusate resulted in a stable increase in the magnitude of peak ICaL 
B Increased concentration of ISO did not reverse the onset of ICaL rundown. 
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3.5.19  Impact  of  patients’  clinical  characteristics  on  the 
adrenergic effect of 0.05  M ISO on ICaL 
There  were  no  significant  differences  observed  in  the  magnitude  of  the  mean 
adrenergic effect of 0.05  M ISO on peak ICaL associated with any recorded patient 
clinical characteristics or pre operative drug therapy, other than the presence of 
pre operative hypertension. The mean adrenergic response of peak ICaL to 0.05 
 M ISO was significantly greater in myocytes isolated from patients suffering from 
hypertension  pre operatively  as  compared  to  myocytes  from  patients  free  from 
hypertension.  (Mean  adrenergic  increase  250.7±  25.3%  n=  46  cells  from  19 
hypertensive patients v. 173.5± 22.2% n= 38 cells from 15 normotensive patients). 
3.5.19.11  Adrenergic response of peak ICaL to ISO 0.05  Mol is not 
predictive of post operative Atrial Fibrillation (AFpcs) 
 
The  mean  adrenergic  increase  in  peak  ICaL  from  myocytes  isolated from  those 
patients who went on to develop post operative Atrial Fibrillation (AFpcs) was not 
significantly different from the mean adrenergic increase in peak ICaL of myocytes 
from  patients  who  remained  in  sinus  rhythm  post operatively  (SRpcs).  (Mean 
adrenergic increase (AFpcs) 193.7± 32.7% n= 28 cells from 12 patients v. (SRpcs) 
229.2± 20.1% n= 58 cells from 23 patients). 
 
3.5.20  The lack of effect of Endothelin 1 alone on peak ICaL 
Endothelin 1 alone at the maximal concentration tested of 10 nM had no effect on 
peak  ICaL  (control   4.8±  0.5  pA/pF  v.  ET 1   4.5±  0.7  pA/pF,  n=  5  cells  from  4 
patients, paired data, p< 0.05 Figure 3.25). An example of this lack of effect of ET 
1 at 10 nM on ICaL is shown in Figure 3.25A and is confirmed by mean data (Figure 
3.25B). 
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3.5.21  The lack of effect of Sarafotoxin S6c alone on peak ICaL 
Sarafotoxin S6c, a selective ET B receptor agonist, at 10 nM had no effect on ICaL 
(control  3.9± 1.1 pA/pF v. S6c  3.3± 0.9 pA/pF, n= 5 cells from 3 patients, paired 
data, p< 0.05 Figure 3.26).  An example of this lack of effect of S 6c on ICaL is 
shown in Figure 3.26A and is confirmed by mean data (Figure 3.26B). 
 
3.5.22  The  effect  of  Endothelin 1  on  adrenergically  pre 
stimulated peak ICaL 
Peak  ICaL  was  pre stimulated  with  ISO  at  a  concentration  of  0.05   M  which 
approximated to the EC50 of the adrenergic stimulatory effect of ISO on peak ICaL. 
Once it was apparent in real time that the adrenergic effect had reached a plateau, 
Endothelin 1, in varying concentrations, was added to the superfusate. Endothelin 
1, at the maximal concentration evaluated of 10 nM reversed the adrenergic effect 
of 0.05  M ISO on peak ICaL, as can be seen in Figure 3.27A (control  4.9± 1.3 
pA/pF v. ISO  16.8± 3.4 pA/pF v. ISO and ET 1 co application  8.2± 2.1 pA/pF n= 
14  cells  from  12  patients,  paired  data,  p=  0.0005  Figure  3.27B).  The  anti 
adrenergic  effect  was  calculated  by  first  measuring  the  magnitude  of  the 
adrenergic effect of ISO on ICaL in absolute terms and then dividing the magnitude 
of  the  effect  of  ET 1  in  pA/pF  permitting  the  expression  of  the  anti adrenergic 
effect of ET 1 as a percentage of the initial adrenergic effect (See Figure 3.27). 
 
3.5.23  Partial reversibility of the anti adrenergic effect of ET 1 
on peak ICaL due to washout 
The anti adrenergic effect was partially reversible with washout in the majority of 
cells tested (Figure 3.28). In 10 of 16 cells in which the experiment continued into 
a washout period, the effect of ET 1 was partially reversible. During washout of all Calum Jon Redpath    Chapter 3 92 
concentrations of ET 1 ≤1 nM partial reversibility was more frequent than not. In 5 
cells it was not possible to assess reversibility due to premature termination of the 
experiment  due  to  cell  death  or  electrical  instability.  No  correlation  between 
preoperative drug therapy or comorbidity could be made as the numbers in each 
group preclude further investigation. 
 
3.5.24  The concentration: response relationship of the anti 
adrenergic effect of ET 1 on peak ICaL 
The magnitude of the anti adrenergic effect of decreasing concentrations of ET 1 
was  assessed  in  order  to  determine  if  there  was  a  relationship  between  the 
concentration of ET 1 and the magnitude of the anti adrenergic effect on peak ICaL. 
Endothelin 1  had  a  significant  anti adrenergic  effect  on  peak  ICaL  in  all 
concentrations tested from 0.01 nM to 10 nM (See Figure 3.29). The beginning of 
a concentration response effect can be determined as the magnitude of the anti 
adrenergic  effect  decreased  with  decreasing  concentrations  of  ET 1  in  the 
superfusate.  
 
3.5.25  The  concentration  response  relationship  of  the  time 
course of the anti adrenergic effect of ET 1 on peak ICaL 
The  time  taken  for  ET 1  to  have  an  anti adrenergic  effect  appeared  to  be 
concentration  dependent.  At  high  concentration,  ET 1  at  10  nM  completely 
reversed the adrenergic effect of ISO at 0.05  M in 140± 9 seconds which was 
significantly earlier than lower concentrations (n= 4 14 cells from 2 12 patients P= 
0.0004. Figure 3.30). 
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Figure  3.25  A)  Time  course  of  10 nM  ET 1  effect, inset are examples  of  raw  current  tracings 
obtained during each phase of the experiment. B) Histograms of mean data of 10 nM ET 1 effect on 
peak ICaL.  ￿ = control  ￿ =  ET 1 10 nM (n=  5 cells from 4 patients, paired data mean ± s.e.m., p= 
ns). 
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Figure 3.26 A) Time course of lack of effect of 10 nM S6c on ICaL. B) Histograms of mean data of 10 
nM S6c effect on peak ICaL.  ￿ = control  ￿ =  S6c 10 nM (n= 5 cells from 3 patients, paired data 
mean ± s.e.m., p= ns). 
A 
B Calum Jon Redpath    Chapter 3 95 
 
0 100 200 300 400 500 600 700
 10
 5
0
10 nM ET 1
0.05       M ISO
i
ii
iii iv
ICaL
(pA/pF)
Time (s)
 25
 20
 15
 10
 5
0
ICaL
(pA/pF)
*
#
 
Figure 3.27 A) Time course of the anti adrenergic effect of 10 nM ET 1 on peak ICaL. B) Histogram of 
mean data of the anti adrenergic effect of 10 nM ET 1 on peak ICaL.  ￿ = control   ￿ =  ISO 0.05 
 M   ￿ = ET 1 10 nM (n=  14 cells from 12 patients, paired data, mean ± s.e.m., * P= 0.0005, # P= 
0.0002). 
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Figure 3.28 Example of the partial reversibility of the anti adrenergic effect of 0.1 nM ET 1 on peak 
ICaL with washout. 
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Figure 3.29 The concentration response relationship of the magnitude of the anti adrenergic effect 
of ET 1 (nM) on peak ICaL. 
10 nM ET 1 n = 14 cells from 12 patients P= 0.0002 
1 nM ET 1 n = 4 cells from 2 patients P= 0.017 
0.1 nM ET 1 n = 5 cells from 3 patients P= 0.013 
0.01 nM ET 1 n = 5 cells from 5 patients P= 0.036 
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3.5.26  Partial  reversibility  due  to  the  blockade  of  ET A 
receptors with FR139317 (FRA) 
Using the ET A antagonist FRA the effect of 10 nM ET 1 was partially reversible in 
6 of 7 seven cells (Figure 3.31). 
 
3.5.27  The blockade of ET A receptors with FR139317 (FRA) 
prevents  the  antiadrenergic  effect  of  10  nM  ET 1  on 
adrenergically pre stimulated peak ICaL 
Superfusion of the myocyte with the ET A antagonist FRA following exposure to 
0.05   M  ISO  prevented  the  anti adrenergic  effect  of  10  nM  ET 1  on  peak  ICaL 
(Figure 3.32). 
 
3.5.28  The lack of effect of Sarafatoxin S6c on adrenergically 
pre stimulated peak ICaL 
The selective ET B receptor agonist Sarafotoxin S6c at 10 nM had no effect on ICaL 
which had been adrenergically pre stimulated with 0.05 M ISO (control 4.7± 0.5 
pA/pF v. ISO  19.2± 2.7 pA/pF v. ISO and S6c co application 18.0± 3.4 pA/pF, 
paired data n=9 cells from 4 patients).  An example of this lack of effect of S 6c on 
ICaL is shown in Figure 3.33 and is confirmed by mean data (Figure 3.34). The 
presence of 10 nM S6 c in the superfusate had no effect on the ability of 10 nM 
ET 1 to reverse the adrenergic effect of 0.05 M ISO on peak ICaL (Figure 3.43B). 
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Figure 3.30 The concentration response effect of the time to peak anti adrenergic effect of ET 1 on 
peak ICaL. (n= 4 14 cells from 2 12 patients. * P= 0.0004) Calum Jon Redpath    Chapter 3 99 
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Figure 3.31 A) The specific ET A receptor antagonist FR 139317 at 10 nM partially reverses the anti 
adrenergic effect of 10 nM ET 1 on peak ICaL. B) The specific ET A receptor antagonist FR 139317 at 
10 nM prevents the anti adrenergic effect of 10 nM ET 1 on peak ICaL. 
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Figure 3.32 The mean effect of 10 nM FR139317 to partially reverse the anti adrenergic effect of 10 
nM ET 1 on peak ICaL.  ￿ = control   ￿ =  ISO 0.05  M   ￿ = ET 1 10 nM ￿ = 10 nM FRA (n = 6 
cells from 4 patients mean ± s.e.m. p= ns). Calum Jon Redpath    Chapter 3 101 
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Figure 3.33 A) The lack of effect of Sarafotoxin S6 c alone on prestimulated peak ICaL. B) The 
absence of effect of Sarafotoxin S6 c on the anti adrenergic effect of 10 nM ET 1 on peak ICaL. 
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Figure 3.34 A) Mean lack of effect of sarafotoxin S6 c on adrenergically prestimulated peak ICaL .  ￿ 
= control   ￿ = ISO 0.05  M   ￿ =  S6c 10 nM (n= 9 cells from 4 patients mean ± s.e.m.) B) The 
impact of sarafotoxin S6 c on the anti adrenergic effect of 10 nM ET 1 on peak ICaL (ET 1 alone n= 
14 cells from 12 patients, ET 1 following exposure to S6 c n= 3 cells from 1 patient mean ± s.e.m. p= 
ns) 
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3.6  Discussion 
3.6.1 Methodological considerations 
These results demonstrate that ICaL can be reliably and reproducibly recorded from 
human  atrial  myocytes  using  the  nystatin perforated  whole cell  patch  clamp 
technique at physiological temperature. This nystatin perforated method had no 
significant  effect  on  activation  nor  inactivation  kinetics,  the  current:  voltage 
relationship nor peak inward calcium current while avoiding the irreversible current 
rundown  in  the  vast  majority  of  cells  under  control  conditions
79;161;163;223. 
Additionally  these  results  indicate  that  the  method  of  electrical  access,  patient 
gender and chronic preoperative drug therapy had no effect on human atrial ICaL 
under control conditions. In contrast, in cells isolated from patients suffering from 
moderate and severe LVSD, as defined by trans thoracic echocardiography (TTE), 
there was a significantly greater peak ICaL observed with no significant alteration in 
the I V relationship. 
 
The clinical characteristics of the patients from whom these atrial myocytes were 
isolated are similar to those reported in recent surgical series
283 and on the UK 
central cardiac audit database (www.ccad.org.uk/ccadweb.nsf). Due to the small 
sample  size  of  patients  in  the  present  study  it  was  not  possible  to  detect  any 
significant  associations  between  clinical  characteristics  and  post operative  AF, 
however this would appear to be a type II error as pooled work from our laboratory 
has recently been published reporting the presence of these associations
284. 
 
An association between pre operative ACE I therapy and greater Rs has not, as 
far  as  the  author  is  aware,  been  previously  reported.  Angiotensin  II  has  been 
implicated in stretch induced fibrosis, reversible increases in cellular expression of 
connexin 43 and other membrane bound proteins, however, these changes were Calum Jon Redpath    Chapter 3 104 
not associated with alterations in resting membrane potential or action potential 
upstroke
285;286. While this possible effect of chronic pre operative ACE I therapy on 
human atrial myocyte plasmalemmae cannot be entirely discounted it is likely to 
be a spurious result representing a type I error. This interpretation is supported by 
the  publication  of  pooled  data  from  our  laboratory  which  did  not  report  any 
significant association between ACE I therapy and greater Rs
284
. 
 
Successful  perforated  patch  recordings  were  more  likely  with  two  periods  of 
enzymatic  incubation  during  the  myocyte  isolation  process  and  also  in  cells  of 
greater capacitance. Nystatin induced pores in the lipid bilayer  permit electrical 
access and in comparison with ruptured patch where the pipette is in direct contact 
with the intracellular milieu it is intuitive that Rs should be greater in NP cf. NR 
recordings. Exactly how nystatin pores, cell size and pre operative ACE I therapy 
interact at the plasmalemmae remains a subject for further research. The present 
study confirms that the stability of ICaL recordings can be maintained far beyond 
that which was previously possible with ruptured patch recordings
202;220;221.  
 
The majority of previous publications describing ICaL used ruptured patch clamp 
experiments  at  room  temperature 
114;155;163;225;281;282;287;288  and  all  report  a  bell 
shaped I V relationship with inward current being detected in the range of > 40 mV 
to <+60 mV, peaking at +10± 10 mV. This ‘peak’ ICaL, measured either at 0 mV or 
at +10 mV in these experiments was in the range of 1.2 pA/pF 
225 to 3.2 pA/pF 
287. 
Early pioneering work in this area was hampered by ICaL being detected in fewer 
than  half  of  cells  studied  and  often  required  amplification  with  dihydropyridine 
agonists (Bay K 8644) in order to become recordable
155. 
 
In contrast when physiological temperature conditions were employed, the current 
voltage relationship of ICaL was bell shaped with peak current consistently at +10 Calum Jon Redpath    Chapter 3 105 
mV
79;161;163;223.  One  report  specifically  examined  the  physiological  effect  of 
temperature on ICaL
161 demonstrating no shift in the IV relationship but an increase 
in  peak  ICaL  from  2  pA/pF  at  room  temperature  increasing  to  6  pA/pF  from  a 
holding potential of  40 mV at physiological temperature. When the effect of raising 
the  temperature  of  the  cells  during  the  experiment  was  tested  directly  it  was 
demonstrated that ICaL had similar I: V relationship but that greater current passed 
at all voltages and that peak current was approximately doubled with more rapid 
activation and inactivation
161. Further corroboration has arisen from subsequent 
work reporting that peak ICaL was in the range of 4.8 to 6.8 pA/pF occurring at +10 
mV under control conditions of 37
0C
79;144;161;163;223. 
 
3.6.2 Interaction  of  patients’  clinical  characteristics  and  human 
atrial isolated myocyte ICaL 
Previous  publications  have  sought  to  determine  whether  chronic  pre operative 
drug therapy alters human atrial myocyte electrophysiology. This was suggested 
by reports indicating altered contractile responses and arrhythmogenicity in cells 
from  patients  who  had  received  chronic  preoperative  beta adrenoceptor  (BB) 
antagonists 
152;289 291.  The data presented are in accordance with previous work, 
including work from our own laboratory, demonstrating that pre operative therapy 
with  BB  has  no  significant  effect  on  human  atrial  ICaL  under  control 
conditions
144;223;281;287.  
 
Initial assessments of the impact of chronic therapy with calcium channel blockers 
(CCB) pre operatively reported no effect on the I V relationship of ICaL but reported 
an  association  with  reduced  peak  ICaL  under  control  conditions 
155;282.  No  such 
association was apparent in this study. The association of reduced peak ICaL and 
chronic  CCB  therapy  has  not  been  corroborated  since  the  initial  two  reports Calum Jon Redpath    Chapter 3 106 
144;223;281;287.  Possible explanations are methodological differences, a type I error 
as both reports contain data from few patients and limited cell sample sizes and 
early experimental difficulties in recording ICaL
155. 
 
Treatment with ACE Inhibitor drugs, while not considered anti arrhythmic therapy 
in the traditional sense have recently been associated with preventive
292 295 and 
supportive effects in the successful cardioversion of atrial fibrillation
296;297. Under 
control conditions there was no significant difference in peak ICaL between cells 
from patients taking ACE I therapy preoperatively and those not. This corroborates 
previously published data which have not demonstrated a statistically significant 
electrophysiological effect of preoperative ACE I therapy, implicating structural or 
cellular remodelling processes
144;223;281;287. 
 
Gender  has  been  implicated  in  altered  human  atrial  action  potential 
repolarisation
298.  No  gender  differences  were  identified  in  the  measured 
characteristics of ICaL under control conditions in this study nor in the published 
literature describing ICaL in vitro
144;223;281;287. 
 
The  same  group  who  published  the  association  between  chronic  preoperative 
CCB  therapy  and  reduced  basal  ICaL  subsequently  described  alterations  in  ICaL 
comparing ‘normal’ to ‘diseased’ human cardiac cells
114. Ouadid et al reported that 
myocytes from patients with severe heart failure requiring cardiac transplantation 
had  significantly  greater  capacitance  and  smaller  ICaL  current  density  when 
compared to cells from patients undergoing cardiac surgery for coronary artery 
disease  or  mitral  stenosis
114.  Although  no  patients  undergoing  cardiac 
transplantation  were  included  in  this  study,  both  studies  enrolled  patients  with 
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Both  studies  are  in  agreement  that  heart  failure,  however  so  defined,  was  not 
associated with an alteration in the I V relationship of ICaL. 
 
In contrast, the present study, under more physiological experimental conditions 
and  with  a  much  greater  sample  size,  has  demonstrated  that,  under  control 
conditions, peak ICaL current density was significantly greater in cells isolated from 
patients  with  subjectively  moderate/  severe  LVSD  compared  with  those  with 
normal/  mild  LVSD  and  that  no  significant  difference  in  capacitance  existed 
between these two groups. In comparison with Ouadid et al
114, when cells from 
patients suffering from severe LVSD were considered alone, the association was 
maintained. However, the subjective presence or absence of LVSD in the present 
study was associated with similar kinetics, I:V relationship and peak ICaL. More 
recent data, again recorded at room temperature
299 reported very small peak ICaL 
(some as low as 0.1 pA/pF) in patients with LVSD. The conclusions presented 
herein are based on the largest single experimental dataset published to date and 
are believed to be sufficiently large to permit accurate interpretation and avoidance 
of type II error. 
 
In  order  to  resolve  this  issue  pooled  data  from  our  laboratory  submitted  for 
publication with approximately a threefold sample size, (and work from another 
laboratory
279) has indicated that atrial myocytes isolated from patients with LVSD, 
defined  objectively  by  TTE,  do  have  greater  capacity  and  that  ICaL  has  similar 
kinetics of activation and inactivation, I: V relationship and peak current magnitude 
regardless of the presence of LVSD after multivariate analysis
300.  
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3.6.3 Adrenergic effect(s) of acute superfusion with ISO 
Isoproterenol,  at  concentrations  ranging  from  0.01  to  1   M,  increased  the 
magnitude  of  the  long  lasting  inward  calcium  current  (ICaL)  in  a  concentration 
dependent manner without altering the I:V relationship, activation or inactivation 
kinetics  in  human  isolated  atrial myocytes. In  the majority  of  cells  studied,  this 
adrenergic  increase  in  ICaL  was  stable  with  a  time  to  maximal  effect  of 
approximately 90 seconds. The mode of electrical access did not appear to affect 
the magnitude of the adrenergic effect, however as indicated in Results chapter 1, 
perforated  patch  recordings  were  associated  with  a  greater  duration  of  stable 
recordings. Patient senescence and gender did not appear to affect the adrenergic 
increase in ICaL. Pre operative drug therapy was not associated with an altered 
response  to  acute  superfusion  with  Isoproterenol  at  the  EC50  (0.05   M).  A 
diagnosis of pre operative hypertension was associated with a significantly larger 
adrenergic response to 0.05  M ISO. In contrast, prior MI, the presence of LVSD, 
regardless of severity, and Aortic Valvular Heart Disease were not associated with 
altered adrenergic responses. The magnitude of the adrenergic response of ICaL to 
0.05  M was not predictive of the development of post operative Atrial Fibrillation 
(AFpcs). 
 
ISO increased the magnitude of calcium current passing into the cell at all voltages 
recorded  in  the  absence  of  a  detectable  change  in  the  current:  voltage  (IV) 
relationship.  The  time  to  peak  current  recorded  at  +10  mV  was  less  than  4 
milliseconds in line with one previous report
161. The concentration: response curve 
of  the  effect  of  ISO  on  ICaL  at  physiological  temperature  using  the  nystatin 
perforated patch clamp method has not been previously published. However, our 
data  is  similar  in  comparison  with  the  concentration:  response  curve  of  the 
inotropic  effect  of  ISO  in  human  right  atrial  preparations
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between 0.01 and 0.1  M ISO and a maximal effect at 1  M ISO. The EC50 of the 
stimulatory effect of ISO on cAMP in human right atrial strips was reported to be 
10
 6.23 with a maximal effect between 1 and 10  M ISO
145;146;228;301 resulting in a 
threefold increase in adenylate cyclase activity
301. Exposure to ISO resulted in a 
rapid increase cAMP over 60 seconds but the positive inotropic effect developed 
to a maximum over 120 to 240 seconds
154. These effects were mediated by both 
β1 AR  and  β2 AR
153;154  and  the  increase  in  cAMP  persisted  for  up  to  15 
minutes
146;228, similar in time scale to that of the TCC data presented herein. 
 
Ligand  binding  of  β AR Gαs  stimulates  PKA/  cAMP  causing  phosphorylation  of 
serine  and  threonine  residues  on  the  α1c  and  β2a  subunits  of  L  type  calcium 
channels augmenting ICaL via an increased mean channel opening time and an 
increased  Po
90;238;239;302 307.  Calcium  entry  into  the  cytosol  acts  as  a  negative 
feedback to ICaL although other gating modalities such as voltage inactivation also 
occur
161. Although there are at least three types of β AR expressed in the human 
heart,  little  is  known  of  the  physiological  role  of  the  β3 AR  in  the  atrium  and 
discussion  in  this  work  will  be  limited  to  β1 AR  and  β2 ARs
308.  In  human  atrial 
myocytes  β1 ARs  couple  to  solely  to  Gαs  stimulating  ICaL  via  PKA  and  cAMP, 
however β2 ARs couple to both Gαs and Gαi which can exert negative feedback on 
ICaL and other cellular processes activated by β2 AR stimulation
232;309 313. PKA is 
anchored to the plasmalemma, co localising with the L type calcium channel and 
being bound by PKA anchoring protein (AKAP) or AHNAK protein
314;315. 
 
No data comparing ICaL kinetics obtained using the differing methodologies has 
been  published  to  date.  The  purpose  of  the  comparison  in  this  project  was  to 
establish if the formation of a ruptured patch with nystatin present in the pipette 
would  preclude  further  analysis  of  ICaL  so  recorded  because  of  the  possible 
confounding effect of nystatin entering the myocyte cytosol via a ruptured patch. Calum Jon Redpath    Chapter 3 110 
The  increased  duration  of  stable  ICaL  recordings  with  nystatin  perforated  patch 
recordings  is  consistent  with  the  published  literature
220;221  and  confirmed  the 
possibility of subsequently performing further yet more complex experiments. 
 
It has been shown that cardiac β AR function decreases with increasing age in 
humans
316;317. Mean β AR density, the ratio of β1 AR: β2 AR and Gαs activity was 
unchanged
157, however, Gαi levels increase in human right atrium in association 
with ageing and correlate with a significant reduction in adenylyl cyclase activity in 
response to mixed β1 AR: β2 AR agonists resulting in a ten fold increase in the 
EC50 of the positive inotropic response to ISO
157. Animal models of ageing have 
demonstrated  that  reduced  responsiveness  to  β AR  stimulation  in  isolated 
myocytes  is  due  to  reduced  receptor:  ligand:  second  messenger  activity  with 
preserved calcium handling protein apparatus
231. The lack of effect of increasing 
age on ICaL could be explained by a significant reserve in the number of L type 
calcium channels available for opening or an age related decrease in the activity of 
PDE4 which transduces the Gαi signal to inhibit cAMP. This possibility highlights 
the  potential  role  of  second  messenger  sub systems  and  compartmentalisation 
within  the  atrial  myocyte  to  separate  ICaL  acting  as  a  trigger  for  excitation 
contraction  coupling  from  an  adrenergic  inotropic  effect  of  ISO
38;318 321. 
Alternatively the lack of an age related effect may represent a type 2 error due to 
the  homogeneity  of  our  sample  of  patients  or  indeed  provide  evidence  of 
significant  reserve  of  second  messenger  coupling  to  ICaL  such  that  increased 
inward current in response to ISO is maintained despite the reduction in Gαs: Gαi 
ratio present in myocytes isolated from senescent patients. 
 
Gender has been associated with altered repolarisation but no reports of altered 
human ICaL have been published to date
298. Data from this laboratory and others 
have consistently failed to identify any significant difference in ICaL characteristics Calum Jon Redpath    Chapter 3 111 
in  human  atrial  myocytes  from  male  as  opposed  to  female 
patients
79;144;223;281;284;287;322. 
 
Pre operative  drug  therapy  had  no  discernible  effect  on  ICaL  under  control 
conditions nor on the adrenergic effect of ISO. Although chronic β B therapy has 
been  associated  with  reductions  in  APD90  and  ERP  these  were  related  to 
reductions in Ito in the absence of an effect on ICaL
144. These electrophysiological 
changes, termed “pharmacological remodelling”, were associated with a reduced 
occurrence  of  AFpcs,  but  were  identified  in  vitro,  independent  of  receptor 
occupancy
144. 
 
Although a third, and possibly a fourth β AR have recently been identified, little is 
known  of  their  physiological  role  in  the  heart
308;323 325.  All  subtypes  of  human 
myocardial  β AR  are  guanine  nucleotide  protein  receptors  which  bind 
Norepinephrine  undergoing  conformational  change  which  in  turn  activates 
membrane  bound  heterotrimeric  G  proteins
326 328.  The  ratio  of  β1 AR  to  β2 AR 
expression in human right atrium is controversial with several reports suggesting 
that the ratio varies between 65:35 to 80:20
145;229;301;329;330. β1 AR activation with 
Norepinephrine  and  β2 AR  binding  with  Epinephrine  can  equally  maximally 
increase inotropy in human atrial myocardium
152;331;332, and the β2 AR selective 
agonist zinterol demonstrates that both β AR receptors are coupled to the Gαs / 
adenylyl  cyclase/  cAMP/  PKA/  PLB  phosphorylation/  TnI  phosphorylation/  TnC 
phosphorylation system resulting in positive inotropic and lusitropic effects
333. 
 
Chronic β1 AR selective β B therapy sensitised β2 AR in human left and right atrial 
myocytes
334 339 resulting in an enhanced inotropic action of mixed and selective β2 
AR  agonists  in  the  absence  of  β1 AR  antagonists  suggestive  of  a  persistent 
modification of receptors and intracellular messenger systems
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However, human atrial β2 AR hyper responsiveness of up to a 10 fold increase
152 
cannot be explained by increased receptor density alone
159;301;340. Following β B 
therapy  in  tissue  samples
335  and  myocytes  marked  increases  in  β2 AR 
responsiveness
152;331;337  and  arrhythmia
290  were  observed.  The  atrial  inotropic 
response to NE via β1 AR 
152;331;337 and E
341 was not enhanced following chronic 
BB  therapy,  however  chronic  β B  therapy  was  associated  with  noradrenalin 
evoked ‘arrhythmia’ mediated via β1 AR
290. 
 
Chronic pretreatment with β B therapy may
330;334;335;337 or may not
324 increase β 
AR  expression  in  human  atrial  myocytes.  Selective  β1 AR  blockade  has  been 
shown to enhance the activity of Gαs protein in human atrial tissue
160;334 and the 
sensitivity of β2 AR
152;338 without any demonstrable increase in numbers of β AR 
or of cAMP responsiveness
152;342;343, is suggestive of enhanced coupling of the β 
AR to adenylyl cyclase via Gαs or perhaps an inhibition of PKA phosphorylation of 
Gαs. Wang et al
160 among others measured the α subunit of Gαs and Gαi and the β 
subunit  of  G  proteins  expression  at  protein  and  mRNA  levels  and  found  no 
significant  difference  in  human  atria  from  BBY  v  BBN  patients,  however  Gαs 
function was found to be significantly (2 fold) enhanced in BBY patients. 
 
There are 4 types of adenylate cyclase found in human atrium (IV VII)
343. β AR 
activation  rapidly  activates  BAR  kinase  which  phosphorylates  β AR  resulting  in 
subsequent loss of G protein coupling
343 and there was no significant difference in 
the absolute levels of gene expression among adenylate cyclase subtypes in BBY 
v  BBN.  As  the  inotropic  effects  of  synthetic  cAMP
152  or  forskolin
291  are  not 
augmented following chronic β B therapy then perhaps a possible role for altered 
amplification of receptor coupling via Gs proteins exists
344. 
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Desensitisation  of  β AR  occurs  via  a  family  of  serine  threonine  kinases  called 
GPRC Kinases (GPRCK) abbreviated to GRK  GRK the ones specific to β AR are 
named βARK. These are similar in structure to other serine threonine kinases such 
as PKA and PKC. When the receptor is phosphorylated by the βARK the β AR is 
desensitised
345. GRK2 is βARK1 and GRK3 is βARK2 and in the myocardium they 
only  recognise  and  thus  phosphorylate  agonist  occupied  receptors
346.  The  Gβγ 
subunit which remains from the ‘splicing’ of the G protein complex then interacts 
with the carboxyl terminal of the cytosolic βARK resulting in the translocation of the 
GRK  to  the  membrane  where  it  phosphorylates  the  activated  receptor
347. 
Desensitisation  in  the  presence  of  persistent  agonism  such  as  catecholamine 
elevation in heart failure (termed homologous desensitisation) requires not only 
GRK but also β arrestin which prevents Gαs coupling to the catecholamine bound 
β AR
348.  Reduced  β AR  density  and  function  in  failing  hearts  is  in  contrast  to 
βARK which is significantly increased in patients with CHF
349, hypertension
350 and 
myocardial ischaemia
351. The premise that elevated βARK1 is protective is being 
suggested by in vitro studies, as reduced βARK expression levels post myocardial 
infarction have been associated with an increased inotropic response to ISO
352   
analogous  to  the  interruption  of  neurohumoural  remodelling  of  CHF  by  β B 
therapy   indeed  β B  therapy  is  associated  with  a  reduction  in  βARK1,  β AR 
downregulation  increasing  agonist  sensitivity  and  improving  cardiac  function  in 
vivo
353. As β ARK preferentially phosphorylates the β2 AR rather than β1 AR
354, yet 
another possible mechanism for selective inactivation of the β2 AR exists. β1 AR 
blockade with selective β B therapy will inhibit β ARK activity in β2 AR resulting in 
more non phosphorylated β2 AR as a result of background autonomic tone. 
 
The lack of effect of chronic CCB therapy on beta adrenoceptor density is less 
controversial. Published reports confirm that CCB has no effect on adrenoceptor 
density  in  human  right  atrium
330;335;337;355;356.  Two  previous  reports  in  humans Calum Jon Redpath    Chapter 3 114 
described  a  decrease  in  ICaL  associated  with  chronic  pre operative  CCB 
therapy
155;282, however a larger study comprised of data from this laboratory and 
three other investigators found no such association
144;223;281;287. In animal models 
most studies reported no association between chronic CCB therapy and ICaL and 
indeed in one study an increase in ICaL was described
357 360. It is not clear why the 
difference  in  results  from  human  atrial  myocytes  occurred,  however  the  initial 
reports described results with significant methodological differences between the 
studies. 
 
There has been only one published report of the acute effect of the ACE I drug, 
enalapril, to increase ICaL
282, but the present study is in total agreement with four 
previously  published  reports  demonstrating  no  association  with  chronic  ACE I 
therapy and altered ICaL characteristics
144;223;281;287. 
 
There  have  been  no  studies  published  to  date  demonstrating  an  association 
between pre existent hypertension and altered human atrial ICaL characteristics. If 
true, one possibility, discussed above, is elevated levels of βARK
350. At first glance 
this would seem counterintuitive as reduced levels of βARK were associated with 
an  increased  inotropic  response  to  ISO
352.  However  there  may  indeed  be  a 
confounder  at  play.  Most  patients  from  whom  we  received  atrial  tissue  were 
undergoing cardiac surgery for CHD and were receiving chronic β B therapy which 
is associated with a reduction in βARK1, increasing agonist sensitivity in vivo
353. In 
retrospect, pooled data from our own laboratory, with a much larger sample size 
and following multivariate analysis similarly does not identify any such association 
between  pre existent  hypertension  and  altered  human  atrial  ICaL 
characteristics
144;284, suggesting that this is a type 1 error due to the small sample 
size. 
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Although the L type calcium current recorded in canine ventricular myocytes from 
the infarct border zone is reduced with altered kinetics and response to adrenergic 
stimulation following MI in vitro
361 363, no such association has been documented in 
human atrial myocytes
144;284. 
 
The acute effects of sympathomimetics are blunted in patients with CHF and this 
has been thought to be related to any or all of the following effects: a CHF induced 
down regulation of β AR, internalisation of the receptor ligand complex with out 
downstream  cellular  effects,  depletion  of  intracellular  stores  of  secondary 
messengers or impaired phosphorylation of intracellular messengers
126;364;365. 
 
The  positive  inotropic  and  lusitropic  effects  of  β1 AR  and  β2 AR  ligand  binding 
persists in human atrial tissue from failing hearts
152;331 333. Despite similar levels of 
expression of β1 AR and β2 AR
339, however, the effects of β2 AR binding E are 
preserved but the β1 AR mediated inotropic effect of NE was reduced fourfould in 
tissue preparations from patients with CHF with no change in lusitropy. Reports of 
reduced  ICaL  response  to  β AR  stimulation  are  controversial,  and  may  reflect 
altered β AR availability and response in myocytes from CHF patients rather than 
impaired intracellular signal transduction mechanisms
114;279;366;367. This hypothesis, 
that β2 AR linked to Gαi proteins
232;309 may oppose the effects of Gαs stimulation in 
human atria, particularly in patients with CHF
312, due to the relative downregulation 
of β1 AR as compared to β2 AR
342 remains unsubstantiated
330;332;340;342. One report 
has suggested that the ISO induced stimulation of adenylate cyclase activity was 
weaker in atrial tissue compared to ventricular specimens from failing hearts
301. 
There  appeared  only  a  weakly  positive  correlation  of  increasing  β AR  receptor 
concentration  and  adenylate  cyclase  activity  in  right  atrial  specimens
301.  Very 
recently human atrial myocytes with very small detectable “down regulated” ICaL at 
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of  developing  AF,  were  observed  to  display  an  exaggerated  response  to 
stimulation with ISO
299. This is on stark contrast to the current work and pooled 
data from our laboratory performed under more physiological conditions. 
 
We, and others, have found, following multivariate analysis, that there were no 
detectable differences in ICaL peak current, I: V relationship or kinetics under basal 
conditions  nor  following  stimulation  with  ISO  at  the  approximate  EC50  (50  nM) 
between cells from patients with as opposed to without LVSD
144;279;284;300;368. 
 
Some  of  the  original  studies  examining  inward  calcium  current  in  human  atrial 
myocytes linked calcium overload via increased ICaL, either alone or as a function 
of  tachycardia,  to  the  subsequent  development  of  AF
81;82;104;369.  It  is  widely 
accepted that the response to AF, that is the electrophysiological remodelling that 
occurs as a result of the presence of AF or as a result of the pathophysiology 
which has also allowed AF to supervene is associated with an approximate 70% 
reduction in ICaL
69;79;82;98;100;370. In contrast to early data which demonstrated an 
association between large ICaL and post operative AF, but not the magnitude of an 
adrenergic  increase  in  ICaL
81,  Dinanian  et  al
299  report  that  the  smaller  the 
magnitude of baseline ICaL the greater the adrenergic response to ISO. However 
no information regarding the subsequent development of AFpcs was available. In 
contrast neither the baseline magnitude of ICaL nor the adrenergic response to ISO 
was  predictive  of  subsequent  AFpcs  in  this  study  nor  in  pooled  data  from  this 
laboratory
284. 
 
3.6.4 Anti adrenergic effect of acute superfusion with ET 1 
ET 1 alone, a mixed ET A and ET B receptor agonist, at the maximal concentration 
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S6 c,  a  selective  ET B  receptor  agonist  had  no  significant  effect  on  peak  ICaL 
indicating that there was no apparent effect rather than a balance of two opposing 
effects on peak ICaL. In contrast, ET 1, in a concentration dependent fashion from 
0.01 to 10 nM, had an anti adrenergic effect on peak ICaL prestimulated by 0.05  M 
ISO. This anti adrenergic effect was partially reversible, both by washout and also 
by either a priori or co application with the selective ET A receptor antagonist FRA 
at 10 nM. Sarafatoxin S6 c at 10 nM had no effect on prestimulated peak ICaL, nor 
did it prevent the anti adrenergic effect of 10 nM ET 1 on peak ICaL which had been 
pre stimulated with 0.05  M ISO.  
 
In human atrial myocytes, ET 1 alone was found to increase
199, decrease
199;200 or 
have no effect
199;200 on ICaL under control conditions. It is not immediately apparent 
why  this  should  be.  Initial  reports  in  animal  models  described 
stimulatory
196;248;258;259,  inhibitory
195;196;248;260 263  or  no  effect
203;247;249;264  of  ET 1 
directly  on  ICaL,  with  an  EC50  between  1  and  10  nM,  mediated  via  ET A 
receptors
195;196;203;248;249;258 264.  In  addition  to  the  possible  direct  effects  on  ICaL, 
activation of NHE
265 and NCX
266 268 via PKC have also been described, but such 
activation  would  be  expected  to  reduce  ICaL  as  a  result  of  calcium  induced 
inactivation which was not observed. 
 
ET 1  has  been  noted  to  inhibit  IK1  via  PKC  in  human  atrial  myocytes  at 
physiological  temperature  using  whole  cell  patch  clamp
371  resulting  in  a 
hyperpolarised  resting  membrane  potential
270;272.  ET 1,  at  a  concentration 
observed in patients with severe CHF
372, induced maximal inhibition of outward K
+ 
and  NCX  currents  in  human  atrial  but  not  ventricular  myocytes  similar  to 
experience  in  animal  models
268;271;273;373.  Whether  these  effects,  not  directly 
measured herein, could in some way compensate for a direct effect of ET 1 on ICaL 
rendering the net effect to be zero cannot completely be discounted. However ICaL Calum Jon Redpath    Chapter 3 118 
was recorded with caesium in the pipette blocking K
+ currents in the cells studied 
and  the  TCC  experiments  discount  a  time  dependency  of  opposing  effects 
reported
199;200. 
 
Differing  methodologies  may  explain  apparently  contradictory  results.  The 
requirement for ET 1 to convey it’s signalling via temperature sensitive secondary 
messengers may result in a population of cells unable to respond conventionally 
depending  on  the  level  of  oxidation  or  phosphorylation  of  the  cell  cytosol 
proteins
84;161;374 379. A similar paradox of apparently opposing effects of ANP on 
ICaL was resolved by ensuring the availability of second messengers, in this case 
cGTP, in the pipette during ruptured patch experiments
199;380;381. 
 
Initial experiments investigating potential arrhythmogenic effects of ET 1 in animal 
models were contradictory confounded by the peptide’s vasoconstrictor induced 
ischaemic  pro arrhythmic  effects
54 60,  however  several  groups  began  to  identify 
acute  electrophysiological  effects  apparently  directly  attributable  to  ET 1  in  the 
absence of ischaemia
56;61 64. 
 
Historically a clearer consensus began to emerge regarding ET 1 having a positive 
inotropic effect and influencing arrhythmogenesis in human tissues although no 
obvious  mechanism  was  initially  apparent
191.  Initially  this  apparent  positive 
inotropic effect was assumed to be related to a direct augmentation of ICaL by ET 
1. However the positive inotropic effect of ET 1 has been demonstrated to occur in 
the absence of an increase in ICaL
179;197;382 384 or the calcium transient suggestive 
of increased myofibrillar sensitivity to calcium
195;385;386. In addition the effect of ET 
1  via  ET A  receptors  in  tissue  preparations  removed  from  failing  hearts  varied 
considerably and was thought to relate to altered ET 1 receptor expression rather 
than any changes in ICaL
175;184;372;387;388. Calum Jon Redpath    Chapter 3 119 
 
The  positive  inotropic  effect  of  ET 1  in  human  atrial  preparations
175;177 
179;188;193;387;388 has now been identified to be mediated by ET A receptors via InsP3/ 
DAG/ PKC
177;184;187;188;193;387;388 in the presence
179;188 and absence of any effect on 
NHE
177;388.  Of  note  is  that  the  positive  inotropic  effect  of  ET 1  was  apparently 
independent of patient age, gender, pre operative drug therapy and LVSD which 
have previously been associated with altered GPCR status and ICaL
386. 
 
In animal models evidence exists for an additional three possible mechanisms by 
which ET 1 can exert a positive inotropic effect in cardiac myocytes in the absence 
of an augmentation of ICaL: stimulation of NHE resulting in increased myocyte [pH]i 
sensitising troponin C to calcium, increasing the [Na]i resulting in mode reversal of 
NCX and PLC activation induced InsP3 formation causing increased SR calcium 
uptake, storage and release
187;194;197;241;265;267;389 392. 
 
The above experiments described the effects of acute exposure to ET 1, however 
one study has described the effects of chronic (≥5 days) exposure of rat myocytes 
to ET 1 which resulted in blunting of the positive inotropic effect of both ISO and 
increased [Ca
2+]ec mediated by ET A, via PKC and NHE
393. 
 
In one of the three studies examining the receptor mediated effects of ET 1 alone 
on ICaL
199, an intrinsic stimulatory effect of ET 1 on ICaL was prevented by pre 
treatment of the atrial myocytes with the ET B receptor agonist BQ 788. In human 
tissue BQ 788 has been shown to have low affinity for and little selectivity for ET B 
receptors
394. This observation could be explained by a lack of effect of ET 1 alone 
which  would  be  consistent  with  that  observed  in  the  other  two  published 
reports
200;322. No additional data other than ICaL current density at baseline was 
provided to explain this apparent dichotomous effect
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data obtained at room temperature with variable effects dependent on small initial 
ICaL density without clearly identifying an obvious mechanism
92;299.  
 
Evidence exists for a basal constitutive cAMP/ ICaL activity level in human atrial 
myocytes
281;287;288;395  which  is  counterbalanced  by  type  1  and  type  2A 
phosphatases (PP1 and PP2A)
91 and it may be that two populations of cells with 
differing phosphatase activity or perhaps altered basal levels of cAMP may explain 
the dichotomous results. In human right atrium ET 1 was demonstrated to have 
little  or  no  effect  on  cAMP  under  basal  conditions,  but  inhibited  the  action  of 
adenylate  cyclase  to  produce  cAMP  due  to  ET A  receptor/  Gαi/  IP3  formation 
independent of ICaL and PKC
187;200. Indeed the anti adrenergic effect of ET 1 was 
abolished during simultaneous intracellular application of 8 Br cAMP
200. 
 
In human atrial myocytes, ET 1 alone was found to increase
199, decrease
199;200 or 
have no effect
199;200 on ICaL under control conditions. Following pre stimulation with 
ISO, ET 1 consistently had an anti adrenergic effect mediated via ET A receptors 
coupled to Gαi
199;200. Numerous groups have developed a theme of ET 1 whether 
via crosstalk in  intracellular messengers or via direct antagonism demonstrates an 
anti adrenergic effect on chronotropy, inotropy and ICaL
245 249. 
 
Adrenergically prestimulated ICaL was inhibited by 10 nM ET 1 via ET A receptors 
acting on Gαi (pertussis sensitive) GPCRs
245;247;262 which reduced cAMP via PDE 
in guinea pig ventricular myocytes
262 and human atrial myocytes
200 in the absence 
of any direct effect on the L type calcium channel itself
198;200. Similar to human 
atrial  ICaL,  ET 1  binding  to  ET A  receptors  had  no  effect  on  basal  ICl  in  animal 
models, however ET 1 with an EC50~ 1 nM, activating Gαi had an anti adrenergic 
effect reducing ISO prestimulated ICl via reducing intracellular cAMP (PDE)
205;273. 
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ET 1  binding  to  ET A  receptors  on  animal  cardiac  myocytes  has  a  number  of 
biological effects mediated via stimulation of Gαi
396 398. ET 1 had an anti adrenergic 
negatively chronotropic effect mediated via ET inhibition of formation of cAMP both 
under basal conditions and following adrenergic stimulation with ISO
399 and ET 1 
prevented  apoptosis  induced  by  10   M  ISO  downstream  to  the  β AR  and  Gαi 
induced alterations in cAMP mediated intracellularly via phosphatidylinositol and 
protein phosphate kinases
400. As apoptosis is a recognized sequel following the 
development of AF or atrial dilation
96, whether ET 1 has a direct effect to promote 
apoptosis  or  has  an  anti adrenergic  effect  to  oppose  apoptosis  mediated  by 
catecholamines remains to be determined. 
 
The selective ET A receptor antagonist FR139317 inhibited the binding of ET 1 to 
ET A receptors in a concentration dependent, monophasic fashion with an IC50 of 
0.53 nM in the absence of agonist activity
401. The possibilities for ET 1 mediated 
anti adrenergic effect on human atrial ICaL are as follows: ET 1 stimulates calcium 
release  from  the  SR  reducing  the  electrochemical  gradient  producing  calcium 
mediated inactivation of ICaL
195;197;258, ET 1 stimulates IP3 formation and in so doing 
inhibits  cAMP  formation  by  adenylate  cyclase  reducing  the  ability  of  cAMP 
dependent kinases to activate ICaL
187;188;200;262;273;399, or that ET 1 stimulates cyclic 
nucleotide  phosphodiesterase  via  cGMP  hydrolyzing  cAMP  antagonizing  the 
adrenergic effect of β AR stimulation
187;199;200;242 on ICaL but not NCX
402;403. The 
apparent contradiction in an inhibitory effect on ICaL but a positive inotropic effect 
could  be  explained  by  the  relative  efficacy  of  the  differing  second  messenger 
systems  effected  by  ET 1  binding  to  ET A  receptors:  sensitising  the  SR  and 
increasing  cytosolic  calcium  during  diastole  will  oppose  calcium  entry  via 
ICaL
195;197;258, PLC activation and IP3/ DAG stimulation produces a positive inotropic 
effect  but  the  associated  inhibition  of  cAMP  will  reduce  ICaL Calum Jon Redpath    Chapter 3 122 
amplitude
187;188;200;262;273;399 and activation of NHE
265 and NCX
266 268 via PKC will 
result in a positive inotropic effect with little or no direct inhibitory effect on ICaL. 
 
If  one  accepts  that  ET 1  is  a  positive  inotrope  but  a  negative  lusitrope,  it  is 
accepted that the PIE of ET 1 differs from that of beta adrenergic agonists such as 
isoproterenol  which  is  positively  inotropic  but  also  positively  lusitropic.  ET 1 
increases  the  calcium  transient  and  is  thought  to  do  this  via  NHE  and  ICaL
404. 
Stimulation  of  NHE  causes  intracellular  alkalinisation  and  an  increase  in 
intracellular Na
265;405;406 which reverses the normal direction of the sarcolemmal 
NCX and thus increases intracellular calcium
407. This may explain why for a given 
PIE  ET 1  requires  a  smaller  increase  in  intracellular  Ca  and  also  the  different 
lusitropic  effects  when  compared  to  beta  adrenergic  agonists
407.  Additionally 
alkalinisation  of  the  cardiac  myocytes  increases  the  affinity  of  troponin  C  for 
calcium, sensitising actomyosin ATP ase to calcium resulting in a positive inotropic 
effect and decreases the rate of dissociation of calcium from the troponin C ca 
complex resulting in negative lusitropy. 4 123 
4  RESULTS (ii) 
Single atrial myocyte action potential studies 
4.1 Introduction and aims 
The primary function of the heart is to pump blood around the body. In order for 
this  to  occur  effectively  a  coordinated  cycle  of  excitation,  contraction  and 
relaxation  in  cardiac  myocytes  must  occur.  The  action  potential  is  a  time 
dependent  integration  of  multiple  ionic  currents  present  on  the  cell  membrane 
which  not  only  initiates  intracellular  excitation contraction  coupling  but  also 
provides the excitatory stimulus for adjacent myocytes. This electrical stimulus, 
when normally propagated around the heart, permits coordinated 3 D contraction 
forcing blood through the cardiac chambers and out into the blood vessels. 
 
In human atrial myocytes action potentials are generated by the rapid inward influx 
of fast sodium current (INa) depolarising the cell membrane. This depolarisation 
opens long lasting L type calcium channels (ICaL) permitting calcium to enter the 
cell triggering mechanical activation of the contractile apparatus within the cell and 
forming the electrical plateau phase characteristic of cardiac myocytes to oppose 
rapid  repolarisation  by  potassium  currents  (ITO).  Action  potential  repolarisation 
electrically  resets  the  myocytes  in  a  rate  dependent  manner  permitting  the 
electrical cycle to be repeated and the ensuing refractoriness ensures sufficient 
time  for  intracellular  processes  to  complete  in  time  for  the  subsequent  action 
potential.  
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Propagation  of  an  action  potential  between  neighbouring  myocytes  transmits 
stimuli from one region of the heart to another. The action potential is modulated 
by the physiological environment surrounding the cell, the cell membrane voltage, 
the membrane ion channels and intracellular regulatory molecules in a complex 
fashion. Up until this point we have limited our investigation to one ion channel, 
ICaL. It is important not only to place the effects of ET 1 on ICaL characteristics in 
context within the action potential but also to translate these changes into myocyte 
functional  properties,  that  is  repolarisation  and  refractoriness,  in  addition  to 
identifying any other changes in action potentials which may indicate the possibility 
of ET 1 effecting cardiac ion channels other than ICaL.  
 
The effect of catecholamines to elevate the plateau phase of mammalian cardiac 
action potentials were described in detail many years ago
227;408 412. Although the 
cellular basis of this plateau elevation took some time to fully be investigated it 
became  clear  that  this  adrenergic  effect  was  the  result  of  cAMP  mediated 
increased conductance of ICaL
227;408 416. However, despite these numerous reports, 
relatively little has been published in detail regarding the effect of ISO specifically 
on human atrial isolated myocyte action potentials at physiological temperature
161. 
 
Initial experiments investigating potential arrhythmogenic effects of ET 1 in animal 
models were contradictory, confounded by the peptide’s vasoconstrictor induced 
ischaemic pro arrhythmic effects
54 60. However, several groups began to identify 
acute  electrophysiological  effects  apparently  directly  attributable  to  ET 1  in  the 
absence of ischaemia producing focal activity
56;61 64. 
 
Endothelin has been reported to have a direct effect on INa
176;200;261, IK
62;269 272;417, 
ICaL
195;196;248;258 261;263;399,  ICl
273,  NHE
265  and  NCX
266 268  ionic  currents  in  cardiac 
myocytes in various animal and human studies. In contrast, very little is known Calum Jon Redpath    Chapter 4 125 
about the effects of ET 1 on human atrial myocyte action potentials. In this report 
we  have  described  an  absence  of  effect  of  ET 1  alone  on  ICaL  but  observed 
powerful anti adrenergic effects of ET 1 to completely reverse the effect of ISO on 
ICaL in human atrial isolated myocytes. 
 
Adrenergic stimulation is recognised to be pro arrhythmic in both human atrium 
and ventricle via automaticity, triggered activity and reentrant mechanisms
69;162;418. 
What is not known is whether ET 1 would modify human atrial myocyte action 
potential characteristics in such a way as to be anti arrhythmic, as suggested by 
its effect on ICaL, or if it would be observed to have other pleiotropic effects which 
could promote arrhythmogenesis. 
 
In  view  of  the  fact  that  initial  reports  described  stimulatory
196;248;258;259, 
inhibitory
195;196;248;260 263  or  no  effect
203;247;249;264  of  ET 1  on  ICaL  we  wished  to 
confirm whether the anti adrenergic effects of ET 1 on ICaL would translate into 
alterations in action potentials. In addition, using concentrations similar to those 
observed to have electrophysiological effects in animal models
195;196;203;248;249;258 
264 and reported to be present in human patients suffering from CHF
123;125;128;255 
we hoped to gain some mechanistic insight into arrhythmogenesis in heart failure. 
 
The aims of these experiments were as follows: 
•  To establish that human atrial isolated myocyte action potentials could be 
reliably recorded using the nystatin perforated patch clamp technique under 
“physiological” conditions 
•  To investigate whether patient characteristics, chronic pre operative drug 
therapy  or  pre operative  comorbidity  was  associated  with  altered 
electrophysiological  properties  such  as  depolarisation,  repolarisation  and 
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•  To determine the effects of ISO, at the EC50 previously demonstrated to 
reliably augment ICaL, on action potential characteristics and spontaneous 
depolarisations. 
•  To  investigate  the  effect(s),  if  any,  of  ET 1  on  action  potential 
characteristics and spontaneous depolarisations. 
•  To compare and contrast the effect(s) on action potential characteristics of 
ET 1 and ISO in combination. 
 
4.2 Methods 
Myocytes  were  isolated  and  superfused  with  solutions  as  previously  described 
(See  Methods  2.3.1).  Experiments  were  performed  in  current clamp  mode 
whereby a constant or pre specified time varying current is applied to the myocyte 
and the resultant change in membrane potential, the action potential, is recorded 
(See Methods section 2.4.1). 
  
Myocytes  in  the  resting  state  were  current  clamped  to   80±  5  mV  and 
subsequently  the  holding  current  was  maintained  <150  pA  thereafter.  Action 
potentials were stimulated at 75 beats per minute (bpm) using 5 ms current pulses 
of 120% threshold strength. 
 
The APD was calculated as the interval between the action potential upstroke and 
repolarisation to the level of 50% (APD50), 75% (APD75) and 90% (APD90) of the 
upstroke amplitude in all cells (See Figure 4.1). Additionally, in order to further 
investigate the effect of CCB drugs action potential repolarisation at 60% (APD60) 
was also calculated. A representative example of the measurements made to the 
raw current tracings to calculate phase 0 characteristics and repolarisation (Figure 
4.1A) and refractoriness in Figure 4.1B. Calum Jon Redpath    Chapter 4 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Diagrammatic representation of measurements of A) repolarisation and B) refractoriness 
in human atrial isolated myocyte action potential recordings. a= amplitude, b= overshoot, c= MDP, 
d=  time  to  peak  amplitude  (a/d=  Vmax),  e=  APD50,  f=  APD60,  g=  APD75,  h=  APD90,  i=  full 
repolarisation, j= 80% amplitude threshold, k= ERP. 
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4.3 Protocols 
Both ERP and REP protocols were performed under control conditions once an 
appreciation of the occurrence of spontaneous depolarisations was realised (See 
Methods  2.4.1).  Both  ERP  and  REP  protocols  were  performed  under  control 
conditions and subsequently acute superfusion with ISO at 0.05  M or 10 nM ET 1 
alone  was  performed  as  soon  as  stable  action  potential  recordings  (ERP  and 
REP) had been completed. Following exposure to ISO or ET 1 for 90 seconds and 
3 minutes respectively, based on time to peak effect on earlier ICaL experiments 
and assuming stable action potential recordings were observed, the addition of 
other  subsequent  reagents  to  the  superfusate  occurred.  A  diagramatic 
representation of action potential experiment is given in Figure 4.2. 
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Figure 4.2 A representative schema of the order and timing of recordings of human atrial isolated 
myocyte action potentials made during acute superfusion with both 0.05  M Isoproterenol and 10 nM 
ET 1 in combination. 
 
4.4 Statistics & data analysis 
Data were recorded and analysed off line as described in Methods section 2.5.1.. 
The  action  potential  characteristics  of  the  entire  dataset  followed  a  normal 
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the degree of difference between sub analysed samples under control conditions. 
This test was selected as it is the most valid, accepted test with which to assess 
the probability of a similar or more extreme result being arrived at by chance in 
samples  of  small  size
79;144;161;223.  Where  a  comparison  between  two  differing 
populations  of  data  are  presented  the  variance  of  the  two  groups  has  been 
assessed to permit the use of the unpaired Student’s t test was employed. As 
previously  stated  this  report  is  based  on  all  available  information  in  order  to 
maximise utility. 
 
4.5  Results 
4.5.1 Human  atrial  myocyte  action  potential  morphology  and 
phase 0 characteristics under control conditions 
Action  potentials  were  characterised  by  rapid  upstrokes  with  depolarisation 
consistently reaching positive potentials (overshoot). We recorded only type 1 and 
2 action potentials demonstrating a brief rapid repolarisation phase followed by a 
plateau phase prior to full repolarisation back to the diastolic potential. In order to 
quantify differences in action potential morphology a number of measurements of 
phase 0 characteristics, repolarisation and later, refractoriness, were made. The 
numerical  values  of  the  various  electrophysiological  characteristics  are 
represented in Table 4.1. A representative action potential recording is displayed 
in Figure 4.3. 
 
Cellular action potential characteristics followed a normal distribution. In order to 
determine whether samples from a particular patient were consistently more than 
2  SD  outwith  the  single  myocyte  distribution  curve  patient  means  were  also 
calculated and comparison with mean data were made. No cells from any patient 
required  to  be  excluded.  There  was  no  significant  difference  in  the  maximal Calum Jon Redpath    Chapter 4 130 
diastolic  potential  (MDP)  nor  of  phase  0  of  the  action  potential  depolarization 
characteristics of single myocytes as compared to patient mean (Figure 4.4 A D). 
The mean MDP of all myocytes following hyperpolarisation was  83.62± 0.6 mV as 
compared with  83.35± 0.7 mV (n= 78 cells from 20 patients, mean± s.e.m., Figure 
4.4A).  The  mean  maximal  rate  of  depolarization  (Vmax)  observed  in  cells  was 
208.7± 5.6 V/s which was not significantly different from patient mean 206.8± 6.8 
V/s (n= 78 cells from 20 patients, mean± s.e.m., Figure 4.4B). The action potential 
overshoot was similar regardless of cellular or patient mean: cell mean 60.7± 0.9 
mV compared to 60.6± 1.2 mV (n= 78 cells from 20 patients, mean± s.e.m., Figure 
4.4C).  As  expected  the  total  amplitude  of  the  phase  0  response  of  the  action 
potential did not significantly differ between cells or patients. Mean amplitude of 
phase 0 response recorded from cells was 144.6± 0.9 mV and was 143.8± 1.2 mV 
(n= 78 cells from 20 patients, mean± s.e.m., Figure 4.4D) from patients. 
 
4.5.2 Action potential duration under control conditions 
Early, mid and late repolarisation are referred to as APD at 50% 75% and 90% 
respectively  calculated  as  indicated  in  Figure  4.1  using  phase  0  upstroke 
amplitude  as  the  denominator.  Action  potentials  were  not  triangular  with  an 
obvious plateau during early and mid repolarisation. In an attempt to confirm that 
cells  were  similar  between  and  within  patients  a  comparison  between  cell  and 
patient means was performed and, as with MDP and phase 0 characteristics no 
significant difference was observed (Figure 4.5).  
 
Mean  action  potential  repolarisation  at  50%  (APD50)  observed  from  cells  was 
20.8± 2.6 ms compared to patient mean of 21.4± 3.5 ms (n= 78 cells from 20 
patients,  mean±  s.e.m.,  Figure  4.5A).  Action  potential  repolarisation  at  75% 
(APD75) observed from cells was 144.4± 7.8 ms and in patients was 147.7± 9.4 ms Calum Jon Redpath    Chapter 4 131 
(n= 78 cells from 20 patients, mean± s.e.m., Figure 4.5B). Similarly action potential 
repolarisation at 90% (APD90) observed from cells was 216.3± 9.3 ms compared to 
mean patient APD90 of 215± 9.8 ms (n= 78 cells from 20 patients, mean± s.e.m., 
Figure 4.5C). 
 
4.5.3 Effective refractory period (ERP) under control conditions 
There  were  no  significant  differences  observed  between  cellular  atrial  myocyte 
refractoriness and patient mean ERP recorded in 10 ms increments (Figure 4.6). 
The mean cellular ERP was 210.0± 8.1 ms compared to a patient mean of 213± 
8.8 ms (n= 74 cells from 20 patients, mean± s.e.m., Figure 4.6A). The relationship 
of  refractoriness  to  repolarisation  (ERP/APD90)  was  similar  between  cells  and 
patients: mean myocyte ERP/APD90 ratio of 1.007± 0.03 compared to 1.042± 0.05 
(n= 74 cells from 20 patients, mean± s.e.m., Figure 4.6B). 
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Figure 4.3 Representative human atrial isolated myocyte action potential recording made under 
control conditions. 
  Parameter  Mean data  Published range to 2008 
Phase 4  MDP   83.62 ± 0.6 mV   71 to  86 mV 
Phase 0  Vmax  208.7 ± 5.6 V/s  149 to 244 V/s 
  Overshoot  60.7 ± 0.9 mV  48 to 53 mV 
  amplitude  144.6 ± 0.9 mV  >90 mV 
Repolarisation  APD50  20.8 ± 2.6 ms  12 to 62 ms 
  APD75  144.4 ± 7.8 ms  118 to 138 
  APD90  216.3 ± 9.3 ms  176 to 447 ms 
Refractoriness  ERP  210 ± 8.1 ms  184 to 233 ms 
  ERP/ APD90  1.007 ± 0.03   
 
Table 4.1 Comparison of mean action potential characteristics data under control conditions from 
this study (nc=78, np=20 for phase 0 and repolarisation data, nc=74, np=20 for refractoriness data) 
with reported ranges in the literature (see text for references). 
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Figure 4.4 Comparison of cell mean with patient mean of phase 1 of the action potentials recorded 
under  control  conditions. A)  Mean  Diastolic  Potential.  B)  upstroke  maximum  velocity.  C)  action 
potential overshoot. D) action potential amplitude (n= 78 cells from 20 patients). 
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Figure 4.5 Comparison of cell mean with patient mean action potential duration. A) Action potential 
duration at 50% repolarisation (APD50) B) Action potential duration at 75% repolarisation (APD75) C) 
Action potential duration at 90% repolarisation (APD90) (n= 78 cells from 20 patients). 
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Figure 4.6 Comparison of cell mean with patient mean refractoriness. A) Effective refractory period 
(ERP) B) Ratio of ERP to APD90 (n= 74 cells from 20 patients). 
 
4.5.4 Impact of methodology on atrial myocyte action potentials 
and refractoriness 
4.5.4.1  Lack  of  effect  of  method  of  electrical  access  to  the  cell  on 
action potential characteristics relating to depolarisation 
 
There was no significant difference in the maximal diastolic potential (MDP) nor of 
phase 0 of the action potential depolarization characteristics of those myocytes in 
which the seal was obtained via a ruptured patch as compared with those cells in 
which the seal was a perforated patch. The mean MDP obtained with a ruptured 
seal was  85.1± 0.7 mV (n= 10 cells from 7 patients, mean± s.e.m.) as compared 
with  83.4± 0.7 mV (n= 68 cells from 13 patients, mean± s.e.m.). The maximal rate 
of depolarization (Vmax) observed in cells in which a ruptured seal was obtained 
was 211.8± 14.9 V/s (n= 10 cells from 7 patients, mean± s.e.m.) which was not 
significantly  different  from  those  cells  in  which  a  perforated  seal  was  obtained 
208.3± 6.1 V/s (n= 68 cells from 13 patients, mean± s.e.m.). The action potential 
overshoot was similar regardless of the method of electrical access:  ruptured seal 
formation was associated with a mean overshoot of 59.4± 3.0 mV (n= 10 cells 
from 7 patients, mean± s.e.m.) compared to 60.9± 0.9 mV (n= 68 cells from 13 
patients, mean± s.e.m.). Consistent with these results the total amplitude of the Calum Jon Redpath    Chapter 4 135 
phase 0 response of the action potential did not significantly differ according to the 
method  of  electrical  access  to  the  cell.  Mean  amplitude  of  phase  0  response 
recorded from cells via a ruptured patch was 144.8± 2.7 mV (n= 10 cells from 7 
patients, mean± s.e.m.) and was 144.6± 0.9 mV (n= 68 cells from 13 patients, 
mean± s.e.m.) from cells via a perforated patch. 
 
 
4.5.4.2  Lack  of  effect  of  method  of  electrical  access  to  the  cell  on 
repolarisation characteristics 
There  was  no  significant  difference  in  the  action  potential  repolarisation 
characteristics of those myocytes in which the seal was obtained via a ruptured 
patch  as  compared  with  those  cells  in  which  the  seal  formed  was  perforated. 
Action potential repolarisation at 50% (APD50) observed from cells in which the 
seal  ruptured  during formation  was  24.6±  8.5 ms  (n= 10  cells from  7 patients, 
mean± s.e.m.) compared to 20.2± 2.8 ms (n= 68 cells from 13 patients, mean± 
s.e.m.) that observed from cells in which the seal formed via perforation. Action 
potential repolarisation at 75% (APD75) observed from cells in which a ruptured 
patch formed was 164.6± 17.7 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared to 141.4± 8.5 ms (n= 68 cells from 13 patients, mean± s.e.m.) observed 
from  cells  in  which  the  seal  formed  via  perforation.  Similarly  action  potential 
repolarisation  at  90%  (APD90)  observed  from  cells  in  which  the  seal  ruptured 
during formation was 234.7± 22.6 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared  to  213.6±  10.1  ms  (n=  68  cells  from  13  patients,  mean±  s.e.m.) 
observed from cells in which the seal formed via perforations. 
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4.5.4.3  Lack  of  effect  of  method  of  electrical  access  to  the  cell  on 
myocyte refractoriness 
There  were  no  significant  differences  observed  in  atrial  myocyte  refractoriness 
associated with ruptured as compared with perforated patch formation. The mean 
effective refractory period (ERP) recorded from cells in which the seal ruptured 
during formation was 223.0± 19.3 ms (n= 10 cells from 7 patients, mean± s.e.m.) 
compared to 207.3± 8.9 ms (n= 64 cells from 13 patients, mean± s.e.m.) observed 
from  cells  in  which  the  seal  formed  via  perforations.  The  relationship  of 
repolarisation to refractoriness (ERP/APD90) was similar regardless of the method 
of  electrical  access  to  the  cell:  recordings  performed  via  ruptured  patch  (NR) 
demonstrated an ERP/APD90 ratio of 0.968± 0.03 (n= 10 cells from 7 patients, 
mean± s.e.m.) compared to 1.013± 0.04 (n= 64 cells from 13 patients, mean± 
s.e.m.) from recordings obtained via a perforated patch (NP). 
 
 
4.5.5 Impact of patient senescence and gender on human atrial 
isolated myocyte action potentials and refractoriness 
4.5.5.1  Lack of effect of patient age (dichotomised) on action potential 
characteristics 
There were no significant differences in the action potential characteristics relating 
to depolarisation, repolarisation or refractoriness under control conditions between 
those myocytes isolated from tissue excised from the right atrial appendage of 
patients aged 75 or over (elderly) as compared with patients aged less than 75 
years (young).  
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4.5.5.2  Impact of patient gender on action potential characteristics 
 
There were no significant differences in the MDP nor Vmax of phase 0 of the action 
potential,  however  a  significantly  greater  amplitude  of  the  action  potential 
upstroke, with similarly greater overshoot that did not reach statistical significance, 
was observed in atrial myocytes isolated from tissues excised from the RAA of 
male  patients  (Figure  4.7  A D).  The  mean  MDP  observed  from  myocytes 
emanating from female patients was  83.4± 0.8 mV (n= 15 cells from 4 patients, 
mean± s.e.m.) compared to  83.7± 0.7 mV (n= 57 cells from 15 patients, mean± 
s.e.m., Figure 4.7A) from male patients. The maximal rate of depolarization (Vmax) 
observed in cells from female patients was 193.9± 10.3 V/s (n= 15 cells from 4 
patients, mean± s.e.m.) which was not significantly different from that observed in 
cells  from  male  patients  208.8±  6.7  V/s  (n=  57  cells  from  15  patients,  mean± 
s.e.m.,  Figure  4.7B).  The  action  potential  overshoot  was  similar  regardless  of 
patient  gender: mean  overshoot  of  57.5±  2.1 mV  (n=  15  cells from  4 patients, 
mean± s.e.m.) in cells from female patients compared to 61.4± 1.0 mV (n= 57 cells 
from 15 patients, mean± s.e.m., p= 0.08. Figure 4.7C) in cells from male patients. 
However the total amplitude of the phase 0 response of the action potential was 
significantly larger in cells originating from male patients. Mean amplitude of phase 
0 response recorded from cells obtained from female patients was 140± 1.6 mV 
(n= 15 cells from 4 patients, mean± s.e.m.) and was 145.8± 0.9 mV (n= 57 cells 
from 15 patients, mean± s.e.m., p= 0.006. Figure 4.7D) from cells obtained from 
male patients. 
 
In  contrast,  there  were  no  significant  differences  in  the  action  potential 
repolarisation nor refractoriness of those atrial myocytes originating from female 
as compared with male patients. 
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Figure 4.7 Effect of patient gender on resting membrane potential and phase 0 action potential 
characteristics of human atrial isolated myocytes under control conditions.  ￿ = myocytes obtained 
from female patients (n= 15 cells from 4 patients)  ￿ = myocytes obtained from male patients (n= 57 
cells from 15 patients). Values are mean± s.e.m., asterisk* indicates p< 0.05. 
 
 
 
4.5.6 Impact  of  chronic  pre operative  drug  therapy  on  human 
atrial isolated myocyte action potentials and refractoriness 
4.5.6.1  Lack  of  effect  of  chronic  pre operative  beta adrenoceptor 
blocker  therapy  on  isolated  atrial  myocyte  action  potential 
characteristics 
There  were  no  significant  differences  in  the  characteristics  of  depolarisation, 
repolarisation nor refractoriness under control conditions when myocytes isolated 
from  tissue  excised  from  the  right  atrial  appendage  of  patients  chronically 
receiving β B therapy pre operatively (BBY) were compared to those from patients 
who were not receiving β adrenoceptor blocking drug therapy (BBN). 
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4.5.6.2  Effects of chronic pre operative calcium channel blocker (CCB) 
therapy on atrial myocyte action potential characteristics 
 
There were no significant differences in the maximal diastolic potential (MDP) nor 
of phase 0 of the action potential depolarization characteristics of those myocytes 
isolated from tissue excised from the right atrial appendage of patients chronically 
receiving  calcium  channel  blocking  drug  therapy  pre operatively  (CCBY)  as 
compared to those patients who were not receiving calcium channel blocking drug 
therapy (CCBN) (Figure 4.8 A D). 
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Figure 4.8 Lack of effect of chronic preoperative calcium channel blocking drug therapy on resting 
membrane potential and phase 0 action potential characteristics of human isolated atrial myocytes 
under control conditions.  ￿ = myocytes obtained from CCBN patients (n= 47 cells from 14 patients)  
￿ = myocytes obtained from CCBY patients (n= 25 cells from 5 patients). Values are mean± s.e.m. 
In contrast, atrial myocytes isolated from RAA preparations obtained from patients 
who  were  chronically  receiving  CCB  therapy  pre operatively  demonstrated 
significantly  accelerated  action  potential  repolarisation  under  control  conditions. 
There  were  significant  differences  in  early,  mid  and  late  action  potential 
repolarisation in comparison to those atrial myocytes originating from patients who Calum Jon Redpath    Chapter 4 140 
were  not  chronically  receiving  CCB  pre operatively  (Figure  4.9  A D).  Early 
repolarisation (APD50) observed from cells from CCBN patients was 25± 4 ms (n= 
47  cells  from  14  patients,  mean±  s.e.m.)  not  significantly  different  than  that 
observed in CCBY patients, 15.6± 3.2 ms (n= 25 cells from 5 patients, mean± 
s.e.m., Figure 4.9A).  
 
However a significant difference in early repolarisation was demonstrated at 60% 
repolarisation, mean (APD60) recorded from cells from CCBN patients was 89.3± 
7.5 ms (n= 47 cells from 14 patients, mean± s.e.m.) significantly different than that 
observed in CCBY patients, 65.2± 8.4 ms (n= 25 cells from 5 patients, mean± 
s.e.m.,  p=  0.049.  Figure  4.9B).  Action  potential  repolarisation  at  75%  (APD75) 
observed from cells from CCBN patients was 162.4± 10.3 ms (n= 47 cells from 14 
patients, mean± s.e.m.) significantly different in comparison to 116.9± 11.8 ms (n= 
25  cells  from  5  patients,  mean±  s.e.m.,  p=  0.0078.  Figure  4.9C)  in  cells  from 
CCBY patients.  
 
Similarly  this  effect  was  maintained  from  early  and  mid   repolarisation  to  late 
repolarisation (APD90). Recordings from cells originating from patients who were 
not receiving CCB drugs pre operatively APD90 was found to be 233± 12 ms (n= 
47 cells from 14 patients, mean± s.e.m.) significantly longer than the 188.2± 15.6 
ms (n= 25 cells from 5 patients, mean± s.e.m., p= 0.029. Figure 4.9D) observed 
from cells obtained from patients who were receiving CCB drugs pre operatively. Calum Jon Redpath    Chapter 4 141 
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Figure 4.9 Effect of chronic preoperative calcium channel blocking drug therapy on human atrial 
isolated myocyte action potential repolarisation under control conditions.  ￿ = myocytes obtained 
from CCBN patients (n= 47 cells from 14 patients)  ￿ = myocytes obtained from CCBY patients (n= 
25 cells from 5 patients). Values are mean± s.e.m., asterisk* indicates p< 0.05. 
 
There were no significant differences observed in single cell refractoriness in atrial 
myocytes  isolated  from  tissue  preparations  obtained  from  patients  chronically 
receiving CCB therapy pre operatively (CCBY) as compared to those patients who 
were  not  (CCBN)  (Figure  4.10  A  and  B).  The  mean  ERP  recorded  from  cells 
obtained from CCBN patients was 214.5± 10 ms (n= 47 cells from 14 patients, 
mean± s.e.m.) compared to 200.4± 14.9 ms (n= 25 cells from 5 patients, mean± 
s.e.m.,  Figure  4.10A)  observed  from  cells  obtained  from  CCBY  patients.  The 
relationship of repolarisation to refractoriness (ERP/APD90) was similar regardless 
of CCB status pre operatively: recordings made from cells obtained from CCBN 
patients  demonstrated  an  ERP/APD90  ratio  of  0.97±  0.02  (n=  47  cells  from  14 
patients, mean± s.e.m.) compared to 1.076± 0.08 (n= 25 cells from 5 patients, 
mean±  s.e.m.,  Figure  4.10B)  from  recordings  of  cells  obtained  from  CCBY 
patients. 
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Figure 4.10 Lack of effect of chronic preoperative calcium channel blocker therapy on human atrial 
isolated myocyte refractoriness under control conditions.  ￿ = myocytes obtained from CCBN 
patients (n= 47 cells from 14 patients)  ￿ = myocytes obtained from CCBY patients (n= 25 cells from 
5 patients). Values are mean± s.e.m. 
 
 
4.5.6.3  Impact  of  chronic  pre operative  Angiotensin  Converting 
Enzyme  Inhibitor  (ACE I)  therapy  on  atrial  myocyte  action 
potential characteristics 
There were no significant differences in the MDP, amplitude nor overshoot of the 
action potential upstroke, however a significantly greater Vmax of phase 0 of the 
action potential was observed in atrial myocytes isolated from RAA preparations 
obtained from patients chronically receiving ACE I therapy (ACE IY) compared to 
myocytes from those patients who were not (ACE IN) (Figure 4.11 A D). 
 
The mean MDP observed from myocytes obtained from ACE IN patients was  83± 
1 mV (n= 24 cells from 6 patients, mean± s.e.m.) compared to  83.9± 0.8 mV (n= 
48 cells from 13 patients, mean± s.e.m., Figure 4.11A) from ACE IY patients. The 
maximal rate of depolarization (Vmax) observed in cells from ACE IN patients was 
187.6± 9.6 V/s (n= 24 cells from 6 patients, mean± s.e.m.) which was significantly 
different from that observed in cells from ACE IY patients 214.7± 6.9 V/s (n= 48 
cells from 13 patients, mean± s.e.m., p= 0.025. Figure 4.11B). Neither the action 
potential  overshoot  nor  overall  phase  0  amplitude  were  associated  with  pre 
operative ACE I therapy induced effects: the mean overshoot in cells from ACE IN 
patients was 59.5± 2.7 mV (n= 24 cells from 6 patients, mean± s.e.m.) compared Calum Jon Redpath    Chapter 4 143 
to 60.9± 0.9 mV (n= 48 cells from 13 patients, mean± s.e.m., Figure 4.11C) in cells 
from ACE IY patients. The total amplitude of the phase 0 response of the action 
potential recorded from cells obtained from ACE IN patients was 142.9± 1.6 mV 
(n= 24 cells from 6 patients, mean± s.e.m.) and was 145.4± 1.0 mV (n= 48 cells 
from 13 patients, mean± s.e.m., Figure 4.11D) from cells obtained from ACE IY 
patients. 
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Figure 4.11 Effect of chronic preoperative angiotensin converting enzyme inhibitor (ACE I) therapy 
on resting membrane potential and phase 0 action potential characteristics of human atrial isolated 
myocytes under control conditions.  ￿ = myocytes obtained from ACE IN patients (n= 24 cells from 
6 patients)  ￿ = myocytes obtained from ACE IY patients (n= 48 cells from 13 patients). Values are 
mean± s.e.m., asterisk* indicates p< 0.05. 
 
 
There were no significant differences observed in action potential repolarisation 
nor  refractoriness  from  single  atrial  myocytes  isolated  from  tissue  preparations 
obtained from patients chronically receiving ACE I therapy pre operatively (ACE 
IY) as compared to those patients who were not (ACE IN). 
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4.5.7 Impact  of  patient  comorbidity  on  human  atrial  isolated 
myocyte action potential characteristics 
4.5.7.1  Impact  of  pre operative  left  ventricular  systolic  dysfunction 
(LVSD) on atrial myocyte action potential characteristics 
Atrial myocytes isolated from RAA tissue preparations obtained from patients with 
LVSD  (LVSDY)  were  significantly  more  polarized  in  the  quiescent  state  under 
control conditions as compared to recordings made from atrial myocytes obtained 
from  patients  diagnosed  as  free  from  LVSD  (LVSDN)  pre operatively  (Figure 
4.12A). There were, however, no significant differences detected in the observed 
amplitude nor the overshoot of the action potential upstroke, nor in Vmax of phase 0 
of the action potential (Figure 4.12 B D). The mean MDP observed from myocytes 
obtained from LVSDN patients was  82.1± 0.7 mV (n= 35 cells from 10 patients, 
mean± s.e.m.) significantly different as compared to  84.8± 0.9 mV (n= 43 cells 
from 10 patients, mean± s.e.m., p= 0.025. Figure 4.12A) from LVSDY patients. 
The maximal rate of depolarization (Vmax) observed in cells from LVSDN patients 
was 208.5± 9.4 V/s (n= 35 cells from 10 patients, mean± s.e.m.) which was not 
significantly different from that observed in cells from LVSDY patients 209± 6.9 V/s 
(n=  43  cells  from  10  patients,  mean±  s.e.m.  Figure  4.12B).  Neither  the  action 
potential  overshoot  nor  overall  phase  0  amplitude  were  associated  with  pre 
operative  LVSD  status:  the  mean  overshoot  in  cells from  LVSDN  patients  was 
60.2± 1.1 mV (n= 35 cells from 10 patients, mean± s.e.m.) compared to 61.4± 1.5 
mV  (n=  43  cells  from  10  patients,  mean±  s.e.m.,  Figure  4.12C)  in  cells  from 
LVSDY  patients.  The  total  amplitude  of  the  phase  0  response  of  the  action 
potential recorded from cells obtained from LVSDN patients was 145± 1.1 mV (n= 
35 cells from 10 patients, mean± s.e.m.) and was 144± 1.5 mV (n= 43 cells from 
10  patients,  mean±  s.e.m.,  Figure  4.12D)  from  cells  obtained  from  LVSDY 
patients. Calum Jon Redpath    Chapter 4 145 
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Figure 4.12 Effect of pre operative left ventricular systolic dysfunction (LVSD) on resting membrane 
potential and phase 0 action potential characteristics of human atrial isolated myocytes under control 
conditions.  ￿ = myocytes obtained from patients without LVSD (n= 35 cells from 10 patients)  ￿ = 
myocytes obtained from patients with LVSD (n= 43 cells from 10 patients). Values are mean± s.e.m., 
asterisk* indicates p< 0.05. 
 
 
There were no significant differences observed in action potential repolarisation 
nor  refractoriness  from  single  atrial  myocytes  isolated  from  tissue  preparations 
obtained  from  patients  suffering  pre operative  LVSD  as  compared  to  those 
patients who were not (Figure 4.13 A C and 4.14 A and B). Calum Jon Redpath    Chapter 4 146 
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Figure 4.13 Lack of effect of pre operative left ventricular systolic dysfunction (LVSD) on human 
atrial  isolated  myocyte  action  potential  repolarisation  under  control  conditions.    ￿  =  myocytes 
obtained from patients without LVSD (n= 35 cells from 10 patients)  ￿ = myocytes obtained from 
patients with LVSD (n= 43 cells from 10 patients). Values are mean± s.e.m. 
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Figure 4.14 Lack of effect of pre operative left ventricular systolic dysfunction (LVSD) on human 
atrial isolated myocyte refractoriness under control conditions.  ￿ = myocytes obtained from patients 
without LVSD (n= 35 cells from 10 patients)  ￿ = myocytes obtained from patients with LVSD (n= 43 
cells from 10 patients). Values are mean± s.e.m. 
 
4.5.7.2  Lack  of  effect  of  prior  myocardial  infarction  (MI)  on  atrial 
myocyte action potential characteristics 
There  were  no  significant  differences  in  the  characteristics  of  depolarisation, 
repolarisation  nor  refractoriness  observed  in  recordings  made  from  those 
myocytes isolated from tissue excised from the right atrial appendage of patients Calum Jon Redpath    Chapter 4 147 
who had suffered a myocardial infarction (MI) pre operatively (MIY) as compared 
to those patients who had not suffered a prior MI (MIN).  
 
4.5.8 Effect  of  0.05   M  isoproterenol  alone  on  human  atrial 
isolated myocyte action potentials and refractoriness 
 
4.5.8.1  Effect of 0.05  M ISO on human atrial isolated myocyte action 
potential characteristics relating to depolarisation 
Isoproterenol, at 0.05  M, had no significant effect on action potential upstroke, 
amplitude nor on phase one overshoot of the action potential but was associated 
with  a  small  but  statistically  significant  depolarisation  of  the  myocyte  during 
diastole as illustrated in Figure 4.15 and 4.16. Calum Jon Redpath    Chapter 4 148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 A representative example of the effect of acute superfusion with 0.05  M Isoproterenol 
on a human atrial isolated myocyte action potential waveform. 
 
The mean MDP under control conditions was  83.6± 0.7 mV whereas following 
acute  superfusion  with  0.05   M  ISO  the  mean  MDP  was  observed  to  be 
significantly different at  78.9± 1.3 mV (n= 22 cells from 12 patients, mean± s.e.m., 
paired data, p< 0.05, Figure 4.16A). The maximal rate of depolarization (Vmax), 
however,  was  not  significantly  different following  acute  superfusion  with  ISO  at 
0.05  M (control Vmax 194.1± 9.1 V/s vs 196.9± 11.3 V/s following 0.05  M ISO, n= 
22 cells from 12 patients, mean± s.e.m., paired data, Figure 4.16B). The action 
potential overshoot was also similar regardless of the presence of 0.05  M ISO in 
the superfusate (55.6± 1.5 mV vs 57.3± 1.6 mV (n= 22 cells from 12 patients, 
mean± s.e.m., paired data Figure 4.16C). Similarly the total amplitude of the phase 
1  response  of  the  action  potential  did  not  significantly  differ  during  acute 
superfusion with ISO at 0.05  M: mean amplitude of phase 1 response recorded 
from cells under control conditions was 140.6± 1.6 mV compared to 136.6± 2.0 
mV during exposure to ISO (n= 22 cells from 12 patients, mean± s.e.m., Figure 
4.16D). 
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Figure 4.16 Effect of acute superfusion with 0.05  M Isoproterenol on resting membrane potential 
and phase 1 action potential characteristics of human atrial isolated myocytes.  ￿ = control  ￿ = 
0.05  M Isoproterenol (ISO) (n= 22 cells from 12 patients, paired data). Values are mean± s.e.m., 
asterisk (*) p< 0.05. 
 
 
4.5.8.2  Effect of ISO on human atrial isolated myocyte action potential 
repolarisation 
Isoproterenol, at 0.05  M, significantly prolonged the early and mid repolarisation 
of  human  atrial  myocyte  action  potentials  resulting  in  elevation  of  the  action 
potential  plateau,  but  had  no  such  effect  on  later  repolarisation  or  effective 
refractory period (Figures 4.17 and 4.19). The APD50 significantly increased from 
28± 5 ms under control conditions to 54± 10 ms following the application of ISO, 
an increase of 93% (n= 22 cells from 12 patients, p< 0.05 Figure 4.17). Neither the 
APD75 (control 154± 13 ms vs 163± 21 ms post ISO, n= 22 cells from 12 patients 
Figure 4.17) nor the APD90 (control 220± 14 ms vs 204± 16 ms post ISO, n= 22 
cells from 12 patients Figure 4.17) was significantly affected.  
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Figure 4.17 Effect of acute superfusion with 0.05  M Isoproterenol on action potential repolarisation 
characteristics of human atrial isolated myocytes.  ￿ = control  ￿ = 0.05  M Isoproterenol (ISO) (n= 
22 cells from 12 patients, paired data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
 
 
4.5.8.3  Effect of ISO on human atrial isolated myocyte refractoriness 
An example of the effect of acute superfusion with 0.05 M ISO on human isolated 
atrial myocyte refractoriness can be seen in Figure 4.20 and mean data in Figure 
4.19. Although 0.05 M ISO did not have a significant effect on the ERP directly 
(control ERP 208.9± 16.7 ms vs ISO ERP 227.9± 28.8 ms, n= 19 cells from 10 
patients Figure 4.19), the combination of this non significant increase in ERP and 
the non significant decrease in the APD90 (see section 4.5.8.2) resulted in a small 
but statistically significant increase in the ERP/ APD90 ratio (control ERP/APD90 
0.976± 0.02 vs ISO ERP/APD90 1.04± 0.03 ms, n= 19 cells from 10 patients, p< 
0.05 Figure 4.19). Calum Jon Redpath    Chapter 4 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Representative example of the effect of acute superfusion with 0.05  M Isoproterenol on 
human atrial isolated myocyte action potential waveforms, A) under control conditions and B) during 
acute superfusion with ISO. 
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Figure 4.19 Effect of acute superfusion with 0.05  M Isoproterenol on human atrial isolated myocyte 
refractoriness.  ￿ = control  ￿ = 0.05  M Isoproterenol (ISO) (n= 19 cells from 10 patients, paired 
data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
 
 
4.5.8.4  Effect of ISO to induce spontaneous depolarisations 
During  the  repetitive  stimulation  protocol  designed  to  evaluate  the  effective 
refractory period following superfusion with ISO, but not under control conditions, 
low  amplitude  sub threshold  spontaneous  depolarisations  would  frequently 
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interrupt  the  stimulation  train.  These  ‘spontaneous  depolarisations’  (SD)  most 
frequently  occurred  during  phase  3  and  4  of  the  action  potential  and  only 
occasionally  reached  threshold  (see  Figure  4.20).  The  occurrence  of  SDs  was 
significantly associated with exposure to ISO and was not observed under control 
conditions (control SD 0% vs ISO SD 64%, n= 11 cells, 3 patients, χ2 test, p< 
0.05). 
 
4.5.9  Effect  of  10  nM  endothelin 1  alone  on  human  atrial 
isolated myocyte action potentials and refractoriness 
4.5.9.1  Effect of ET 1 alone on human atrial myocyte action potential 
characteristics related to depolarisation 
 
Acute  superfusion  of  human  atrial  myocytes  with  10  nM  Endothelin 1  had  no 
apparent effect on the MDP, amplitude nor on phase one overshoot of the action 
potential  but  was  associated  with  a  significant  reduction  in  action  potential 
upstroke velocity (Figure 4.21). Under control conditions the MDP was  84.8± 1.5 
mV and following acute superfusion with 10 nM ET 1 was observed to be  83.6± 2 
mV (n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21A). The 
maximal rate of depolarization (Vmax), however, was significantly reduced following 
exposure to 10 nM ET 1 (control Vmax 211± 12.3 V/s vs 165± 11.9 V/s following 10 
nM ET 1, n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21B). 
The action potential overshoot was similar regardless of the presence of ET 1 in 
the  superfusate  (61.9±  1.7  mV  vs  55.9±  2.9  mV  (n=  21  cells  from  5  patients, 
mean±  s.e.m.,  paired  data,  Figure  4.21C).  The  total  amplitude  of  the  phase  1 
response of the action potential did not significantly differ during acute superfusion 
with 10 nM ET 1: mean amplitude of phase 1 response recorded from cells under 
control conditions was 146.9± 1.6 mV compared to 139± 4.3 mV during exposure 
to ET 1 (n= 21 cells from 5 patients, mean± s.e.m., paired data, Figure 4.21D). 
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 Control 
 
Figure 4.20 A representative example of the effect of acute superfusion with 0.05  M Isoproterenol 
on  a  human  atrial  isolated  myocyte  action  potentials  stimulated  during  a  repetitive  stimulation 
protocol demonstrating phase 3 spontaneous depolarisations (*). 
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Figure 4.21 Effect of acute superfusion with 10 nM ET 1 on resting membrane potential and phase 1 
action potential characteristics of human atrial isolated myocytes.  ￿ = control  ￿ = 10 nM ET 1 (n= 
21 cells from 5 patients, paired data). Values are mean± s.e.m., asterisk (*) p< 0.05. 
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4.5.9.2  Effect of ET 1 alone on action potential repolarisation 
 
The  acute  superfusion  of  human  atrial  myocytes  with  10  nM  ET 1  had  no 
discernible effect on action potential repolarisation (Figures 4.22 and 4.24). The 
APD50 was similar under control conditions compared to during superfusion with 
ET 1 (12.8± 1.9 ms vs 13.8± 1.8 n= 21 cells from 5 patients, Figures 4.22 and 
4.24). Neither the APD75 (control 132.4± 13.1 ms vs 141.8± 13.2 ms post ET 1, n= 
21 cells from 5 patients, Figure 4.22) nor the APD90 (control 210.1± 17.1 ms vs 
226.2± 19.7 ms post ET 1, n= 21 cells from 5 patients) was significantly different 
during exposure to 10 nM ET 1 (Figure 4.22).  
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Figure 4.22 Effect of acute superfusion with 10 nM ET 1 on action potential repolarisation 
characteristics of human atrial isolated myocytes.  ￿ = control    = 10 nM ET 1 (n= 21 cells from 5 
patients, paired data). Values are mean± s.e.m. 
 
4.5.9.3  Effect of ET 1 alone on effective refractory period 
 
An  example  of  the  effect  of  acute  superfusion  with  10  nM  ET 1  on  human 
refractoriness can be seen in Figure 4.23 and mean data in Figures 4.23 & 4.24. 
Superfusion of myocytes with 10 nM ET 1 did not have a significant effect on the 
ERP (control ERP 190.6± 14.9 ms vs ET 1 ERP 207.5± 15.5 ms, n= 16 cells from 
5 patients Figures 4.23 and 4.24), nor the ERP/ APD90 ratio (control ERP/APD90 Calum Jon Redpath    Chapter 4 155 
0.903± 0.03 vs ET 1 ERP/APD90 0.957± 0.04 ms, n= 16 cells from 5 patients, 
Figure 4.23). 
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Figure 4.23 Effect of acute superfusion with 10 nM ET 1 on human atrial isolated myocyte 
refractoriness.  ￿ = control    = 10 nM ET 1 (n= 16 cells from 5 patients, paired data). Values are 
mean± s.e.m. 
 
4.5.9.4  Effect of ET 1 alone on spontaneous depolarisations 
 
Acute superfusion with 10 nM ET 1 alone was not significantly associated with SD 
occurrence (control SD 0% vs ET 1 SD 15%, n= 13 cells, 5 patients, χ2 test, p= 
ns). 
 
4.5.10  Effect  of  0.05   M  ISO  alone  and  in  combination  (co 
application) with 10 nM ET 1 on human isolated atrial 
myocyte action potentials and refractoriness 
4.5.10.1  Effect of ET 1 on adrenergically prestimulated action 
potential characteristics relating to depolarisation 
 
Acute superfusion of human atrial myocytes with 0.05  M Isoproterenol followed 
by the addition of 10 nM Endothelin 1 to the superfusate (co application) after 5 
minutes had no apparent effect on the MDP, action potential upstroke velocity, 
amplitude nor on phase one overshoot of the action potential (Figure 4.25). Under 
control conditions the MDP was  83.3± 0.8 mV, following acute superfusion with 
0.05  M ISO the MDP was  79.8± 1.1 mV and was  79.5± 1.3 mV following the Calum Jon Redpath    Chapter 4 156 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24 Lack of effect of ET 1 on basal action potential repolarisation and ERP. A, Action 
potential waveform and mean APD50, and B, Restitution and mean ERP, in absence of a drug (
 
) 
and following 10 nM ET 1 (
 
). Upper panels: superimposed responses to (A) 7th conditioning pulse 
and (B) in a different cell, to the 7th and 8th conditioning pulses followed by premature test pulses. 
Horizontal bars=ERP. Lower panels: paired means of APD50 (21 cells, 5 patients) and ERP (16 cells, 
5 patients). Values mean ± s.e.m. Figure taken from Redpath et al, JMCC 2006; 40: 717 724. 
 
 
addition of 10 nM ET 1 to the superfusate (n= 15 cells from 10 patients, mean± 
s.e.m., paired data, Figure 4.25A). The maximal rate of depolarization (Vmax) did 
not significantly change following superfusion with ISO, nor with ISO and ET 1 in 
combination (control Vmax 191.4± 11.3 V/s, ISO Vmax 203.4± 9.6 V/s and ISO/ET 1 
Vmax 182.9± 15.6 V/s, n= 15 cells from 10 patients, mean± s.e.m., paired data, 
Figure  4.25B).  The  action  potential  overshoot  was  similar  regardless  of  the 
presence of ISO or subsequently simultaneous ISO and ET 1 in the superfusate 
(control overshoot 56.9± 1.8 mV vs ISO 59.1± 1.5 mV vs ISO/ET 1 59.5± 2.5 mV, 
n= 15 cells from 10 patients, mean± s.e.m., paired data, Figure 4.25C). The total 
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amplitude of the phase 1 response of the action potential did not significantly differ 
following superfusion with 0.05  M ISO alone or in combination with 10 nM ET 1: 
mean amplitude of phase 1 response recorded from cells under control conditions 
was 140.5± 1.9 mV compared to 139.1± 1.1 mV during exposure to 0.05  M ISO 
alone and was 138.9± 2.3 mV during superfusion with ISO and ET 1 (n= 15 cells 
from 10 patients, mean± s.e.m., paired data, Figure 4.25D). 
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Figure  4.25  Effect  of  acute  superfusion  with  0.05   M  ISO  alone  and  then  0.05   M  ISO  in 
combination  with  10  nM  ET 1  on  resting  membrane  potential  and  phase  1  action  potential 
characteristics of human atrial isolated myocytes.  ￿ = control  ￿ = 0.05  M ISO      = 0.05  M ISO 
and 10 nM ET 1 co application (n= 15 cells from 10 patients, paired data). Values are mean± s.e.m. 
 
 
4.5.10.2  Effect of ET 1 on adrenergically prestimulated action potential 
repolarisation (APD) 
As described in sections 4.5.8.2 and 4.5.8.3, 0.05  M Isoproterenol significantly 
prolonged  the  early  and  mid  repolarisation  of  human  atrial  myocyte  action 
potentials resulting in elevation of the action potential plateau, but had no such 
effect on later repolarisation or effective refractory period, the “adrenergic effect” 
on action potentials (Figures 4.17 to 4.19). In cells in which the adrenergic effect of Calum Jon Redpath    Chapter 4 158 
ISO alone was recorded prior to addition of 10 nM ET 1 to the superfusate the 
APD50 significantly increased from 30± 6.3 ms under control conditions to 45.7± 
6.9 ms following the application of ISO, an increase of 52% (n= 15 cells from 10 
patients,  paired  data,  p<  0.05,  Figure  4.26)  was  then  significantly  reversed  to 
19.8± 3.3 ms during superfusion of myocytes with 0.05  M ISO and 10 nM ET 1 in 
combination (n= 15 cells from 10 patients, paired data, p< 0.05, Figure 4.26).  
 
Neither the APD75 (control 144.9± 16 ms vs 137.3± 14.9 ms post ISO vs 111± 13 
ms post ISO and ET 1, n= 15 cells from 10 patients) nor the APD90 (control 210.3± 
17.3 ms vs 187.9± 16.1 ms post ISO vs 173.5± 13.2 ms post ISO and ET 1, n= 15 
cells from 10 patients) was significantly affected either by ISO alone nor ISO in 
combination with ET 1 (Figure 4.26). 
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Figure  4.26  Effect  of  acute  superfusion  with  0.05   M  ISO  alone  and  then  0.05   M  ISO  in 
combination with 10 nM ET 1 on action potential repolarisation of human atrial isolated myocytes.  ￿ 
= control  ￿ = 0.05  M ISO      = 0.05  M ISO and 10 nM ET 1 co application (n= 15 cells from 10 
patients, paired data). Values are mean± s.e.m., asterisk (*) and hash (#) indicate p< 0.05. 
Figure taken from Redpath et al, JMCC 2006; 40: 717 724. Calum Jon Redpath    Chapter 4 159 
4.5.10.3  Effect of ET 1 on adrenergically prestimulated action potential 
effective refractory period 
An  example  of  the  effects  of  acute  superfusion  with  0.05   M  ISO  alone  and 
subsequent  co application  of  0.05   M  ISO  with  10  nM  ET 1  on  human 
refractoriness can be seen in Figure 4.27 and mean data in Figures 4.28 & 4.29. 
Superfusion of myocytes with ISO alone and in combination with 10 nM ET 1 did 
not have a significant effect on cellular ERP (control ERP 204± 19 ms vs ISO ERP 
198.7± 15.9 vs ISO/ET 1 ERP 180± 15 ms, n= 15 cells from 10 patients Figures 
4.27 and 4.28), nor the ERP/ APD90 ratio (control ERP/APD90 0.962± 0.03 vs ISO 
ERP 1.078± 0.04 vs ISO/ET 1 ERP/APD90 1.04± 0.04 ms, n= 15 cells from 10 
patients, Figure 4.27). 
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Figure  4.27  Effect  of  acute  superfusion  with  0.05   M  ISO  alone  and  then  0.05   M  ISO  in 
combination with 10 nM ET 1 on human atrial isolated myocyte refractoriness.  ￿ = control  ￿ = 
0.05  M ISO      = 0.05  M ISO and 10 nM ET 1 co application (n= 15 cells from 10 patients, paired 
data). Values are mean± s.e.m. 
 
4.5.10.4  Effect  of  ET 1  on  adrenergically  prestimulated  spontaneous 
depolarisations 
During  repetitive  stimulation  protocol  testing  to  evaluate  the  effective  refractory 
period  following  superfusion  with  ISO,  but  not  under  control  conditions,  low 
amplitude  sub threshold  phase  3 and  4  spontaneous  depolarisations  frequently 
occurred, as described in section 4.5.8.4 (Figures 4.20 and 4.29). These SDs did  Calum Jon Redpath    Chapter 4 160 
 
 
Figure 4.28 Anti adrenergic effect of ET 1 on action potential early repolarisation, but not refractory 
period. A, Action potential waveform and duration at 50% repolarisation (APD50) and B, Restitution 
and effective refractory period (ERP) in atrial cells, in absence of a drug (
 
), following 0.05  M ISO 
(
 
) and subsequent co application of 10 nM ET 1 (
 
). Upper panels: original, superimposed action 
potentials, each from the same cell, produced by (A) the 7th of a train of conditioning current pulses 
(75 beats/min) and (B) 7th and 8th conditioning pulses followed by progressively premature test 
pulses. Horizontal bars= cell ERP. Lower panels: histogram data; paired means (n=15 cells, 10 
patients). Values are mean± s.e.m. Figure taken from Redpath et al, JMCC 2006; 40: 717 724. 
 
 
not occur under control conditions, were significantly associated with exposure to 
ISO  and  following  the  co application  of  10  nM  ET 1  with  0.05 M  ISO  were 
significantly abolished (control SD 0% vs ISO SD 100% vs ISO/ET 1 SD 0%, n= 5 
cells, 3 patients, χ2 test, p< 0.05 Figures 4.20 & 4.29). 
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Figure 4.29 Spontaneous depolarisation induction by isoproterenol, and anti adrenergic effect of ET 
1.  A,  Original  action  potentials  (APs)  evoked  by  trains  of  current  pulses  (75  beats/min)  in  the 
absence of a drug (
 
), with 0.05  M ISO (
 
) and subsequent 10 nM ET 1 (
 
) in (i) a cell with a 
normal  AP  plateau,  and  (ii)  a  cell  with  relatively  large  plateau.  Arrows  indicate  “spontaneous 
depolarisations” (SDs): any AP phase 3 transient depolarisation or phase 4 depolarisation >3 mV. 
Dots indicate driven beats. iii, typical absence of response to ET 1 without ISO. All initial APs are 
post rest. B, Histograms showing significant production of SDs by ISO (i), abolition of SDs by ET 1 
(ii), and lack of significant (NS) SD induction by ET 1 alone (iii). Numbers within columns=n cells 
displaying SDs/total studied. Figure taken from Redpath et al, JMCC 2006; 40: 717 724. 
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4.6 Discussion 
4.6.1 Methodological  considerations  and  action  potential 
morphology 
Action  potential  characteristics  as  displayed  were  in  accordance  with  those 
published  previously.  There  have  previously  been  a  number  of  descriptions  of 
differing human atrial myocyte action potential morphologies
381. More recently a 
consensus  is  emerging  of  three  types  of  action  potential  morphologies 
demonstrated in human atrial RAA specimens has been reached
381;419 426.  
 
Type 1 or typical adult human atrial myocyte action potentials demonstrate a spike 
and  dome  morphology  and  have  been  previously  reported  to  have  a  maximal 
diastolic  potential  (MDP)  of   71  to   86  mV  broadly  in  line  with  characteristics 
mathematically modeled from ion current data
421;427.  
 
A second type of action potential morphology was described as having a spike but 
no dome, reported to be due to the continued presence of ITO but reduced IKr, 
related to the enzymatic isolation method
419;420;422 425. At physiological stimulation 
rates  of  60  bpm  there  were  no  significant  electrophysiological  difference  in 
electrophysiological  characteristics  between  these  two  action  potential 
morphologies
425.  Mathematical  modelling  of  the  human  atrial  myocyte  action 
potential provides support for this assertion and determines that at physiological 
heart rate and temperature the action potential morphology is primarily effected by 
ICaL, ITO and IKsus
421;427.  
 
A  third,  infrequent  action  potential  of  triangular  morphology  (absent  spike  and 
dome),  previously  associated  with  infants  with  congenital  heart  disease
420  and 
described in ventricular myocytes from hearts removed at cardiac transplantation, Calum Jon Redpath    Chapter 4 163 
was not identified in this study
425. It was expected that had cells displaying this 
action potential morphology been encountered they would likely be excluded as at 
stimulation rates greater then 60 bpm, these myocytes have previously been found 
to become unresponsive due to the prolonged APD at rest exceeding the PCL
425. 
 
Initial depolarisation, or phase 0 characteristics, of atrial myocyte action potentials 
have  varied  among  investigators:  Vmax  of  149  V/s  to  244  V/s,  an  upstroke 
amplitude  >90  mV  and  an  overshoot  of  48  to  53  mV  have  been 
reported
79;144;284;419;420;422 425;428 435. Mean data for phase 0 characteristics in this 
study are within this published range (See Table 1). 
 
Repolarisation and refractoriness characteristics of human atrial isolated myocytes 
are  particularly  susceptible  to  methodological  variation;  the  APD  and  ERP 
physiologically adapt to changes in the cycle length of stimulation and a reduction 
in environmental temperature accelerates human atrial myocyte repolarisation at 
identical  PCL
72;79;161;419;436.   At physiological  stimulation  rates  of 60 75  bpm  the 
range of repolarisation was found to be APD50 of 12 to 62 ms, an APD75 of 118 to 
138 ms, an APD90 between 341 and 447 ms and refractoriness (ERP) of 184 244 
ms
79;144;284;419;420;422 425;428 435. Our data, obtained with a stimulation rate of 75 bpm 
with  the  myocytes  maintained  at  physiological  temperature,  was  within  this 
published range (See Table 1). 
 
The  two  differing  morphologies  of  action  potential,  although  similar,  could 
potentially be explained by heterogeneity in IKr and ITO as a result of enzymatic 
isolation or between cells from differing regions of the heart
437, albeit that in the 
present study all cells  were isolated using identical methodology  and all tissue 
samples were obtained from the RAA of consenting patients undergoing corrective 
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and further work  will  be required to resolve this issue. Alternative explanations 
such  as  varying  disease  states  and  pharmacological  therapy  will  be  discussed 
below. 
 
4.6.2 Patients’ characteristics and action potential characteristics 
This  study  was  not  prospectively  powered  to  determine  potential  associations 
between  patients’  clinical  characteristics  and  human  atrial  isolated  myocyte 
electrophysiology. The data emanating from this study were pooled with data from 
colleagues in our laboratory and forms the results section of our recently published 
manuscript
300. What has been presented herein represents univariate analysis of 
the  data  solely  from  this  project  which  was  performed  in  order  to  inform 
multivariate analysis of our laboratories collective efforts. This, limited, data has 
been discussed in order to generate hypotheses which were later tested as part of 
the collective effort
300. 
 
Patient  senescence  had  no  significant  effect  on  human  atrial  action  potential 
characteristics in line with previously published reports from this laboratory
79;144;284. 
This is supported by data from experiments examining INa activation suggesting 
little if any data supports an alteration in INa as a function of age bar small shift in 
the half inactivation potential towards less negative potentials
381;438 440.  
 
Male gender was associated with an increased phase 0 amplitude, however there 
exists no precedent for this in the literature. Gender has not been identified in 
previous  work  on  human  atrial  action  potentials,  and  in  pooled  data  from  this 
laboratory the association of male gender and an increased phase 0 amplitude 
has not been replicated, suggesting that this may be a type 2 error
79;144;284. 
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The effects of chronic therapy with β B on ICaL and action potential repolarisation 
and  refractoriness  have  recently  been  described  in  humans
144;284.  The 
prolongation of APD90 and ERP in the absence of an effect on ICaL was identified 
on  univariate  analysis,  persisted  on  multivariate  analysis  and  was  found  to  be 
independent of heart rate
144. However, in this smaller patient dataset, although the 
recorded  measurements  of  repolarisation  and  refractoriness  in  this  study  are 
consistent with that published by our laboratory, no statistical difference myocyte 
repolarisation or refractoriness was observed. Thus apparent inconsistency may 
be explained by the lack of a significant decrease in heart rate related to β B use 
(heart rate BBY 58.8± 2.8 v. BBN HR 64.7± 2.8 bpm p= ns, Np= 13 BBY and Np= 7 
BBN).  The  lack  of  a  significant  heart  rate  response  may  be  a  corollary  for 
underdosing, medication error or non compliance with chronic β B therapy pre 
operatively  rather  than  any  absence  of  effect  of  β B  on  ITO,  APD90  or  ERP
144. 
Another explanation is that this inability to reject the null hypothesis represents a 
type 1 error as pooled data from our laboratory including data from this study, with 
a significantly larger dataset has maintained the association between β B therapy 
and an approximate 20% reduction in APD90 and ERP
300. 
 
Pre operative CCB drug therapy was associated with more rapid early (APD60), 
mid (APD75) and late (APD90) repolarisation but no effect on ERP in the absence 
of a direct effect on ICaL. The apparent effect of chronic CCB therapy on mid and 
late repolarisation, combined with a possible effect on APD50 which approached 
statistical  significance  (p=  0.051)  prompted  the  measurement  of  APD60.  Both 
Diltiazem and Verapamil have previously been associated with acutely reducing 
the AP plateau as recorded by APD50
430;441. Chronic pre operative therapy with 
CCB has also been associated with reduced ICaL and accelerated repolarisation
282. 
However, in contrast, a larger study in this laboratory confirmed a lack of effect of 
chronic CCB therapy on ICaL
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was observed
144. Patients in both studies form this laboratory were predominantly 
receiving  dihydropyridine  (Amlodipine  or  Nifedipine)  CCBs  pre operatively  at 
similar dosages. After merging the datasets the apparent effect of CCB therapy on 
action potential repolarisation ceased to be statistically significant on univariate 
analysis.  
 
ACE I therapy was associated with a small increase in action potential upstroke 
velocity (Vmax) during phase 0 depolarisation but no other significant effects on 
action  potential  characteristics.  Data  from  multicellular  recordings  in  animal 
models suggestive of a role for AII antagonism reducing cellular and structural 
remodelling such as atrial fibrosis may suggest a link, however there is no data 
from  single  cellular  recordings  to  suggest  a  direct  effect  of  ACE I  therapy  on 
INa
118;442 446. However INa was not measured in this study and thus would require 
further  work  to  determine  the  presence  of  any  direct  effect  on  INa  and  the 
reproducibility of any effect on Vmax in human atrial myocytes. 
 
Initial reports describing human atrial action potentials correlated diseased, dilated 
atria with a depolarized MDP, however no specific associations between atrial AP 
characteristics and disease processes have been identified
115;430;432;433;447;448. Data 
on atrial dimensions were not available for this study, however an analysis of the 
effect of LVSD was made and a small but significant hyperpolarisation of the MDP 
was  observed.  This  had  no  apparent  effect  on  phase  0  depolarisation 
characteristics and this has not previously been reported. No effect was identified 
for LVSD nor prior MI on any other action potential characteristic in this study. 
 
The  possible  effects  of  LVSD  on  human  atrial  myocyte  repolarisation  and 
refractoriness  are  controversial  with  previous  reports  describing  no  change  in 
early
449;450 or late
451 repolarisation, accelerated early and late repolarisation
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prolongation  of  APD90
449;450.  The  present  study  failed  to  identify  any  significant 
association  with  altered  repolarisation  or  ERP  but  in  order  to  resolve  the 
controversy,  pooled  data  from  our  lab,  subject  to  multivariate  analysis  and 
incorporating  data  relating  to  patients  with  objective  assessments  of  LVSD 
identified  that  LVSD  is  associated  with  abbreviated  APD90  and  ERP  by 
approximately 10 20%.  
 
Similarly  controversial  to  the  possible  impact  of  LVSD  on  atrial  ICaL  and  atrial 
action potential characteristics is the possible interplay of effects of ISO and ET 1 
on  ICaL  and  action  potentials  in  the  presence  and  absence  of  LVSD.  The  next 
Results chapter will build on the data presented in this chapter on action potentials 
under control conditions by investigating the effects of acute superfusion of ISO 
and ET 1, alone and in combination, on human atrial action potentials. 
 
4.6.3 Effect(s) of ISO on action potentials 
The first experimental recordings of human atrial action potentials almost 50 years 
ago  were  able  to  demonstrate  that  adrenergic  stimulation  with  epinephrine  or 
isoproterenol  increased  the  action  potential  plateau  and  caused 
afterdepolarisations  without  alteration  of  phase  0  characteristics
419;428;429;452  as 
observed  in  this  study.  The  presence  or  absence  of  β B  therapy  was  not 
associated with alteration in action potential characteristics, also consistent with 
our  findings  (See  Chapter  3  Results  section).  Due  to  the  small  sample  of 
recordings  further  sub analysis  of  the  association  with  prior  β B  therapy 
modulating either the ability of ISO to elevate the action potential plateau or to 
induce SDs is not possible. The lack of effect on later repolarisation and cellular 
ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that  in  addition  to  increasing  APD50  there  must  also  be  ‘compensation’  of  late Calum Jon Redpath    Chapter 4 168 
repolarisation in order to fully repolarise ‘on time’ and to preserve ERP
164;165;424;453. 
It also suggests that SDs are related to elevated ICaL rather than some hithertofore 
unappreciated effect on K repolarising currents as the SDs occur in cells in which 
there has not been lengthening of ERP. This suggests that, at least insofar as 
human  atrial  isolated  myocytes  in  vitro  can  be  described  to  undergo 
arrhythmogenesis,  triggered  activity,  traditionally  associated  with  arrhythmia 
initiation, is a potential arrhythmogenic effect of adrenergic stimulation. 
 
4.6.4 Effect(s) of ET 1 on action potentials 
ET 1 has been noted to enhance INa in animal studies and a small number of 
human  atrial  myocytes  associated  with  a  hyperpolarized  resting  membrane 
potential  and  an  increased  amplitude  and  upstroke  velocity  of  phase  0  of  the 
human atrial action potential
176;200;261. In contrast a small but significant reduction 
in Vmax in the absence of an effect on MDP was detected in this the largest study 
to date of the direct effect of ET 1 on human atrial myocyte action potentials at 
physiological temperature with preserved cellular integrity. As no recordings of INa 
were made in this study we can only speculate as to a potential reduction in INa 
associated with acute superfusion with 10 nM ET 1. Methodological differences 
such as a 10 mV less depolarized holding potential in this study as compared to 
prior studies of INa may, in part, explain the difference in results. Further direct 
measurements  of  the  effect  of  ET 1  on  INa  would  be  required  to  resolve  this 
question. 
 
Initial  reports  described  stimulatory
196;248;258;259,  inhibitory
195;196;248;260 263  or  no 
effect
203;247;249;264 of ET 1 on ICaL, with an EC50 between 1 and 10 nM, mediated via 
ET A receptors in animal models
195;196;203;248;249;258 264. In human atrial myocytes, 
ET 1 alone was found to increase
199, decrease
199;200 or have no effect
199;200 on ICaL Calum Jon Redpath    Chapter 4 169 
under control conditions. The action potential data in this study confirms the earlier 
finding (See Results Chapter 3) that under conditions of physiological temperature 
with a ruptured patch preserving human atrial myocyte integrity 10 nM ET 1 alone 
has no effect on ICaL. In human right atrium ET 1 was demonstrated to have little or 
no  effect  on  cAMP  under  basal  conditions,  but  significantly  inhibited  adenylate 
cyclase  due  to  ET A  receptor/  Gαi/  IP3  formation  independent  of  ICaL  and  PKC 
following adrenergic stimulation
187;200. Indeed the anti adrenergic effect of ET 1 is 
abolished during simultaneous intracellular application of 8 Br cAMP
200. 
 
4.6.5 Effect(s) of ISO and ET 1 in combination on action potentials 
In accordance with the data presented herein, adrenergically prestimulated ICaL 
has been consistently found to be inhibited by 10 nM ET 1 via  ET A receptors 
acting on Gαi (pertussis sensitive) GPCRs
245;247;262 reducing cAMP in human atrial 
myocytes  in  the  absence  of  any  direct  effect  on  the  L type  calcium  channel 
itself
198 200. 
 
In  addition  to  an  anti adrenergic  effect  of  on  ICaL,  ET 1  has  been  reported  to 
activate NHE
179;241;265;393 and NCX
241;266;268;393 via PKC and inhibit ICl via reducing 
intracellular cAMP
205;273. This would be expected to indirectly affect ICaL because of 
increasing  intracellular  calcium  levels  which  may  explain  the  positive  inotropic 
effect of ET 1
174;197;265;271;382 384;454;455 in the absence of a simultaneous increase in 
ICaL
179;197;382 384.  However  an  increased  intracellular  calcium 
transient
192;197;264;267;392;456;457 despite the sensitisation of myofibrils to calcium
265;384 
has  previously  been  associated  with  the  generation  of  SDs
319;391;392;457;458.  The 
data  presented  do  not  support  this,  however  again  in  the  absence  of  direct 
measurements of the ion currents this possibility cannot be discounted. 
 Calum Jon Redpath    Chapter 4 170 
Endothelin  has  also  been  reported  to  have  direct  effects  on  in  human  atrial 
myocyte repolarising potassium channels
371 which also contribute to determining 
the  amplitude  and  duration  of  the  action  potential
459.  ET 1  induced  marked 
inhibition of IK1 via PKC in human atrial myocytes at physiological temperature 
using  whole  cell  patch  clamp
371.  A  reduction  in  an  inward  rectifying  current 
necessary for maintaining the resting membrane potential of atrial myocytes may 
induce early or delayed afterdepolarisations and abnormal automaticity
270;272. In 
animal studies ET 1 modulation of K
+ outward currents is conflicting
62;269 272. In 
various models ET 1 was observed to increase the delayed rectifier IK
264;456, and 
IKss
271;454 however also to inhibit IK
62;271, IKss
271;454, ITO
417, IKACh
269;460 and IKATP via 
ET A receptors. Data on the resulting effects on action potential repolarisation are 
also mixed with no change
454, an increase
383 and a decrease
61 in APD reported. 
The present study does not support, but cannot exclude, a direct effect of ET 1 on 
K
+  currents  in  human  atrial  myocytes.  The  lack  of  change  in  action  potential 
repolarisation  with  superfusion  of  ET 1  alone,  the  lack  of  spontaneous 
depolarisations following exposure of myocytes to ET 1 and the ‘symmetrical’ anti 
adrenergic  effect  of  ET 1  co application  following  exposure  to  ISO  all  would 
suggest an ET 1 effect predominantly limited to ICaL. 
 
In summary, in contrast to ISO, 10 nM ET 1 did not appear to be associated with 
any arrhythmogenic effect on human atrial isolated myocytes in vitro. Indeed ET 1 
could be viewed as being anti arrhythmic as the pro arrhythmic effect(s) of ISO 
were abolished by the addition of 10 nM to the ISO containing superfusate. It is 
appealing, but premature, to ascribe all the anti arrhythmic effects of ET 1 as a 
direct translation of the anti adrenergic effect on ICaL through to early repolarisation 
and SDs. 5 171 
5  GENERAL DISCUSSION 
5.1 Main Conclusions 
The data presented herein confirm that under these experimental conditions ET 1 
modulates the effects of ISO on ICaL and action potentials via ET A receptors in 
human atrial isolated myocytes. There was no apparent effect of ET 1 alone on 
either  ICaL  or  action  potential  repolarisation  or  refractoriness  and  the  anti 
adrenergic effects of ET 1 were not modified by chronic pre operative β B therapy. 
Whether the anti adrenergic effects of ET 1 are anti arrhythmic in humans is yet to 
be determined. 
The anti adrenergic effect of ET 1 on ICaL was observed at concentrations of ET 1 
which have been reported in the venous blood of patients suffering from severe 
CHF. This ET 1 effect was prevented by the ET A receptor anatagonist, FRA, and 
was partially reversible both by washout and subsequent superfusion with FRA. 
ET 1  alone  was  associated  with  a  reduction  in  Vmax  but  not  repolarisation  or 
refractoriness. ET 1 did however reverse the adrenergically induced increase in 
APD50 and spontaneous depolarisations. 
The  possible  physiological  mechanisms  of  these  effects,  such  as  secondary 
messenger  systems  and  interactions  with  other  atrial  ion  channels,  and  their 
potential implications for arrhythmogenesis in human atria will be discussed. Calum Jon Redpath    Chapter 5 172 
5.2  Possible physiological mechanisms of the effects of 
ET 1 in human atrial myocytes 
ET 1, binding to ET A receptors expressed on cardiac myocytes has a number of 
biological effects mediated via stimulation of Gαi
396 398: ET 1 was found to directly 
inhibit or reduce cAMP
187;246;261;399 and increase InsP3
187;384;391;392;455;458 with direct 
experimental  evidence  for  anti muscarinic
269  and  anti adrenergic 
effects
187;246;249;261;262 in a number of animal models. 
 
In  human  atrial  myocytes  evidence  exists  for  a  basal  constitutive  cAMP/  ICaL 
activity
281;287;288;395. Upon binding to β AR, ISO rapidly induces a threefold rise in 
cAMP  activity  which,  via  PKA induced  phosphorylation  of  ICaL  results  in  a 
sustained elevation of long lasting inward calcium current
90;238;239;302 307. ET 1, with 
an EC50 of 1 10 nM, binds to the ET A receptor on human atrial myocytes rapidly 
stimulating Gαq activating PLC which hydrolyses phosphatidylinositol present in 
the  plasmalemma.  The  resultant  1,4,5 inositol  triphosphate  (InsP3)  enters  the 
cytosol  and  diacyl glycerol  (DAG)  remains  in  the  plane  of  the 
membrane
327;457;458;461;462. In human right atrial specimens, ET 1 was not found to 
have any effect on cAMP levels under basal conditions but could reversibly inhibit 
an adrenergically activated adenylate cyclase/ cAMP cascade
187;200 the effects of 
which were not limited to ICaL
199;200. In addition, within seconds, PKC (δ and ε)
313 is 
activated
462;463 and translocates close to the membrane to activate small Ras G 
proteins and extracellular signal related kinase (ERK) within 3 minutes
464. InsP3 
also  stimulates  SR  calcium  release  resulting  in  a  rapid  increase  in  [Ca
2+]i, 
independent  of  external  calcium,  followed  by  a  sustained  increase  in  [Ca
2+]i 
facilitated by increased SR calcium uptake
457;458;465 467. 
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ET 1 binding to ET A also activates phospholipases A and D, altering arachidonic 
acid  metabolism  and  providing  sufficient  supply  of  DAG  for  sustained  PKC 
activation
468;469.  PKC  then  selectively  phosphorylates  the  α1c  subunit  of  ICaL 
resulting in decreased calcium entry
90. Recently, the possibility that ET 1 induced 
upregulation  of  PKC  may  play  a  role  in  the  augmentation  of  constitutive  IKACh, 
increased in AF and a cause of APD abbreviation, and IKATP has been raised
470 473. 
 
Alternative  second  messenger  systems  may  be  activated  by  ET 1  directly. 
Evidence  is  accumulating  that,  in  addition  to  an  inhibitory  action  on  cAMP  via 
Gi/o
396 398, the anti adrenergic effect of ET 1 is via stimulation of a phosphatase 
which  opposes  the  PKA phosphorylation  of  calcium  handling  regulatory 
proteins
242;245  independent  of  PKC  activation
242;248.  Human  atrial  ICaL  has  been 
shown be modulated via the cGMP cascade, albeit that the overall effect varies 
with  the  relative  balance  of  the  three  cGMP  effector  proteins
281;287;288;380;395. 
Modest  activation  of  cGMP  increases  cAMP  via  inhibiting  PDE3  resulting  in  a 
positive inotropic effect and an increase in ICaL, however strong activation of cGMP 
produces  both  an  activation  of  PDE2,  opposing  PDE3,  and  activation  of  PKG 
resulting in an overall inhibitory effect on ICaL
287. 
 
A further level of complexity in understanding the effects of ET 1 is due, in part, to 
the  crosstalk  present  between  the  angiotensin,  adrenergic  and  endothelin 
receptors’ secondary messenger systems
243;248;474;475. Endothelin is synthesised, 
stored and released in human atrium and crosstalk between AII and ET 1 as an 
autocrine phenomenon has been described
474. 
 
In summary it appears that the possibilities for an ET 1 mediated anti adrenergic 
effect on ICaL and subsequently action potentials are as follows: ET 1 stimulates 
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ICaL
195;197;258, ET 1 stimulates IP3 formation and in so doing inhibits cAMP formation 
by adenylate cyclase reducing the ability of cAMP dependent kinases to activate 
ICaL
187;188;200;262;273;399, or that ET 1 stimulates cyclic nucleotide phosphodiesterase 
via  cGMP  hydrolyzing  cAMP  antagonizing  the  adrenergic  effect  of  β AR 
stimulation
187;199;200;242 on ICaL but not NCX
402;403. The apparent contradiction in an 
inhibitory effect on ICaL but a positive inotropic effect could be explained by the 
relative  efficacy  of  the  differing  second  messenger  systems  effected  by  ET 1 
binding  to  ET A  receptors:  sensitizing  the  SR  and  increasing  cytosolic  calcium 
during diastole will oppose calcium entry via ICaL
195;197;258, PLC activation and IP3/ 
DAG stimulation produces a positive inotropic effect but the associated inhibition 
of cAMP will reduce ICaL amplitude
187;188;200;262;273;399 and activation of NHE
265 and 
NCX
266 268 via PKC will result in a positive inotropic effect with little direct effect on 
ICaL. 
 
5.3  The  potential  effects  of  ET 1  on  the  fundamental 
mechanisms of arrhythmogenesis in human atria 
The three fundamental mechanisms underpinning arrhythmogenesis are triggered 
activity, reentry and abnormal automaticity. The occurrence of these fundamental 
mechanisms  is  promoted  by  several  pathophysiological  remodelling  processes 
(Figure 1.1). The potential for ET 1, alone or in combination with ISO, to affect 
human  atrial  arrhythmogenesis  could  be  modified  by  the  duration  of  exposure, 
local  concentration  and  tissue  exposure  within  the  heart,  pathological  disease 
states,  pharmacological  therapy  and  the  presence  of  physiological  stress. 
Evidence suggesting a possible role of ET 1 in any of these three fundamental 
processes, and impact on AF or CHF induced remodelling will be discussed. 
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5.3.1 Triggered Activity 
ET 1 was, at first, thought likely to predispose to EADs and DADs by reducing IK 
and  causing  increased  intracellular  calcium  loading
50  via  augmenting  ICaL. 
However the data suggesting that ET 1 decreases IK
62;271 are controversial
264;456 
and in the present study and one other ET 1 did not affect APD
322;454. ET 1 did 
augment  the  calcium transient  via  increased  calcium mobilisation from  SR and 
perinuclear  stores
192;197;264;267;392;456;457  activating  NHE
179;241;265;393  and 
NCX
241;266;268;393. This may potentially be pro arrhythmic, with ET 1 increasing the 
magnitude  of  calcium  sparks  sufficiently  to  induce  diastolic  calcium  waves 
correlating  with  spontaneous  depolarisations
319;391;392;458.  However,  in  an  open 
chest dog model ET 1 had an anti adrenergic protective effect on ISO induced 
atrial fibrillation and ventricular arrhythmia
476. Although the data presented here 
relate  to  single  myocyte  recordings,  ET 1  abolished  both  the  early  and  late 
spontaneous depolarisations initiated by ISO during action potential recordings
322, 
directly analagous to the anti adrenergic phenomenon described in the open chest 
dog model
476. Further evidence of a potential anti arrhythmic effect of ET 1 comes 
from clinical trials in human patients of long term ET A receptor blockade. Despite 
promising results in animal testing
274;275, results of clinical trials in human patients 
with  CHF  have  been  disappointing
276  with  two  larger  studies  being  terminated 
prematurely  due  partly  to  an  unexpected  increase  in  atrial
277  and  ventricular
278 
arrhythmia. 
 
The  acute  effects  of  ISO  on  ICaL  and  IK  translate  into  altered  action  potential 
repolarisation and refractoriness. Data from early experiments in line with the data 
presented  here  confirm  that  acute  superfusion  with  ISO  increased  the  action 
potential  plateau  and  caused  afterdepolarisations  without  alteration  of  phase  0 
characteristics
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ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that  in  addition  to  increasing  APD50  there  must  also  be  ‘compensation’  of  late 
repolarisation in order to fully repolarise ‘on time’ and to preserve ERP
164;165;424;453. 
It also suggests that SDs are related to elevated ICaL rather than some hithertofore 
unappreciated effect on K repolarising currents as the SDs occur in cells in which 
there has not been lengthening of ERP. This is also suggested by the lack of effect 
of ET 1 alone on ICaL and the absence of a significant effect of ET 1 alone to cause 
SDs. This suggests that, at least insofar as human atrial isolated myocytes in vitro 
can  be  described  to  undergo  arrhythmogenesis,  triggered  activity,  traditionally 
associated with arrhythmia initiation, is a potential arrhythmogenic effect of acute 
adrenergic stimulation and that this arrhythmogenic effect is opposed by ET 1. 
 
Unopposed β AR agonism, such as that experienced during decompensated CHF, 
would be expected to increase both ICaL and IKur / IKs and these opposing effects on 
APD may protect against excessive APD prolongation in human atria
69;165. Any 
increase  in  cAMP  or  PKA  activity  will  result  in  increased  phosphorylation  of 
calcium  handling  proteins  and  augmentation  of  CHF  induced  remodelling
69. 
Elevated  PKA  hyperphosphorylates  RyR2  disassociating  calstabin  and 
CaMKII
477;478 in human ventricular preparations resulting in depleted SR calcium 
stores because of diastolic calcium leak from the SR
477 479 activating inward NCX 
and  potentially  culminating  in  triggered  arrhythmia
210.  The  potential 
arrhythmogenic  effect  of  leaky  RyR2  in  CHF  is  only  beginning  to  be 
investigated
477;480 483, however. Fortunately, although Ca ATP ase (SERCA2a) and 
phospholamban (PLB) levels remain unaltered, PLB phosphorylation is decreased 
because of subsequent increased phosphatase activity in CHF
484 488. This results 
in  decreased  calcium  uptake,  SERCA2a  function  and  CaATP ase 
activity
479;485;487;489 494  reducing  subsequent  calcium transient and  rate of decay, Calum Jon Redpath    Chapter 5 177 
culminating in a reduced force frequency relationship
491;495 and a lower probability 
of triggered activity. 
 
Despite  this  adaptation,  in  animal  models  adrenergic  stimulation  and  altered 
phosphorylation  status  of  PKA  and  CaMKII  in  combination  appear  to  result  in 
sufficiently leaky SR calcium release channels to produce diastolic calcium waves 
which can result in triggered arrhythmia
43;496;497 with evidence of altered CaMKII 
activity in human CHF
479, despite reduced myocyte calcium stores
210;496 because 
of  hyperphosphorylated  SR  calcium  release  channels,  the  electrogenicity  of 
calcium  extrusion  by  NCX  and  the  increased  membrane  resistance  due  to 
decreased IK1 resulting in greater depolarisation for any given inward current
69. 
 
AF induced electrical remodelling is accompanied over a longer time course by 
cellular  remodelling
98.  AF  has  been  associated  with  human  atrial  myocyte 
apoptosis
96  and  the  surviving  atrial  myocytes  demonstrate  significant  ultra 
structural  abnormalities
97;498;499.  Atrial  myocyte  degeneration  with  sarcoplasmic 
reticulum fragmentation, marked collagen formation, widening of the intercalated 
discs and replacement of myofibrils results in patchy fibrosis, atrial dilatation and 
myopathy
97;498;499.  More  frequent  calcium  sparks  and  calcium  waves  were 
observed in atrial myocytes isolated from patients in AF when compared to those 
from  patients  in  sinus  rhythm  despite  apparently  similar  levels  of  SR  calcium 
loading and greater NCX activity suggesting a direct role for the calcium release 
channel
16. Elevated levels of PKA induced hyperphosphorylation of RyRs resulting 
in dissociation of calstabin2 (FK506) and thus increasing the Po due to calcium 
hypersensitivity could also contribute to increased leak of calcium from the SR in 
human  atria  initiating  AF  via  triggered  activity  or  supporting  arrhythmia 
maintenance in patients already suffering AF
16;477;500. 
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5.3.2 Intra atrial Reentry 
Intra atrial reentry is promoted by any factor which reduces conduction velocity 
and refractoriness or increases path length or conduction time. Thus decreased 
INa/ Vmax, decreased ICaL or increased IK, decreased APD and ERP, atrial dilation 
and stretch all promote reentry. We did not measure INa or IK directly and therefore 
can only speculate on the direct effect of ET 1 on these ion currents. The small 
reduction  in  Vmax  following  acute  superfusion  with  10  nM  ET 1  in  this  study 
suggests a possible decrease in INa, however this is contrary to previous reports in 
human right atrial myocytes
176;200;261 and should interpreted with caution. The lack 
of effect of ET 1 on APD suggests that in the present model ET 1 does not acutely 
affect IK. However, one study of human atrial myocytes reported that ET 1 induced 
a marked inhibition of IK1
371. In view of the absence of an ET 1 effect on APD and 
ERP  in  this  study,  at  the  very  least  it  can  be  said  that  using  this  model  of 
arrhythmogenesis there is little or no evidence for ET 1 alone to promote intra 
atrial reentry via a direct effect on ion channels or refractoriness in human atrial 
isolated myocytes. 
 
Heart  Failure,  whether  acute
501  or  chronic
502  results  in  left  atrial  stretch  and 
dilatation which has been associated with reductions in ICaL, APD shortening and 
plateau depression
115. Myocytes isolated from dilated human atria are larger with 
smaller ICaL and demonstrate abbreviated APD, perhaps due to elevated levels of 
ANP, altered redox state or kinase/ phosphatase activity
84;115;199;299;379;503. Whether 
this reduced ICaL translates into a reduction in atrial ERP is unclear
115;117 however 
the  relationship  between  atrial  dilatation,  altered  atrial  electrophysiology  and 
prognosis appears robust
115;504;505. Certainly atrial dilatation and calcium overload 
as a result of tachycardia will result in oxidative stress, as indicated by glutathione Calum Jon Redpath    Chapter 5 179 
depletion  and  increased  NADPH  activity  which  have  been  linked  with  impaired 
contractility, reduced ICaL and IKur AF in man
97;375;377;379;506 508. 
 
Altered phosphorylation as a result of stretch induced oxidative stress can also 
modulate  the  response  of  ICaL  and  cellular  calcium  processing  to  adrenergic 
stimulation
84;379;509;510  perhaps  directly  via  the  RyR  and  L type  calcium 
channels
374;376;379;395;511.  This  mechano electric  feedback
512;513,  demonstrated  in 
humans
514  and  animal  models
515 517  via  vagal  efferent  stimulation,  results  in 
electrical  instability  by  accelerated  repolarisation  and  ERP  shortening
518  further 
predisposing  to  arrhythmia
519.  Acute  atrial  stretch  may  have  variable  effects 
throughout  the  atria  thereby  generating  non  uniformity  of  conduction  and  this 
combined with increased atrial size is more likely to permit accommodation of the 
multiple daughter wavelets seen in fibrillating atria
520 promoting reentry or enhance 
the automaticity of arrhythmogenic foci
448. 
 
CHF,  in  addition  to  direct  cardiac  electrophysiological  remodelling 
effects
69;114;115;117;119;158;449,  is  associated  with  increased  levels  of  circulating 
catecholamines and adrenergic tone which in turn can have profound effects on 
human cardiac performance
122;151;255;331;332;521 523. In human atrial myocytes acute 
exposure  to  ISO  has  a  concentration  dependent  effect  via  β AR  stimulation 
increasing ICaL, IK and IKur via PKA/ cAMP, and α AR stimulation by Phenylephrine 
decreases IKur and Ito via PKC
165. This indicates that the repolarisation prolonging 
effect  of  ISO  by  increasing  ICaL  and  inhibition  of  Ito  outweighs  opposition  by 
stimulatory effects on IKur
164;165;321;424. 
 
In  the  present  study,  no  measurements  of  K
+  currents  were  made  but  acute 
superfusion with ISO augmented ICaL in a concentration dependent manner without 
altering  the  I:V  relationship,  activation  or  inactivation  kinetics  in  human  atrial Calum Jon Redpath    Chapter 5 180 
isolated myocytes. This adrenergic increase in ICaL has previously been attributed 
to an increased mean channel opening time and an increased Po
90;238;239;302 307. 
 
The  acute  effects  of  ISO  on  ICaL  and  IK  translate  into  altered  action  potential 
repolarisation and refractoriness. Data from early experiments in line with the data 
presented  here  confirm  that  acute  superfusion  with  ISO  increased  the  action 
potential  plateau  and  caused  afterdepolarisations  without  alteration  of  phase  0 
characteristics
419;428;429;452.  The lack of effect on later repolarisation and cellular 
ERP, in combination with the known effect of ISO to augment ITO and IKur suggests 
that  in  addition  to  increasing  APD50  there  must  also  be  ‘compensation’  of  late 
repolarisation in order to fully repolarise ‘on time’ and to preserve ERP
164;165;424;453. 
 
5.3.3 Abnormal Automaticity 
Abnormal  automaticity  in  the  atrium  occurs  when  atrial  or  pulmonary  vein 
myocytes, which are not normally pacemaker cells, begin to spontaneously fire at 
a faster rate than the SAN as a result of accelerated phase 4 depolarisation (See 
Section 1.2.3).Although fractionation or fibrillatory conduction has been observed 
in  patients,  no  direct  evidence  for  a  role  of  abnormal  automaticity  has  been 
identified to date in patients
67 69. Currently there is no data to suggest that ET 1 
has an effect on If or phase 4 of the human atrial action potential. 
 
5.4 Limitations of this work 
Despite the obvious scientific benefits, there are inherent practical and theoretical 
limitations in studying human tissues. The availability of tissue is limited, by virtue 
that cardiac tissue is only available at the time of cardiopulmonary bypass during 
cardiac  surgery,  a  small  sample  of  tissue  is  obtained  and  thus fewer  cells  are Calum Jon Redpath    Chapter 5 181 
available  for  experiments.  In  addition  the  confounding  effects  of  competing 
comorbidities  and  pharmacological  therapies,  effects  of  age  and  gender  and 
hithertofore unknown other factors can potentially limit the applicability of some 
experimental results. 
 
The  enzymatic  dissociation  method  is  recognised  to  result  in  cells  which  are 
depolarised at rest after experimentation. Furthermore, despite strenuous attempts 
to maintain and protect the myocytes, prolonged recording protocols are limited, 
despite the success of perforated patch recordings. 
 
5.5  Future Directions 
AF remains the most common disorder of cardiac rhythm
1;524 526, affecting more 
than half a million people in the UK alone
527 and estimated to cost the UK NHS 
more than £1 Billion in 2000
527. The prevalence of AF in the UK has risen
528 and 
will  continue  to  do  so  as  the  population  ages
1;529  and  improvements  in  the 
management of associated conditions such as CHF are implemented
530 
 
AF results in several deleterious, yet reversible, effects on cardiac physiology: loss 
of  Atrio Ventricular  synchrony  and  rapid  irregular  ventricular  systole  negatively 
effect  cardiac  output
2;3;531 535  increasing  the  risk  of  atrial
536  and  ventricular 
tachycardiamyopathy
537  and  ultimately  CHF
538 540.  Even  in  the  absence  of 
coronary  atheroma,  AF  increases  myocardial  oxygen  demand  whilst 
simultaneously  decreasing  coronary  perfusion  resulting  in  myocardial 
ischaemia
541;542 and hence potentially precipitating further arrhythmia
543. 
 
These experiments have prompted me to consider investigating the links between 
the intracellular calcium handling effects of ET 1 and alterations of ICaL and action 
potential  characteristics  at  the  plasmalemma.  Experiments  performed  with Calum Jon Redpath    Chapter 5 182 
confocal microscopic measurements would provide further insight into the effects 
of neurohormonal activation on human atrial myocytes but also the multifaceted 
process  of  atrial  excitation  contraction  coupling.  This  work  would  enhance  our 
knowledge  of  the  generation  of  EADs  and  DADs.  Expansion  to  multicellular 
preparations  would  allow  further  assessment  of  the  ability  of  adrenergically 
induced afterdepolarisations to be propagated linking to arrhythmogenesis. The 
interaction  between  other  neurohormones,  such  as  ANP  and  AII,  and 
catecholamines and ET 1 may prove another fruitful piece of experimental work. 
Do these autocrine/ paracrine substances interact at the receptor level, crosstalk, 
or  within  the  cell  at  the  level  of  secondary  messengers  or  indeed  via 
complementary  or  opposing  effects  on  calcium  handling,  or  indeed  all  of  the 
above. If such interaction exists is this pro or anti arrhythmic? 
 
Expanding the area of interest into the K
+ currents involved in repolarisation may 
also  permit  further  insight  into  atrial  myocyte  electrophysiology.  Although 
investigation of IKr and IKs in human atrial myocytes is difficult due to the chunk 
method of isolation
544, an investigation into the impact of ET 1 on these important 
repolarising currents is much needed. 
 
Investigation  of  a  potential  role  for  tyrosine  phosphorylation  and  PKC  in  the 
modulation  of  ICaL  in  human  atrial  myocytes,  whether  membrane  bound  or 
cytosolic,  warrants  further  examination.  Interest  in  reports  of  a  role  of  Ca2+/ 
calmodulin dependent protein kinase II (CAMKII) activity in modulating ICaL and 
RyR  function  have  been  aroused  by  the  data  relating  to  the  role  of  protein 
phosphatases in AF and CHF induced structural remodelling
84;483;496;497;545 547. 
 
By the very nature of the experimental method, studies of an acute exposure of 
myocytes to single, biologically plausible, contender molecules, such as ISO and Calum Jon Redpath    Chapter 5 183 
ET 1 in this study, have commonly been performed. The possibility of performing 
integrated  physiology  experiments  in  animal  models  examining  the  effect(s)  of 
chronically elevated ET 1 levels on atrial and ventricular electrophysiology should 
be  explored.  A  comparison  with  those  electrophysiological  effects  occurring  in 
cardiac  tissue  following  an  induced  heart  failure  syndrome  would  assist  in  the 
understanding of the links between CHF, AF, ion currents and calcium handling. 
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Appendices 
(i)  Patient consent form 
 
Right atrial appendage 
 
Glasgow Royal Infirmary University N.H.S. Trust 
 
PATIENT INFORMATION AND CONSENT FORM 
 
Title of Project: Electrophysiological and molecular properties of isolated human 
cardiac myocytes. 
 
Summary: 
You are shortly to undergo a heart operation. The reasons for this, and the type 
of  operation  to  be  performed,  will  have  been  discussed  with  you  by  your 
cardiologist and by the heart surgeon. 
We  are  undertaking  research  into  why  some  patients  have  abnormal  heart 
rhythms and how these cardiac arrhythmias affect the heart cells. In order to 
understand the biological properties of heart cells we would like to obtain a 
small sample of your heart muscle.  
During the operation, the surgeon routinely makes a small cut in the heart to 
allow the operation to proceed. Many surgeons perform this by removing a small 
piece  of  heart  tissue  (about  the  size  of  a  pea),  which  would  normally  be 
discarded. Some surgeons do not routinely remove this piece of tissue, but are 
willing to do so, since they know that such a procedure would not do you any 
harm. We are asking for your consent to use this small piece of the heart to 
obtain heart cells for our study. Part of the tissue will be studied directly for 
electrical activity and then discarded, and the remainder will be deep-frozen at 
the  hospital  for  future  analysis  of  molecular  activity,  after  which  it  will  be 
destroyed. Participation in our study will not change the operation or result in 
additional risk or discomfort to you. 
In addition, we would ask your permission to obtain details of your condition 
from  your  medical  records.  These  details  will  be  kept  confidential  and  your 
identity will be concealed by the use of a coding system. Such information will 
be retained for comparison with the results of the tissue analysis, and will not be 
disclosed to anyone outside the hospital.     226 
This research project will not be of direct benefit to you, but the results may 
help  other  patients  in  the  future.  If  you  are  unwilling  to  take  part,  you  are 
entirely  at  liberty  to  refuse  permission.  This  would  not  affect  your  medical 
treatment in any way. 
 
Consent: 
I, (Name) ………………………………………………………………………………. 
of (Address) …………………………………………………………………………… 
agree to take part in the Research Project described above. 
Dr …………………………………………….. has explained to me what is involved, how it 
might affect me and the purpose of the Research Project. 
 
Signed …………………………………………………………… Date …………….. 
 
Witness ….……………………………………………………… Date …………….. 
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